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Abstract 
Cell migration is an integral process for diverse physiological and pathological processes, 
including embryonic and tissue development, wound healing, immune response, chronic 
inflammation and cancer metastasis. Cancer metastasis, a coordinated and complex multistep 
process by which tumor cells disseminate from primary tumors to secondary sites, is responsible 
for up to 90% of all cancer-related death. During metastasis, tumor cells must interact, migrate 
and navigate through considerably different microenvironments including tissues at the local and 
distal sites, as well as within the circulatory system. As such, enhanced cell motility has been 
widely associated with increased cancer aggressiveness and metastatic potential, and overall poor 
patient outcome. A thorough understanding of the biochemical and physicomechanical driving 
forces underlying cell motility can therefore provide critical insights for the development of 
novel and effective diagnostic, preventative, therapeutic and prognostic strategies against cancer. 
 
We start by first examining the role of podocalyxin on the migratory behavior of pancreatic 
cancer cells. The sialoglycoprotein podocalyxin is absent in normal pancreas but is 
overexpressed in pancreatic cancer and is associated with poor clinical outcome. Here we 
investigate the role of podocalyxin in migration and metastasis of pancreatic adenocarcinomas 
using SW1990 and Pa03c as cell models. Although ezrin is regarded as a cytoplasmic binding 
partner of podocalyxin that regulates actin polymerization via Rac1 or RhoA, we did not detect 
podocalyxin-ezrin association in pancreatic cancer cells. Moreover, depletion of podocalyxin did 
not alter actin dynamics or modulate Rac1 and RhoA activity in pancreatic cancer cells. Using 
mass spectrometry, bioinformatics analysis, co-immunoprecipitation, and pulldown assays, we 
discovered a novel, direct binding interaction between the cytoplasmic tail of podocalyxin and 
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the large GTPase dynamin-2 at its GTPase, middle, and pleckstrin homology domains. This 
podocalyxin-dynamin-2 interaction regulated microtubule growth rate, which in turn modulated 
focal adhesion dynamics and ultimately promoted efficient pancreatic cancer cell migration via 
microtubule- and Src-dependent pathways. Depletion of podocalyxin in a hemispleen mouse 
model of pancreatic cancer diminished liver metastasis without altering primary tumor size.  
 
We next apply our knowledge of cell migration to develop a device for glioblastoma prognosis. 
Glioblastoma is the most aggressive form of brain cancer, characterized by high recurrence and 
dismal prognosis. Presently, there is no effective in vitro platform that can rapidly measure 
complex cellular phenotypic traits and accurately predict patient-specific clinical outcomes. 
Here, we employed a proprietary in vitro testing platform, Microfluidic Invasion Network 
Device (MIND), and screened a panel of 22 patient-derived primary glioblastoma specimens in a 
blind manner. We evaluated the ability of glioblastoma cells to navigate and squeeze through 
confined microenvironments that mimic in vivo tight perivascular conduits and white matter 
tracts in the brain parenchyma, as well as the proliferative capacity of highly motile 
subpopulations. By combining migratory- and proliferative-based indices, MIND predicts 
progression-free survival (p=0.008) and time to recurrence (p=0.006) retrospectively with high 
sensitivity (85%), specificity (89%), and accuracy (86%).	 In a pilot prospective study, MIND 
classified all patients accurately based on their survival outcomes.  
 
Overall, this dissertation illustrates the importance of studying cell migration, both at the basic 
science as well as the translational levels, to better understand the mechanisms of cancer 
aggressiveness and develop potentially useful clinical applications.  
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Chapter 1 - Introduction 
1.1 Cancer 
Cancer refers to a group of diseases in which normal cells acquire the ability to proliferate 
uncontrollably and develop the capacity to locally invade nearby healthy tissues and spread 
systemically to distant body parts (1). Despite the tremendous efforts that have been devoted to 
the research and management of cancer over the past several decades, cancer still remains a 
major and global public health issue. In fact, with a projection of 1,735,350 new cancer 
diagnoses (equivalent to more than 4,700 new diagnoses per day) and 609,640 cancer-related 
deaths (equivalent to about 1,700 deaths per day) in 2018, cancer is the second leading cause of 
death in the United States, trailing only behind cardiovascular disease (2). While the incidence 
and death rate of cancer in general have both declined steadily over the years as a result of 
improved cancer prevention, screening, detection and management, these improvements are 
mostly restricted to the more commonly observed cancers affecting the prostate (specifically in 
men), breast (specifically in women), lung and colorectum (2). This is in stark contract to some 
of the other less common but yet aggressive cancer types, such as pancreatic and brain cancers, 
which continue to suffer from increasing mortality and poor patient outcome (2). There is 
therefore a dire need to better understand the pathology and progression of these highly lethal 
cancers in order to devise more specific and effective preventative, diagnostic, therapeutic and 
prognostic strategies.  
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1.1.1 Pancreatic cancer 
Pancreatic cancer is an extremely lethal malignancy, with mortality almost paralleling its 
incidence (3). In 2018, the number of new cases and deaths of pancreatic cancer are projected to 
be 55,440 and 44,330 respectively in the United States, and 458,918 and 432,242 respectively 
worldwide (2,4). Despite a continuous 26% decline in death rate of all cancer types combined 
from 1991 to 2015, pancreatic cancer still remains as the most deadly cancer with a 
tremendously low 5-year relative survival rate of only 8% for all stages combined, making it the 
4th leading cause of cancer-related death in both men and women (2). The mortality of pancreatic 
cancer in men has also risen by 0.3% per year during 2011 through 2015 (2). In fact, pancreatic 
cancer is predicted to become the 2nd leading cause of cancer-related death by 2030 if there is no 
further improvement to its clinical management and outcome (5).  
 
The main reason for the poor prognosis of pancreatic cancer is delayed diagnosis due to lack of 
specific and noticeable symptoms during the early stages of the disease (6). In addition, 
prevention or early diagnosis is difficult because there are no reliable, specific and sensitive 
biomarkers, and effective imaging modalities for early staged pancreatic cancer (7). The overall 
low lifetime risk of developing pancreatic cancer (about 1.3% before age 70) also precludes 
widespread implementation of population-based screening of unselected population (6,8). As 
such, most patients remain asymptotic until they are diagnosed at an advanced stage where 
distant metastases, typically to the liver and peritoneum, have already developed (2,6). Although 
surgical resection is the only curative treatment option that has proven to prolong pancreatic 
cancer patient survival, only less than 20% of patients are eligible for surgical resection at the 
time of diagnosis due to vascular involvement and/or widespread metastasis (6). Even for these 
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small subpopulations of patients with surgically resectable disease, approximately 80% relapse 
after curative resection and adjuvant therapy, eventually dying from the disease with a 5-year 
survival rate of just 25% (3,6). For patient diagnosed with locally advanced or metastatic disease 
ineligible for surgery, the 5-year survival rate dropped even further to only 3-10%, where the 
average life expectancies after diagnosis are merely 6-9 months and 3 months for locally 
advanced and metastatic disease respectively (4). 
 
Pancreatic ductal adenocarcinoma is the most common type of pancreatic malignancy and 
originates from incipient premalignant lesion in the pancreas known as pancreatic intraepithelial 
neoplasia after successful accumulation of multiple mutations over time (3,9). Molecular 
profiling has identified four key driver genes that are widely associated with the pathogenesis 
and progression of pancreatic cancer. Specifically, more than 90% of pancreatic tumors exhibit 
activating oncogenic KRAS mutation, and about 50-90% of pancreatic cancers develop 
inactivating mutation of tumor suppressor genes including CDKN2A (encoding p16), TP53, 
SMAD4, through either genetic or epigenetic alterations (3,10,11). Located on chromosome 12, 
RAS is a small GTPases that relay growth factor receptor signaling (e.g. EGF) into enhanced 
cellular growth, differentiation and survival. Ras is point mutated to its oncogenic constitutively 
active GTP-bound form KRAS is more than 90% of pancreatic tumors and even the lowest grade 
of pancreatic intraepithelial neoplasia, suggesting that it is one of the earliest and most critical 
genetic alterations that initiate pancreatic cancer pathogenesis (12,13). The tumor suppressor 
gene CDKN2A, which encodes the cell cycle regulator p16, is inactivated in almost 90% of 
pancreatic carcinomas (12). TP53, a well-known tumor suppressor gene responsible for sensing 
cellular stress response and inducing DNA repair and apoptosis, is inactivated in 50-75% of 
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pancreatic ductal adenocarcinoma, leading to loss of proper cell cycle checkpoint function (12). 
Lastly, SMAD4 (also known as gene deleted in pancreatic carcinoma, locus 4 DPC4), which 
mediates downstream growth inhibitory signaling exerted by TGF-β, is frequently deleted and 
inactivated in 55% of pancreatic cancer. Coupled with aberrant and overactive signaling 
resulting from external growth factors (e.g. EGF, IGF1, FGF, HGF, TGF-β) and tyrosine kinase 
receptors (e.g. EGFR, Her2, Her3, IGF1R, FGFR, HGFR), all these cumulative mutational 
changes serve to activate and amplify a diverse array of intracellular signaling pathways (e.g. 
Ras/Raf/MEF/ERK, PI3K/Akt/mTOR, NF-κB, STAT3, Wnt, Hedgehog, Notch), ultimately 
increasing proliferation, enhancing migration, and promoting apoptosis resistance and survival of 
pancreatic cancer cells (14).  
 
Currently, the only treatment option capable of significantly extending the survival of pancreatic 
cancer patients is surgical resection (3). However, as mentioned earlier, only about 20% of 
patients are diagnosed with surgically resectable disease (6). For the other 80%, chemotherapy 
aiming for symptomatic relief and, unfortunately in many instances, palliative care remains the 
only other viable option to improve the quality of life of patients afflicted with this deadly 
disease (15). Gemcitabine, a nucleotide analog, is routinely prescribed as the first line 
chemotherapeutic agent against pancreatic cancer (3,6). Other agents that have been investigated 
clinically thus far, either as monotherapy or in combination with gemcitabine, have failed to 
significantly improve patient survival or demonstrated greater activity over gemcitabine 
monotherapy (15). These include EGFR inhibitors (e.g. erlotinib, cetuximab) which are only 
minimally effective as they act mechanistically upstream of KRAS, which are typically 
overactive in most pancreatic cancer (16). Anti-angiogenic agents such as VEGF inhibitors (e.g. 
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bevacizumab, aflibercept) and multikinase inhibitors with anti-angiogenic activity (e.g. sunitinib, 
sorafenib, axitinib, semaxanib) have also proven to be futile due to the inherent hypovascular 
stroma surrounding pancreatic cancer cells (10,16). Despite these challenges, many other 
targeted chemotherapeutics are still being actively investigated in the clinic. They include 
JAK/STAT inhibitors (e.g. ruxolitinib and momelotinib), BTK inhibitor (e.g. ibrutinib), IGF1R 
inhibitor (e.g. MM 141), CDK4/6 inhibitor (e,g, palbociclib) (6). Immunotherapy has also 
garnered increasing interest as a potential therapeutic option for pancreatic cancer. Blocking 
immune checkpoint and activating T cell function by inhibiting proteins involved in T cell 
checkpoints such as cytotoxic T-lymphocyte protein 4 with ipilimumab and programmed cell 
death protein with nivolumab and pembrolizumab have demonstrated promising results (16).  
 
Overall, pancreatic cancer represents one of the, if not, deadliest cancer. The low survival and 
high mortality of pancreatic cancer stem from the inability for early detection, which often lead 
to advanced systemic metastatic disease that is difficult to eradicate. While there have been some 
significant progress in elucidating the molecular mechanism of the disease, there is still 
unfortunately a lack of specific and effective treatment options for pancreatic cancer once it 
reaches the metastatic state. As such, a continued and more in depth understanding of the 
underlying molecular pathology of pancreatic cancer holds the key to potentially identify novel 
molecular targets, which may subsequently aid in the development of diagnostic strategies to 
detect premalignant curable pancreatic lesion, and more effective targeted therapies. 
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1.1.2 Brain cancer 
Malignant brain tumors represent one of the most lethal and feared cancer types, not only for 
their dismal prognosis, but also for their devastating effects on patient overall quality of life and 
cognitive function (17). In 2018, there are about 23,889 new cases and 16,830 deaths associated 
with cancers affecting the brain and nervous system in the United States (2). Globally, brain and 
nervous system cancers account for 296,851 new cases and 241,037 deaths in 2018 (4). The 
death rate of cancers of the brain and nervous system had been increasing in both men and 
women (18). While brain cancers are most prevalent in the elderly population, specifically in the 
sixth to eighth decades of life, they are extremely deadly in younger individuals. In fact, brain 
and other nervous system tumors are the top leading cause of cancer–related death in men before 
40 and women before 20 years old (2).   
 
Glioblastoma (GBM) is the most common form and highest grade (grade IV astrocytoma) of 
primary brain malignancy in adults (19). There are approximately 50,000 patients with GBMs 
with 10,000 new cases being diagnosed each year in the United States (20). With dismal 1- and 
5-year survival rates of 35.7 and 4.7 % respectively, GBM is responsible for more than 13,000 
deaths annually in the United States (21,22). The aggressiveness of GBMs primarily stem from 
their pronounced ability to proliferate and infiltrate. GBMs rapidly diffuse into surrounding brain 
parenchyma, and frequently spread to the contralateral hemisphere through the corpus callosum, 
thus confounding local therapy and rendering gross total resection nearly impossible (23-25). 
Interestingly, while GBM is highly invasive, the spread of GBM is mostly confined within the 
central nervous system and systemic metastasis is extremely rare (17). Nevertheless, even 
aggressive radical surgical resection coupled with concurrent chemo- and radiotherapy, GBM 
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remains incurable and frequently recur (26). The median patient survival of GBM is only 14.6 
months with less than 5% of patients surviving past 5 years (19,25).  
 
GBM either develops de novo (primary) or as a result of malignant progression from lower grade 
astrocytoma (secondary) (17). The cells isolated from a single primary GBM tumor are often 
pleomorphic (exhibiting varying size and morphology), along with extensive molecular and 
cellular heterogeneities (27,28). Despite the highly varied intra- and intertumoral molecular 
profiles of GBMs, molecular expression analyses have revealed three core signaling pathways 
that are repeatedly altered and implicated in GBMs. They are namely receptor tyrosine 
kinase/RAS/PI3K signaling which is altered in 88% of GBMs, TP53 signaling which is altered in 
87% of GBMs, and RB signaling which is altered in 78% of GBMs (29). Based on a genome 
wide expression study with unsupervised hierarchical clustering, GBMs can be further classified 
into 4 different transcriptional subtypes based on their molecular neuropathology (30). The 
classical subtype exhibit the most common genetic aberrations of GBM and is characterized by 
EGFR amplification and/or activating point mutation to EGFRvIII, focal homozygous deletion of 
CDK2NA, chromosome 7 amplification paired with chromosome 10 deletion and the lack of 
TP53 mutation (30). The mesenchymal subtype is enriched for mutation/deletion of NF1, TP53 
and CDKN2A, and expression of mesenchymal markers such as CHI3L1 and MET, and 
increased expression of genes involved in TNF and NF-κB pathways (30). The proneural subtype 
display frequent alteration of PDGFRA and point mutations in IDH1, loss of heterozygosity and 
inactivating mutation of TP53, shared gene expression features associated with oligodendrocytic 
developmental gene (e.g. PDGFRA,	NKX2-2	and	OLIC2) and proneural developmental gene (e.g. 
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SOX,	DCX,	DLL3,	ASCL1,	TCF4) (30). Lastly, the neural subtype is the least clearly defined and is 
typified by the expression of neuronal markers like NEFL, GABRA1, SYT1 and SLC12A5 (30).  
 
Neurosurgery is typically indicated for cytoreduction to relieve mass effect, as well as to obtain 
biopsy tissue samples for histologic and molecular characterizations (17). Further eradication of 
tumor mass is achieved with intensity modulated radiotherapy and a DNA alkylating agent, 
temozolomide (17). Currently, the gold standard of care for GBM includes a triple combination 
of surgical resection, radiotherapy and adjuvant chemotherapy with temozolomide, but the 
overall survival of GBM remains unsatisfactory. The median survival of patients receiving such 
triple therapy is only between 15-18 months, with only less than 10% of patients going to survive 
past 5 years (25,31). Bevacizumab, an anti-angiogenic monoclonal antibody targeting VEGF, is 
an emerging drug option for recurrent GBM (32,33). While initial studies on the use of 
bevacizumab for recurrent GBM have demonstrated slight clinical improvement and longer time 
to progression, no overall survival benefits were observed (34). In fact the primary use of anti-
angiogenic is mostly to increase vascular permeability for symptomatic relief of neurologic 
symptoms associated with brain edema (17). A biodegradable polymer with alkylating carmustin 
is also used for implantation into tumor bed after surgery with yet only modest survival benefits 
(35). Other physical and molecular-targeted therapies have been investigated but none have 
demonstrated significant improvement over conventional management strategies. These include 
tumor treatment fields with alternative electrical current (36), EGFR inhibitors (e.g. erlotinib, 
gefitinib) (37) and immunotherapy with checkpoint PD-1 inhibitor (e,g, nivolumab, 
pembrolizumab ipilimumab) (38) or chimeric	antigen	receptor	T	cell	therapies	(39). 
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While the prognosis for GBM is generally poor, there are still several patient specific factors that 
correlate with improved outcomes and better survival. The commonly used prognostic factors for 
long-term GBM survival include age at presentation, Karnofsky performance score, tumor size 
and location, tumor histology and aggressiveness of treatment modality, but they are often 
confounded by patient comorbidities, and thus rarely affect GBM treatment decisions (40). 
While increasing evidence that clinically relevant distinct molecular subtypes of GBM exist, 
these molecular subtypes also play limited roles in guiding clinical decisions. Aggressive therapy 
seems to be able to delay mortality in the classical and mesenchymal subtypes, while patients 
with the neural and proneural subtypes generally survive longer (41). Importantly, patients with 
the neural or proneural subtypes are also often associated with younger age, confounding the true 
utility of using molecular subtypes as independent prognostic marker for GBM survival (30). 
 
Recent advances in proteomics and genomics have revealed novel molecular markers as 
independent predictors of GBM survival. One of the most notable molecular predictor of GBM is 
the methylation status of O6-methylguanine-DNA methytransferase (MGMT) promoter, an 
enzyme responsible for DNA repair (42). MGMT promoter methylation is associated with longer 
survival and enhanced chemosensitivity to temozolamide, as reduction in DNA repair capacity 
arising from MGMT silencing generates more unrepaired DNA lesions that can subsequently 
induce more effective cytotoxic killing in response to temozolamide (43). Importantly the overall 
survival of patients with methylated MGMT promoter is almost doubled from 12.7 months to 
21.7 months, along with a marked increase in 2-year survival rate from 14% to 46% (43). 
Despite being an independent and favorable predictive factor to temozolamide responsiveness 
and GBM survival, MGMT promoter methylation status has yet to attain broad clinical 
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applicability. This is primarily attributed to the lack of standardized and reliable methods to 
accurately classify a patient’s MGMT methylation status, which in itself also suffer from 
significant intratumoral heterogeneity (44,45).  
 
Another popular and emerging molecular predictor for GBM survival is the mutation status of 
isocitrate dehydrogenase (IDH) (46). IDH1 and IDH2 are enzymes that catalyze oxidative 
decarboxylation of isocitrate to alpha ketoglutarate, while in the process also reduce NADP+ to 
NADPH (47). The most common IDH mutation is a replacement of arginine with histidine 
residues at position 132 of IDH1 (R132H), which causes the enzyme to instead reduces alpha 
ketoglutarate to 2-hydroxyglutarate while converting NADPH to NADP+ (48). 2-
hydroxyglutarate is an oncometabolite that may contribute to tumorigenesis (48). Decreased 
formation of alpha ketoglutarate also leads to increased level of HIF-1 alpha that can promote 
cell growth and angiogenesis (49). Mutation in IDH genes constitute one of the earliest and 
possibly also initiating mutational events in gliomas, as it is most commonly observed in lower 
grade II and III gliomas and secondary GBMs (80%) but rare in primary GBMs (5%) (46,50). 
Since secondary gliomas are more often observed in younger patients, IDH1 mutation, which 
happens to be more dominant and prevalent in progressive secondary gliomas, is therefore 
associated with better prognosis and longer survival (46,50). The prognostic value of IDH1 in 
primary GBM, however, remains to be elucidated. 
  
Similar to pancreatic cancer, GBM is another form of highly aggressive and deadly cancer with 
dismal patient prognosis. While great strives have been taken to understand the molecular 
pathology of GBM, the inherently complex and intricate heterogeneities of GBM present 
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significant challenges for scientists and clinicians to fully grasp the mechanism underscoring the 
their aggressiveness and come up with effective therapeutic strategies. In view of the extremely 
short average lifespan of GBM patients and the rapid decline in their quality of life, there is 
therefore also a need to devise a better way to predict patient survival, and potentially also 
response to therapy, that can supplement currently available prognostic markers for the ultimate 
goal of personalized GBM care.  
 
1.2 Cell migration and cancer metastasis 
Cancer pathogenesis is a complicated and orchestrated multi-step process in which normal cells 
acquire multiple activating mutations that enable them to proliferate uncontrollably and invade 
surrounding tissues (1). In order for normal cells to transform into cancerous cells and form a 
primary tumor, they need to acquire certain key characteristics or hallmarks. These key 
characteristics include the ability to sustain proliferative signaling, evade growth suppressors, 
resist cell death, enable replicative immortality, induce angiogenesis, reprogram energy 
metabolism and evade immune destruction (1). Once a primary tumor is formed and successfully 
colonizes the initial site, the cancer cells will then start to detach from its original location, enter 
the circulatory system and migrate to distant organs to establish secondary colonies in a process 
known as metastasis (51).  
 
Cancer metastasis is a highly coordinated process by which tumor cells disseminate from a 
primary tumor to secondary sites (51). Most of the cancer-related deaths are caused by 
metastasis. In fact, owing to the ability to effectively contain and eradicate primary tumors, the 
5-year survival rates of most cancer types exceed 90% if the patients are diagnosed with 
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localized tumors (2). In contrast, the survival rates of patients suffering from distant metastatic 
diseases reduce considerably to less than 20% (2). The metastatic cascade is a multistep process, 
in which cancer cells have to first degrade surrounding extracellular matrixes, migrate away from 
the primary tumor, squeeze through and enter the circulatory system via intravasation, resist 
hydrodynamic shear stress, roll and arrest on endothelial wall before eventually extravasating 
and finally migrating into and colonizing a distal organ to eventually form a secondary tumor 
(52). Throughout this process, tumor cells must interact, migrate and navigate considerably 
different microenvironments including tissue at the primary and distal sites as well as within the 
circulatory system (6).  Interestingly, there are some cancers such as GBMs that rarely 
metastasize out of the primary sites (i.e. central nervous system) (17). However these cancerous 
cells still exhibit enhanced mobility within the brain itself, and can invade locally and infiltrate 
across the corpus collosum to the other brain hemisphere (23-25). Cell migration is therefore 
pivotal not just for distant metastasis but also for local invasion, and is hence a crucial 
determinant for the aggressiveness of cancer and more importantly patient clinical outcome. 
 
In this dissertation, we aim to understand and predict the aggressiveness of cancer cells by 
focusing on their ability to migrate and metastasize. We first start by providing a comprehensive 
review of the intricate, complex and plastic mechanisms in which cancer cells utilize to move in 
both unconfined and confined microenvironments that the cancer cells typically experience in 
vivo (Chapter 2). Next, by using pancreatic cancer as a case study, we characterize and delineate 
the role of an oncogenic membranous protein, podocalyxin, on the migratory behavior and 
metastatic potential of cancer cells (Chapter 3). We then attempt to make use of the knowledge 
we know about cell migration for useful clinical application. Specifically, we describe the 
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development of a novel microfluidic-based device, that can rapidly and unbiasedly assess the 
migratory and proliferative phenotypes of patient-derived GBM specimens, to be used as a 
prognostic tool for GBM patient survival (Chapter 4). Finally, we conclude by discussing 
potential future directions for each of the different projects centering on cell migration (Chapter 
5 and 6). In sum, this dissertation reviews and illustrates how cell migration can be used to both 
understand the molecular basis underpinning cancer aggressiveness with basic science, as well as 





Chapter 2 - Exposing Cell-itary Confinement: Understanding The 
Mechanisms Of Confined Single Cell Migration 
2.1 Abstract 
Cells in vivo migrate in a complex microenvironment and are subjected to varying degrees of 
physical confinement provided by neighboring cells, tissues and extracellular matrix. The 
molecular machinery that cells utilize to migrate through confining pores or microtracks shares 
both similarities and differences with that used in unconfined 2D migration. Depending on the 
exact properties of the local microenvironment and cell contractile state, cells can adopt distinct 
phenotypes and employ a wide array of mechanisms to migrate efficiently in confined spaces. 
Remarkably, these various migration modes are also interconvertible and interconnected, 
highlighting the plasticity and inherent complexity underlying confined cell migration. In this 
chapter, an overview of the different molecular mechanisms utilized by cells to migrate in 
confinement is presented, with special emphasis on the extrinsic environmental and intrinsic 
molecular determinants that control the transformation from one mechanism to the other. 
 
2.2 Introduction 
Cell migration is an integral process for diverse normal physiological and homeostatic functions, 
including embryogenesis, tissue morphogenesis, wound healing and immune response, as well as 
pathological processes, such as chronic inflammatory diseases and cancer metastasis (53). There 
is thus a dire and important need to understand the biochemical and physicomechanical driving 
forces underlying cell motility, as it can provide critical insights to inform the development of 
novel and effective therapeutic strategies to ensure proper physiological cellular functions or 
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abate diseases. However, cell migration is an intricate and well-orchestrated biological 
phenomenon that is modulated by multiple intrinsic (i.e., cell type, actomyosin contractility, 
integrin-mediated adhesion, cellular and nuclear deformability etc.) and extrinsic factors 
(extracellular matrix (ECM) composition and stiffness, porosity, adhesiveness, elastic behavior 
etc.) (54,55). Much of what we currently know about the mechanisms of cell migration stems 
from in vitro experiments performed on 2D planar surfaces. Although 2D migration is relevant to 
certain physiological processes like wound healing and neutrophil trafficking on inflamed 
endothelium, 2D in vitro migration models fail to recapitulate the complex topographical cues 
presented by the tissue microenvironment that cells experience in vivo (56). 
 
Cells in vivo are typically embedded in and migrate within 3D dense fibrillar ECM with narrow 
pores. Many of times, the pores present in the ECM network are smaller than the average cell 
diameter, ranging from 1µm to 20µm (57). In such instances, cells have to either rely on matrix 
metalloproteinase (MMP)-dependent pericellular proteolysis to degrade surrounding ECM to 
generate tracks large enough for cells to migrate into (58), or MMP-independent alternative 
modes of migration where cells rearrange cytoskeleton and increase actomyosin contractility to 
facilitate cellular and nuclear deformation and translocation through tight pores (59-61). In 
addition to tracks generated de novo by migrating cells with MMP, there also exist pre-formed 
3D longitudinal ECM-free channels that provide paths of least resistance in which cells can 
exploit to migrate efficiently. These in vivo 3D longitudinal channels can manifest themselves in 
many forms and are widely prevalent in the human body. Many of these 3D channels form 
between the connective tissue and the basement membrane of nerve, muscle and epithelium (54), 
and in fibrillar interstitial tissues between adjacent bundles of collagen fibers (62). Microtracks 
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are also present along and within blood (63,64) and lymphatic vessels (65), as well as in white 
matter tracks and perivascular spaces within the brain (66). Additionally, follower cancer cells 
can also migrate in 3D longitudinal tracks remodeled by leader fibroblasts or surrounding 
stromal cells (67,68). These 3D channels vary considerably in cross sectional area, ranging from 
10 to 1000 µm2 (57). As such, cells in vivo have to navigate through tight spaces, be it pores in 
ECM or tunnel-like tracks, and experience different degrees of physical confinement. Numerous 
recent studies have provided mounting evidence highlighting the differences between unconfined 
2D migration and confined migration in terms of cellular morphology, intracellular signaling and 
molecular mechanisms (69). Indeed, many of the hallmarks of conventional 2D migration model 
are found to be dispensable in confined microenvironments, suggesting a specific and critical 
role that physical confinement plays in modulating cellular responses. 
 
In this chapter, we focus on the behaviors and mechanisms by which single cells migrate in 
confinement. Specifically, confined single cell migration is defined as the phenomenon in which 
a single cell (not tethered or attached to neighboring cells) migrates in an environment where at 
least one of the three dimensions is about or below cell-size; in such a case, the cell has to form 
additional non-basal contact with the surrounding matrix and deform its cytoplasm and/or 
nucleus in order to move forward. Recent advances in bioengineering and microfabrication 
techniques have enabled us to engineer in vitro models to study confined single cell migration at 
precisely controlled experimental conditions mimicking aspects of the in vivo microenvironment. 
These models include polydimethylsiloxane (PDMS) microfluidic devices, microcontact printed 
patterns of prescribed geometries, micro/nanogrooves substrates, vertical confinement devices 
and 3D patterned hydrogels. A detailed description of the various techniques and systems to 
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simulate physiologically-relevant confined conditions can be found in a recent comprehensive 
review (70). Nevertheless, these experimental models are vital, as they have provided us with a 
rapid and high-throughput platform to study the mechanisms of confined single cell migration, 
which are discuss below. 
 
2.3 Conventional paradigm of 2D cell motility cycle 
Most of our existing understanding of cell migration originates from initial observations showing 
how metazoan cells adhere and crawl on 2D flat surfaces (71,72). Since then, a plethora of 
studies have been carried out to decipher the various steps involved in this highly orchestrated 
process termed as cell motility cycle. The detailed step-by-step mechanisms of 2D cell motility 
cycle have been extensively reviewed elsewhere (72-75), but they can be briefly summarized 
into four sequential steps, namely protrusion, adhesion, contraction and retraction. At first, a 
stationary cell receives motogenic signals, either biochemically with growth factors (76,77) or 
cytokines (78) or physicomechanically via physical confinement, differential substrate rigidity 
(79) or electrical current (80), and becomes polarized, developing distinct leading and trailing 
edges. This polarized cell state is achieved primarily by internal polarization of microtubule and 
secretory apparatus (81) that direct the vesicular transport of lipids (e.g. phosphatidylinositol 
(3,4,5)-trisphosphate, PIP3) (82) and proteins (e.g. small Rho GTPases such as Rac1 and Cdc42 
(83,84) to localize polarized signals. Accumulation of these polarized signals at the leading edge 
facilitates Arp2/3-dependent polymerization of branched actin filaments (F-actin), initiating the 
formation of wide, fan-like membrane protrusions known as lamellipodia (85). Adhesion 
molecules such as integrins present on the lamellipodial protrusions then bind to matrix ligand, 
forming new small nascent adhesions underneath the leading edge (86). RhoA and formin family 
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of actin nucleators such as mDia1 and mDia2 subsequently assemble actin stress fibers to 
connect with adhesions sites (87-89). Actomyosin contraction of the stress fibers pulls and exerts 
tension on nascent adhesions, enlarging and maturing them into focal adhesions (FAs) (90). At 
the same time, actomyosin contractility also enhances the contractile tension between the leading 
and trailing edge of the cell. The overall increase in cellular contractility, coupled with localized 
increase in myosin II activity towards the back of the cell, signals the disassembly of rear 
adhesions, releasing the rear of the cells from the 2D surfaces in a process known as trailing edge 
retraction, consequently leading to directed cell movement (91). As the cycle progresses, 
retrograde F-actin flow helps to push membrane and lipids rearward and position the nucleus 
towards the back of the cells, resetting the cell to respond to the next round of motogenic signal 
(92). 
 
While it is widely believed that most epithelium-derived cells migrate in similar cyclic manner 
on 2D environments (53), the story becomes increasingly more complicated and less predictable 
as cells transition to the more physiologically relevant 3D environments where they are now 
confined within dense fibrillar matrix or preexisting migration tracks. Some of the hallmarks of 
the conventional 2D cell motility cycles, such as substrate adhesions and actomyosin 
contractility, are sometimes even dispensable in cells migrating in complex in vivo 3D 
environment. In fact, numerous studies conducted over the past decade have demonstrated that 
cells are extremely plastic and are able to adopt a multitude of different migration mechanisms in 
response to their surrounding environment to enable efficient locomotion. A schematic of the 




2.4 Pseudopodial-based mesenchymal confined migration 
2.4.1 Comparison to 2D mesenchymal migration 
In 3D artificial hydrogel networks in vitro and ECM tissues in vivo, cells can migrate with an 
elongated morphology with protrusions driven by actin polymerization, which we broadly term 
as pseudopodia and includes actin-rich structures such as lamellipodia, filopodia and 
invadopodia, similar to classical 2D mesenchymal migration (59,93,94). This mode of migration 
is also evident in pre-formed tunnel like conduit in vivo, in collagen/polyacrylamide-based 
patterned microtracks (79,95,96) and in PDMS microfluidic microchannel devices (97-99). Cells 
cultured on 1D lines created by microphotopatterning or microcontact printing, in which cells are 
laterally confined due to limitation of adhesion sites, also exhibit similar elongated morphology 
as they do on oriented 3D fibrillar ECM in vivo, where a strong correlation between migration 
speed and movement persistence is noted (94,100).  
 
During confined 1D or 3D (1D/3D) mesenchymal migration, cells employ similar polarized 
signals of Rho-GTPases and PIP3 to form actin-based pseudopodia protrusions at the leading 
edge like they do on 2D surfaces, form adhesions with the substrate via integrins and activate 
actomyosin contractility to subsequently detach cell rear (93,101). Though both 2D and 1D/3D 
confined mesenchymal migration appear to be rather analogous, there still exist some 
fundamental differences between the two in terms of cytoskeletal and adhesion dynamics, 
dependence on actomyosin contractility and force generation. First, 1D or 3D confinement 
induces drastic cytoskeletal remodeling accompanied by fewer F-actin stress fibers (97,102). In 
confined cells, actin is primarily localized at the cortex and/or concentrated on the leading edge 
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as actin-rich wedge-like slab (96,103). Second, the role of adhesion is reduced (but not 
necessarily eliminated) in confinement compared to 2D migration, with FAs demonstrating a 
smaller size and more diffuse cytoplasmic distribution rather than distinct locations around the 
cell periphery underneath the pseudopods on 2D surfaces (97,102). Third, while actomyosin 
contractility is indispensable for 2D migration, under specific conditions for example within 
rigid PDMS-based confined microchannels, cells are able to migrate efficiently even if 
actomyosin contractility is disrupted (97,104). However, the role of actomyosin contractility in 
confinement can also be cell-line dependent, and in certain instances are key for efficient 
confined migration (98,105). Fourth, the traction forces exerted by cells in confinement (either in 
microchannels or on 1D printed lines) are significantly lower than those on 2D flat surfaces, and 
are typically directed towards microchannel walls instead of to the center of the cell on 2D 
surfaces (102,106). In fact, phosphorylated myosin light chain (pMLC) dependent traction 
generation is not required for migration in microtracks (96). All these salient differences suggest 
that cells are able to modulate intracellular signaling, thereby optimizing their mobility in 
response to varying degree of confinement. In order to fully understand the mechanisms of 
confined mesenchymal migration, we have to dissect each of these factors individually and 
methodically.  
 
2.4.2 Molecular determinants of confined mesenchymal migration  
Pericellular proteolysis is essential for maintaining the mesenchymal phenotypes of tumor cells 
in 3D matrices. In 3D fibrillar collagen gels, HT1080 and MDA-MD-231 cells display a 
mesenchymal morphology during migration through proteolytically-generated tube-like tracks 
with β1 integrin co-clustering with MT1-MMP at interaction sites with collagen fibers; MT1-
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MMP is a membrane-associated surface protease whose activity is needed for focalized ECM 
degradation (59). This mode of mesenchymal 3D migration can also be observed in vivo for 
HT1080 cells migrating in the mouse dermis as imaged with intravital multiphoton microscopy. 
Interestingly, inhibition of collagenolysis with MMP inhibitors converts mesenchymally 
migrating cells into a more spherical amoeboidal phenotype (discussed in section 4) that is 
phenotypically and mechanistically distinct from pseudopodial migration without negatively 
affecting migration speed. In the presence of pre-existing microtracks, either generated in vitro 
with laser ablation or micromolding in 3D hydrogel matrices or in vivo by surrounding or leader 
cancer-associated stromal cells, cells can still assume a mesenchymal migratory phenotype even 
when MMP functions are compromised or absent (95,96). ECM-free microtracks enable rapid 
and persistent migration of non-invasive MCF10a breast epithelial cells and MMP-depleted 
MDA-MD-231, which are unable to invade otherwise in 3D collagen matrices (95). Microtracks 
provide a clear unimpeded path of low resistance for migrating cells, reducing the requirement 
for cell-matrix mechanocoupling, traction force generation and matrix remodeling required for 
efficient migration, thereby lowering the mechanistic threshold for local tissue invasion.  
 
Matrix adhesion is needed for pseudopodial migration on 2D but its role in confinement is 
markedly diminished. On 2D surfaces or in wide microchannels emulating a 2D 
microenvironment, FAs (as visualized with phospho-paxilin and phospho-FAK) are localized 
alongside at the periphery of pseudopod protrusions as distinct complexes. In contrast, FAs are 
significantly reduced in size in cells migrating inside narrow microchannels (<20µm), and 
display a uniform distribution along the cell’s migratory axis (97). On 1D lines, similar long 
linear localization of adhesion components such as α5 integrin, β1 integrin, FAK, vinculin and 
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paxillin are also observed spanning the entire length of the cell axis (94). As a result of the 
diminished role of substrate adhesion in confinement, blocking β1 integrin has little or no 
appreciable effect on migration speed in narrow channels or cell-scale collagen microtracks 
despite completely abrogating planar 2D migration or reducing speed in 3D collagen matrices 
(96,97). 1D migration speed is also resistant to varying ECM ligand density, as migration speed 
exhibit a saturating relationship as ligand density increases rather than a classical biphasic 
phenomenon observed on 2D surfaces (94). It is however worth noting that while β1 integrin is 
not required for the maintenance of migration speed in microtracks, they are needed to promote 
the elongated morphology of the migrating cells. Instead of a stable elongated morphology with 
pseudopodial protrusion, β1-depleted cells undergo rapid dynamic oscillation between elongated 
(mesenchymal) and spherical (amoeboidal) morphologies (96). 
 
The effect of actomyosin modulation on confined pseudopodial migration is more variable and 
dependent on the cell type and matrix dimensions. Inhibiting myosin II activity with blebbistatin 
impairs migration of fibroblasts and human epithelial keratinocytes on 1D lines and in 3D ECM 
(94). In 3D collagen gels, ROCK inhibition with Y27632 significantly diminishes human 
foreskin fibroblast lamellipodial-based migration, as for other epithelial cells (107). However, 
blebbistatin treatment on human foreskin fibroblasts migrating on top of 2D cell-derived matrix 
is unaffected, consistent with effect of blebbistatin on 2D fibroblast migration (108). On the 
other hand, confined migration of various cancer cells, such as MDA-MD-231 breast cancer cells 
and S180 murine sarcoma cells, is resistant to inhibition of actomyosin contractility. Whilst 
inhibiting the Rho/ROCK/myosin II signaling cascade with CT04/Y27632/blebbistatin-ML7 
suppresses migration on 2D unconfined substrates, these pharmacological interventions have no 
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appreciable effect on confined cell migration through 3µm narrow microchannels (97,99). Along 
these lines, modulation of actomyosin contractility via the use of blebbistatin (inactivation) or 
calyculin A (activation) does not alter the traction forces exerted by NIH-3T3 or HOS human 
osteosarcoma migrating in narrow channels (106).  
 
Microtubules play a key role in regulating the velocity, directionality and persistence of cell 
migration in confinement. On 1D microprinted lines, the centrosome (pericentrin) is located 
behind of nucleus (versus in front of nucleus on 2D) (94,109) while stabilized microtubules (i.e., 
detyrosinated glu tubulin) are localized as polarized parallel bundle arrays anterior to nucleus, 
extending into lamellipodia (94,96). Confinement induces alpha-tubulin localization and 
microtubule growth towards the leading edge, as opposed to the rather isotropic microtubule 
polymerization from microtubule-organizing center on 2D surfaces. Interfering with microtubule 
dynamics with either taxol (which prevents depolymerization) or colchicine (which promotes 
disassembly) significantly decreases cell velocity and directionality in 3µm narrow channels, 
indicating a critical role of microtubule in establishing migratory persistence in confinement 
(97). Similarly, inhibiting microtubule polymerization with nocodazole or microtubule 
depolymerization with taxol causes rounded cell morphology with uncontrolled protrusions in all 
directions, decreases motile fraction and reduces migration speed along 1D lines, microtracks 
and in 3D ECM, suggesting that MT is important in maintaining uniaxial morphology and 
alignment in 1D and 3D migration (94,96).  
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2.5 Bleb-based amoeboidal migration  
2.5.1 General morphological and molecular features of amoeboidal migration 
When actomyosin contractility is elevated and/or cellular adhesions are diminished, cells 
typically transform from an elongated, spindle-like mesenchymal morphology that is dependent 
on adhesion and actin-based pseudopodial protrusion into a rounded amoeboidal morphology 
resembling that of Dictyostelium amoeba and migrating leukocytes. This process is termed as 
mesenchyme-to-amoeboid transition (MAT), and has been observed both in vitro and in vivo in 
mouse xenograft models (61,110). Amoeboidal migration is associated with rounded cell 
morphology with spherical membrane protrusions that are devoid of filamentous actin known as 
blebs, limited and diffuse distribution of cellular adhesion (e.g. β1, paxillin) and higher 
actomyosin contractility (61). Moreover, amoeboid cells also exert lower traction forces and 
exhibit higher cortical tension than mesenchymally-migrating cells. Traction forces exerted by 
Walker 256 carcinosarcoma when they are undergoing non-adherent blebbing motion are several 
orders of magnitude lower than those exerted during integrin-based FA-dependent mesenchymal 
motility (111).  Furthermore, the forces are directed outwards from the cell body to expand rather 
than contract the substrate in order to generate sufficient friction to drive migration. Lateral 
expansion of cells are also able to generate enough traction by extending inter-digitating with the 
surrounding discontinuous confined matrices to provide traction in the absence of adhesion 
(110). 
 
Cell mechanics represents one of the key determinants of MAT. Whether or not a cell prefers to 
form blebs or lamellipodia depends on a delicate balance between actin protrusivity, as 
controlled primarily Rac1 and Arp2/3 complex, and cellular contractility, as dictated by the 
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RhoA/ROCK/myosin signaling axis. The transition between these two phenotypes can be 
achieved even locally at the cell leading edge without any global change in cell shapes, polarity 
and adhesion (111). Activating Rac1, which recruits and activates downstream Arp2/3 to 
facilitate nucleation of actin filaments, switches blebs to lamellipodia, increases cell cross-
sectional area and decreases cortical tension. This lamellipodia-promoting role of Rac1 is 
intimately linked with Arp2/3 activity, whose inhibition via the pharmacological agent CK666 or 
via siRNA decreases lamellipodial formation in Walker 256 carcinosarcoma (111). Conversely, 
Rho/ROCK/myosin signaling promotes rounded bleb-associated mode of motility. Inhibiting 
actomyosin contractility with RhoA inhibitor C3 transferase, ROCK inhibitor Y27632 or myosin 
II inhibitor blebbistatin decreases bleb formation while promoting lamellipodia protrusion in 
Walker 256 Carcinosarcoma (111) as well as A375m2 melanoma and LS174T colon carcinoma 
cells (61). On the other hand, increasing cell contractility via the use of constitutively active 
ROCK or overexpression of Rho enhances cell blebbing.  
 
Cells prefer to switch to an amoeboidal mode of migration when cell-ECM adhesion is 
diminished or eliminated. This can be achieved by either downregulating integrins or decreasing 
substrate adhesiveness (112,113). Typically, amoeboidal migration occurs without FAs, and can 
proceed efficiently even if components of the adhesion machinery such as integrin α1β2 or talin 
are knocked down or adhesion is completely prevented in non-adhesive PDMS microchannels or 
in the presence of EDTA which chelates divalent ions needed to establish integrin binding 
(112,113). This is in stark contrast to elongated mesenchymal migration where motility ceases 
when adhesion is eliminated. The effect of migration phenotypes exerted by changing substrate 
adhesiveness is also rapid and reversible, as cells (suspension subline of Walker 256 
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carcinosarcoma) plated on micropatterned surface with alternating adhesive and non-adhesive 
areas form lamellipodia immediate upon contacting adhesive region which then quickly 
disappear and resumed blebbing when they move on to non-adhesive region (111). In HT1080, 
MAT is associated with decreased surface coverage of α2β1 integrin heterodimers, diminished 
integrin-mediated adhesion and downstream signaling via p-FAK (113). Consequently, 
inhibition of calpain2 and Src kinase, which participate in FA turnover, suppressed mesenchymal 
invasion drastically but exerted little or no effect on amoeboid migration where the role of 
adhesion is already diminished. Interestingly, Rho/ROCK inhibition is able to restore integrin 
function and calpain2 sensitivity, and reverses MAT, indicating that Rho/ROCK signaling also 
contributes to integrin modulation in addition to enhancing actomyosin contractility to promote 
amoeboid migration. 
 
Besides altering cellular contractility and adhesion, inhibiting matrix metalloproteinase (MMP) 
can also induce MAT. HT1080 and MDA-MB-231 transform from an elongated mesenchymal 
into a spherical amoeboidal morphology that still move at the same speed upon MMP inhibition 
in vitro in 3D collagen gels as well as in vivo (59). Similar phenotypic conversion is also 
observed for BE and WM266.4 melanoma cells during invasion through 3D matrigels (61). This 
protease-independent amoeboidal migration occurs without any matrix remodeling and 
generation of any migration tracks, suggesting that the cells have to now squeeze through the 
tight collagen fiber network in order to maintain efficient migration. Indeed, during MAT, the 
cells lose their β1 integrin clusters and surface localization of MT1-MMP, and develop diffuse 
cortical actin rims and narrow region of constriction rings to aid in deforming the cells through 
narrow pores.  
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It is noteworthy that MMP inhibition is certainly not a prerequisite for amoeboidal migration. To 
the contrary, a paradoxical elevated secretion of MMPs, specifically MMP9, was observed in 
melanoma cells that are already prone to migrate amoeboidally as compared to their elongated 
mesenchymal counterparts (114). MMP9 promotes amoeboidal migration through activating 
actomyosin contractility by binding to CD44 receptor in a non-catalytic, paracrine and autocrine 
manner. In turn, the increase in actomyosin contractility activates ROCK/JAK/STAT3 cascade, 
forming a positive feedback loop that upregulates MMP9 gene expression. Indeed, MMP9 
expression was shown to increase over the course of melanoma progression and is highly 
enriched in invasive lesion front, which incidentally also display more rounded amoeboidal 
morphology positive for p-STAT3.  
 
The roles of MMP on MAT are hence variable and cell-line dependent. Nevertheless, the ability 
for the tumor cells to sustain efficient 3D motility via a protease-independent mechanism and the 
non-catalytic role of MMPs in promoting amoeboidal migration could explain the many failures 
of MMP inhibitors in human clinical trials despite demonstrating promising potentials in halting 
migration in vitro and in vivo (115,116).  
 
2.5.2 Bleb-based migration in physical confinement 
Fascinatingly, physical confinement triggers MAT. Using a sandwich system consisting of two 
surfaces of tunable surface adhesion characteristics, normal human dermal fibroblasts have been 
shown to retract and adopt a more compact phenotype with fewer lamellipodia but more 
elongated pseudopodia when confined to a low ceiling of 3-5µm (117). Under high confinement 
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(i.e., 3µm) and low adhesion, most normal human dermal fibroblasts become immobile with very 
rounded morphology characterized by continuous uncoordinated blebbing activity. A portion of 
these confined cells, however, display a round cell body with small leading edge local protrusion 
and are able to move with an amoeboidal mode of migration, termed as A1 blebbing mode. This 
subpopulation of cells exhibiting the A1 blebbing mode migrates faster than the remaining 
spread cells that display a partial mesenchymal morphology when being vertically confined 
(117). Similarly, a suspension subline of Walker 256 carcinosarcoma that typically form non-
adherent blebs migrate limitedly on 2D surface, but efficiently when being confined vertically 
between glass and agarose and within 3D gels with directional persistence (111,112). 
Confinement in this case is essential for cell motility as it enables force transmission in the 
absence or near absence of adhesions to substrate. 
 
Indeed, computational modeling suggests that cell matrix adhesion is dispensable for cell 
migration in discontinuous confined environments where blebbing predominates (110). On an 
unconfined 2D surface, cells migrate with an elongated morphology with actin-driven protrusion, 
and highest velocity is predicted at intermediate cell-ECM adhesion. This biphasic migration 
speed behavior to substrate adhesiveness has been verified experimentally with multiple cell 
lines on 2D platforms (98). While on discontinuous confined environment, such as those 
represented by dense fiber mesh network, blebbing mode of migration mechanism dominates and 
maximum cell velocity scale inversely with adhesion. The modeling prediction is verified in 
vitro where β1 integrin or talin depletion reduces migration on 2D surfaces but increases 
amoeboidal migration speed in confined environments. 
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Under high confinement and low adhesion, numerous cell types, including normal or 
transformed cells of either epithelial or mesenchymal origins, are able to adopt an additional 
mode of stable bleb-based migration, termed as A2 blebbing, characterized by an elongated 
ellipsoidal morphology with a large rear uropod and a smooth rounded leading edge, reminiscent 
of migrating neutrophils (117). Cells displaying the A2 blebbing morphology typically migrate 
faster than their A1 blebbing counterparts. The proportions of cells that display the A2 blebbing 
morphology for each cell type though vary considerably across the group depending on their 
basal cellular contractility. In general, cell lines that display higher intrinsic cortical contractility 
also have a higher proportion of cells that migrates via the A2 mode. Similar fast and 
directionally persistently A2 mode of bleb-based migration is also evident in zebrafish 
embryonic progenitor cells both in vitro under vertical confinement between two planar glass 
slides though these cells are immobile on 2D surfaces, and in vivo during early development, for 
instance at sites of local wounding site where there exist higher actomyosin contractility (118). 
 
Mechanistically, A1 and A2 blebbing differ in their requirement for actomyosin contractility. 
Increasing contractility via calyculin A treatment or knocking down MYPT1, the PP1 partner 
targeting myosin II, results in an increased frequency of A2 blebbing cells. The converse is 
accordingly true upon cell treatment with the ROCK inhibitor Y27632 or myosin II inhibitor 
blebbistatin where more cells exhibit the A1 rather than A2 mode of migration (117). 
Additionally, treating zebrafish embryonic progenitor cells with serum or lysophosphatidic acid, 
a serum phospholipid capable of activating cortical contractility via the Rho/ROCK pathway, 
also transforms cells reversibly into the A2 stable bleb morphology, thereby providing further 
evidence that A2 blebbing depends on high myosin-based contractility (118). 
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The organization and role of actin are also different between the A1 and A2 blebbing migration 
modes although they both lack FAs and organized actin stress fibers. In A1 cells, fast retrograde 
flow of actin is localized at the small protruding leading edge. In A2 cells, however, actin and 
myosin II are absent from the cell front but instead concentrated around the cell cortex where the 
uropods are. Both actin and myosin II exhibit fast and global cortical retrograde flow around the 
central region of the A2 cells, with little to no flow towards the rear, suggesting that the uropod 
is a dragged passive body (117). Similar rearward gradient of contractility, cortical actomyosin 
enrichment and retrograde flow are also evident in non-adherent blebbing Walker 256 
carcinosarcoma (112). Relaxing cortical contractility at the rear of the cells but not the front by 
cortex ablation decreases migration velocity. Via computational modeling, it was revealed that 
rearward contractility gradient is able to drive adhesion-independent amoeboidal migration via 
two complementary mechanisms. First, frictional forces from counteracting retrograde cortical 
flow generate propulsive force. Second, when the friction becomes sufficiently large enough to 
hold cell body in place, rearward contractility of myosin results in leading edge expansion, 
leading to net cell movement. Interestingly, the model predicts that cell migration velocity 
correlates not with amplitude of stress exerted by the cells but rather velocity of the actomyosin 
flow, highlighting the importance of cortical actomyosin flow in facilitating amoeboidal A2 
migration. In summary, cells could fall into two different contractility regimes when they are 
undergoing MAT following vertical confinement. Under a high contractility regime, global 
cortical actin retrograde flow results in myosin-dependent mechanical instability of cortex, 
leading to formation of A2 stable blebs. When contractility is inhibited, the cortex become more 
stable, allowing for more protrusive activity, ultimately leading to an A1 blebbing phenotype. 
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2.5.3 Establishing polarity in blebbing cells 
Amoeboid migration is responsive to chemotractant cues and is not a form of random motility 
(61). In mesenchymal cells, specific spatial localization of Rac1, Cdc42 and PIP3 are needed to 
establish polarization and direction of migration, but such differential spatial enrichment is 
absent in amoeboid cells (93). So then how are amoeboidal cells able to achieve similar 
polarization? Localization of ezrin/moesin/radixin (ERM) protein family, which are linkers 
between the plasma membrane and actin cytoskeleton, appears to be involved in this process. 
Asymmetry contractility is positively related with asymmetry in cortex-membrane linkage (110). 
ROCK is able to phosphorylate ERM, and ezrin localization is also dependent on Rho activity. In 
fact, colocalization of contractile machinery (pMLC) and pERM promotes blebbing and favors 
migration in confinement (119). This is achieved by the STRIPAK components, MST3/4 kinases 
that locally coordinate phosphorylation of ERM and inhibit dephosphorylating of MLC, leading 
to increased phosphorylation and cortical colocalization of MLC and ERM, resulting in 
enhanced cortex-membrane linkage and more frequent membrane blebbing. Indeed, increasing 
actomyosin-membrane linkage with MST3/4 overexpression is associated with increased In vivo 
metastasis from mammary fat pad to lymph node. Colocalization of actomyosin contractile 
function and ERM proteins promotes more efficient pulling of contractile cytoskeleton on the 
plasma membrane, exerting more force on the plasma membrane instead of being coupled to 
integrins via FAs, thereby producing more blebbing. 
 
A recent study on zebrafish embryonic progenitor cells, however, suggests that that polarization 
in A2 migrating cells is initiated by stochastic contractility that is driven by cortical network 
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instabilities and subsequently maintained by a positive cortical feedback loop (118). Specifically, 
addition of lysophosphatidic acid causes rapid redistribution of myosin II to the cell cortex, 
upregulating cortical contractility and increasing bleb expansion. Interestingly, similar increases 
in myosin II accumulation, bleb formation and cortical contractility are also observed in serum-
free confined condition, indicating that confinement in itself is able to trigger an increase in cell 
contractility independent of external biochemical cues, possibly via a yet to be discovered 
mechanism involving cell and/or nuclear deformation. Nevertheless, these local fluctuations in 
cortical contractility at the cell periphery disrupt cell symmetry, leading to initial polarization. 
Polarization is then further enhanced and stabilized by a positive feedback between continuous 
cortical actin and myosin flow towards cell rear and formation of cortical contractility gradient 
that reinforces the flow, resulting in the formation and maintenance of stable blebs. Unlike 
conventional 2D migrating cells where polarization hinges on PIP3 is impaired with PI3K 
inhibition, polarization in A2 blebbing mode is resistant to PI3K inhibition. Instead it is 
dependent on proper actin turnover as inhibition of actin turnover by latrunculin A or 
jasplakinolide resulted in disappearance of stable blebs (118). 
 
2.5.4 Mechanotransduction pathway to optimize contractility in confinement 
Cells are able to identify, integrate and respond to external environmental cues and physical 
stimuli in a process known as mechanotransduction. However, the exact mechanotransduction 
mechanisms by which cells sense physical confinement and translate this signal into elevated 
cortical contractility is still underexplored. Prior work suggested that the existence of an intricate 
cross talk between Rac1 and RhoA/myosin II signaling (98) that serves to optimize actomyosin 
contractility in order to facilitate efficient migration in confined microchannels. Specifically, 
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Rac1 activity is enhanced in cells migrating on 2D surfaces or inside wide microchannels (≥ 
20µm) to facilitate the formation of lamellipodia protrusions. Conversely, RhoA/myosin II 
signaling is amplified when cells are migrating inside narrow microchannels (≤ 10µm), resulting 
in higher actomyosin contractility and a migration mode with amoeboidal characteristics (98). 
These distinct signaling strategies employed by cells in response to physical confinement are 
modulated by mechanosensors, which can be broadly classified into three major classes: stretch-
activated ion channels (120), cytoskeletal and nuclear elements (121) and integrins (122).  
 
We recently discovered that the membrane-bound stretch-activated cation channel PIEZO1 is 
responsible for the intracellular calcium increase observed as cells transition from an unconfined 
2D environment into confined microchannels (105). In particular, elevated membrane tension 
induced by physical confinement activates PIEZO1, leading to increased intracellular calcium 
levels, which in turn mediate suppression of protein kinase A (PKA) via a phosphodiesterase 
type 1 (PDE-1) dependent pathway. Interestingly, confinement-induced inhibition of PKA 
activity is only negated when both PIEZO1 and myosin II are blocked (but not when either one is 
individually inhibited), implying that myosin II can also sense physical confinement and 
suppress PKA directly and independently of PIEZO1. Indeed, external physical forces have been 
reported to induce assembly of myosin II bipolar filaments and actomyosin bundles (123,124). 
Moreover, myosin II has also been implicated in sensing surface topographical cues in 
fibroblasts (125) and tumor cells (99). In relation to mechanosensing of physical confinement, it 
has been hypothesized that myosin II decreases PKA activity indirectly via downregulation of 
Rac1 activity, due to the negative crosstalk between Rac and Rho/myosin, that subsequently 
reduces recruitment of A-kinase anchoring proteins (AKAPs) to the cell leading edge that is 
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capable of activating PKA. Together, these two independent yet interconnected mechanosensing 
mechanisms serve to suppress PKA and amplify actomyosin contractility in confinement. Of 
note, components of adhesion complexes, such as α4 and α5 integrins, do not appear to be 
essential for cell to sense physical confinement. Rather, they primarily serve to amplify the 
differential response of contractility increase induced by confinement. 
 
2.6 Lobopodial migration in linearly elastic matrices 
Cells are able to sense the mechanical and rheological properties of extracellular matrices and 
adopt distinct migration mechanisms in different 3D microenvironments. While most migration 
studies using 3D matrices, such as polyacrylamide or collagen gels, have focused on the ability 
of the cells to respond to substrate stiffness and pore sizes, limited attention has been devoted to 
the elastic behavior of the matrix material like strain stiffening (101). Strain stiffening refers to 
the ability of a material to resist deformation and handle applied stress. In general, materials can 
be classified broadly as nonlinearly elastic where they undergo strain stiffening (i.e. the stiffness 
of the material increases with increasing force application), and linearly elastic where strain 
stiffening is not observed (i.e. the stiffness of the material is independent of the magnitude of 
force applied to it). 
 
Fibroblasts are able to recognize the differences in the elastic behaviors of 3D matrices and 
migrate via two distinct mechanisms (101). In 3D collagen gels, which are non-linearly elastic 
and softer, fibroblasts migrate via the classical flat lamellipodial protrusions, similarly to how 
they would migrate on unconfined planar 2D surfaces. In highly cross-linked, stiffer and linearly 
elastic materials such as dermal tissue explant or cell-derived matrix (CDM), however, 
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fibroblasts switch to a diametrically opposed morphology, where blunt cylindrical protrusions 
termed as the lobopodia and small lateral blebs are observed (93). Notably, the lobopodial mode 
of migration only occurs when the cells are being confined within the 3D mesh-like structure of 
CDM but not on top of 2D CDM, indicating that lobopodia-based migration is a unique 
mechanism that cells can use inside linearly elastic matrices. Unlike lamellipodia where PIP3, 
Rac1 and Cdc42 are polarized to the leading edge of the cells, lobopodia are devoid of these 
polarized signals as well as of other lamellipodial markers such as cortactin, VASP and F-actin. 
Instead, the lobopodial protrusions are mainly driven by high intracellular pressure that is highly 
dependent on RhoA/ROCK/myosin contractility. Fibroblasts continue to migrate using lobopodia 
after depletion of Rac1, Cdc42 or formin mDia1 with slight variation in velocity in certain 
instances. In contrast, inhibiting contractility by knocking down RhoA or inhibiting ROCK 
causes the fibroblasts to switch from a lobopodial to lamellipodial mode without affecting 
migration velocity. Interestingly, while myosin inhibition also results in the same lobopodial-to-
lamellipodial transition, cell migration was significantly impaired, presumably due to inefficient 
nuclear migration. 
 
Indeed, further studies revealed that the nucleus play a pivotal role in pressurizing the anterior 
cytoplasm at the cell leading edge by acting as a piston to generate lobopodia (126). There exists 
a high intracellular hydrostatic pressure differential between the front and back, as separated by 
the nucleus, of a lobopodially migrating cells in 3D linearly elastic matrices. The nucleus is 
being connected to the anterior cell membrane via a myosin II-vimentin-nesprin complex and is 
being pulled forward coordinately as cells traverse through the confined pores of linearly elastic 
matrices (127). Knocking down nesprin3 reverses the lobopodial phenotype back to 
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lamellipodia, equalizes intracellular pressure and reduces the velocity of migrating fibroblasts 
independent of affecting Rho-mediated contractility, indicating the importance structural role of 
nesprin3 as a nucleoskeleton-cytoskeleton linker in lobopodial-based migration. Unlike the 
critical role of microtubules in ensuring directionality and polarization of migrating cells 
displaying a lamellipodial morphology, microtubules do not seem to be involved in promoting 
the coordinated nucleus movement observed in lobopodial cells. The effect of microtubule 
inhibition on the velocity and persistence of lobopodial cells, however, remains to be further 
investigated. Despite the differences in morphology, polarized signals and motility mechanism, 
lamellipodia- and lobopodia-based migration do share a similar requirement for adhesions. Both 
types of protrusion possess paxillin and vinculin-based FAs. Blocking integrins also significantly 
impairs lobopodial migration speed and directionality in fibroblasts. 
 
The discovery of this non-polarized, contractility-dependent and intracellular pressure-driven 
lobopodial-based migration in normal fibroblasts naturally begs the question: can other cell types 
such as cancer cells also use a lobopodia-based mode of migration in 3D linearly elastic 
matrices? While initial studies suggested that HT1080 fibrosarcoma cells do not undergo 
lobopodial migration but instead migrate via either an amoeboidal (i.e., large blebs with no 
adhesions) or mesenchymal (lamellipodia with actin stress fibers and adhesions) mode, recent 
work shows that fibrosarcoma cells (i.e. HT1080 and SW684) are able to activate lobopodia 
upon protease inhibition in 3D CDM (60). In general, MMPs are needed for matrix degradation 
and generation of migration tracks through which cells move using primarily a pseudopodial 
mode of migration. Upon inhibition of protease activity, cells switch to a bleb-based amoeboidal 
migration mechanism (59,61). It is worth noting that these observations were made using non-
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linearly elastic materials such as collagen gels. In linearly elastic 3D CDM, however, MMP 
inhibition triggers the activation of nuclear piston mechanism in fibrosarcoma cells without 
switching to an amoeboid phenotype, possibly as a result of difficulty of efficient nuclear and 
cell translocation through low porosity confined 3D microenvironments. Similar to fibroblasts, 
lobopodial migration in tumor cells still depends on integrin adhesion, actomyosin contractility 
and nesprin3-vimentin connection. 
 
While it is intriguing that fibroblasts and fibrosarcomas are able to migrate with a lobopodial 
mode that is completely distinct from the conventional lamellipodial one, it is still unknown how 
the cells are able to sense the differences of the elastic behaviors of the surrounding 3D 
microenvironment and trigger the switch of migration mode. Furthermore, it is still unclear how 
MMP inhibition triggers the switch from lamellipodial to lobopodial migration in fibrosarcomas. 
More studies are also warranted to determine if the lobopodial migration mode is also applicable 
in other cancer cell types that are not fibroblast-like, and also to elucidate the in vivo functional 
significance of lobopodial migration. 
 
2.7 The osmotic engine model 
Up to this point, all of the confined migration mechanisms that we have discussed so far require 
intact actin and myosin contractility functions. For instance, actin polymerization is critical for 
the formation of lamellipodial protrusions; Rho/ROCK/myosin contractility is needed for 
nucleus to pressurize lobopodial cells; actomyosin contractility and retrograde actin flows are 
essential to generate blebs and maintain amoeboidal migration. Actin polymerization and myosin 
contractility are indispensable for cell migration on 2D and 3D microenvironments. 
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It was fascinating to observe that several tumor cell lines, such as S180 sarcoma and MDA-MB-
231 breast carcinoma, are able to migrate through stiff, narrow (W=3 µm and H=10 µm) PDMS-
based microchannels even when actin polymerization is completely disrupted by high doses of 
latrunculin A (97). Also, efficient migration through narrow channels occurs upon inhibition of 
β1 integrin function or actomyosin contractility (97).  We proposed the “osmotic engine model” 
of confined cell migration, which depends on the fluxes of water and ions in and out of the cells 
through the cell membrane (104). In this model, cells expand by taking up water at their leading 
edge and shrink by expelling water at the trailing edge, thereby leading to cell locomotion. 
Mathematical modeling predicts that the velocity of cell motility is independent of parameters 
that are influenced by actin polymerization or actomyosin contractility but instead depends on 
the number and localization of water channels, ion channels and pumps along the longitudinal 
cell axis (104). Indeed, the Na+/H+ exchanger-1, NHE-1, is polarized at the cell leading edge 
during confined migration. Knocking down NHE-1 or aquaporin-5 markedly suppress confined 
migration (104).  
 
The osmotic engine model operates based on the principles of cell volume regulation as a result 
of differential osmotic and hydrostatic pressure across the cell membrane of leading and trailing 
edges. Therefore, any perturbation to the osmolarity of the fluid at either the cell leading or 
trailing edge has an immediate and pronounced effect on the flow of ions or water across the cell 
membrane, thereby affecting migration directionality and velocity. Indeed, application of a 
hypotonic osmotic shock to the cell leading edge or a hypertonic osmotic shock to the trailing 
edge reverses the direction of cell migration in narrow channels. It is worth noting that though 
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actin is dispensable in maintaining directionally persistent confined migration in these cells once 
the initial polarization of aquaporins and ion transporters has been established after channel 
entry, actin is pivotal for the cells to respond to osmotic shock and reverse direction by 
facilitating NHE1 repolarization (104). This is in contrast to the role of microtubule in confined 
migration, where microtubule disruption with nocodazole drastically impairs the persistence and 
velocity of cells pre-shocked, but only has minor effect post osmotic shock without affecting 
NHE1 repolarization.  
 
The osmotic engine model relies on the polarization of key molecules, such as aquaporins, ion 
channels and pumps, aided by the actin cytoskeleton and the geometry of confined channels, 
which induce cells into a longitudinal pill-shaped morphology. Moreover, mathematical 
modeling predicts that the water permeation mechanism is key to migration inside stiff, narrow 
microchannels in which cells experience high hydraulic resistance, which is related to the 
extracellular pressure on the cell (unpublished data). Thus, it remains to be established whether 
the osmotic engine model operates in vivo where tissues and extracellular matrices are soft, 
porous and permeable to water in all directions. In light of the plasticity of the different 
migration mechanisms, it is still unclear how the osmotic engine model of confined migration is 
related or convertible to other migration mechanisms discussed in previous sections, or whether 
it represents an auxiliary mechanism. It is noteworthy that ROCK1, which phosphorylates 
myosin light chain, has been reported to be an upstream activator of NHE1, and could potentially 




The osmotic engine model of migration may be relevant to cancerous cells which typically 
overexpress aquaporins, ion channels and pumps (129-131), and can thus uptake and/or expel 
water more effectively than their normal counterparts. If cells cannot uptake water, then they 
need to push against a column of water during migration in stiff, confined microchannels. This 
so called barotaxis mechanism was demonstrated for differentiated HL60 neutrophil-like cells 
(132) as evidenced by the fact that the bulk velocity of the moving fluid anterior to the cell is 
identical to that of moving cells. When HL60 cells encounter an asymmetric bifurcation of 
different hydraulic resistances, cells tend to follow the path of lower resistance. The leading edge 
of HL60 cells protruding into the lower resistance channel extends at significantly faster rate 
than the other competing edge, eventually causing the losing edge to retract, thereby 
precipitating the final cell decision to the lower resistance channel. This directional bias becomes 
more evident as the hydraulic resistance difference increases to the point that almost no HL60 
cells are able to enter a dead-end branch where it presents infinite hydraulic resistance. In 
marked contrast, about 20% of MDA-MB-231 breast cancer cells, which employ the osmotic 
engine model, enter the dead-end branch channel (unpublished data). Taken together, cells, and 
in particular cancerous cells, may both push and take up water concurrently when moving in 
stiff, confined channels, and thus the two mechanisms are not mutually exclusive. Cells may use 
hydraulic resistance to probe the path of least resistance in order to determine the most efficient 
path of migration, and directed flow of water from the osmotic engine model could serve as 




Cell migration is a complex process which necessitates the interplay of various intrinsic and 
extrinsic factors. Confinement further contributes to the complexity of cell migration 
mechanisms by providing a physical cue that cells have to integrate and alter intracellular 
signaling to ensure optimized and efficient cell migration. Recent breakthroughs in 
bioengineering and microfabrication techniques have provided researchers with various useful 
tools to orthogonally control biochemical and physical inputs and recapitulate physiologically 
relevant microenvironments encountered in vivo in order to systematically investigate the effects 
of physical confinement on cell signaling and motility. These studies have provided us with 
invaluable insights on how confined cell migration occurs. Several intrinsic cellular factors, such 
as actomyosin contractility, integrin expression, MMP activity, actin and microtubules, as well as 
extrinsic characteristics of surrounding matrix, such as adhesiveness, porosity, stiffness, elastic 
property and osmolarity, contribute to this intricate network that controls the mechanism of 
confined migration. Cells choose their preferred mode of migration depending on the 
physicochemical properties of the local microenvironment and the cellular contractile state. Cells 
display high plasticity and are capable of switching from one migration mode to another with 
ease. Understanding the mechanisms of confined cell migration thus offers promise for the 
development of novel therapeutic strategies, that can target the different facets of cell motility, 

















Figure 2.1 Schematics of the various confined cell migration modes 
(A) Pseudopodial cell migrates with an elongated morphology and actin-based protrusions 
initiated by polarized Cdc42, Rac1 and PIP3 localized at the cell’s leading edge. Focal adhesions 
are distributed in a diffused pattern along the elongated cell. Actomyosin contractility is 
concentrated towards the trailing edge to aid in rear retraction. Actin are organized around the 
cell cortex and at the cell’s leading and trailing edges. Centrosome is located behind the nucleus 
while microtubules are concentrated anterior to the nucleus as parallel bundles.  (B) A1 blebbing 
cell has a round cell body with small actin-based protrusions at the leading edge. Fast retrograde 
actin flow is localized at the protruding leading edge. A1 blebbing cells also lack polarized 
signals, focal adhesions and actin stress fibers. (C) A2 blebbing cell has en elongated ellipsoidal 
morphology with a rear uropod and a rounded leading edge. Actin and myosin II are 
concentrated around the cell cortex and the uropods, and demonstrates fast and global retrograde 
flow towards the cell rear. A1 blebbing cells also lack polarized signals, focal adhesions and 
actin stress fibers. (D) Lobopodial cell possess blunt cylindrical protrusions and small lateral 
blebs around the cell body. Focal adhesions are required for lobopodial migration. Lobopodial 
cell is separated into a high-pressure compartment anterior to the nucleus and a low-pressure 
compartment posterior to the nucleus. The nucleus is connected to the anterior cell membrane via 
a vimentin and nespri3. Polarized signals are absent in lobopodial cell. High cellular contractility 
and a linearly elastic matrix are necessary for cell to migrate using lobopodia. (E) Osmotic 
engine is activated when cells are being confined into a pill shape within rigid channels. Ion and 
water channels such as NHE1 and AQP5 are polarized to the cell leading edge to facilitate water 
and ion flux that serve to propel the cells forward. Focal adhesion, contractility and actin 
polymerization are dispensable in cells migrating using the osmotic engine. 
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Table 2.1 Comparison between unconfined 2D versus confined 1D or 3D mesenchymal 
migration 
 
 2D 1D or 3D 
Occurrence 
In vitro - Flat 2D substrates 
- Wide PDMS channels 
- Microcontact printed 1D line 
- 3D hydrogel network 
- Hydrogel patterned microtracks 
- Narrow PDMS channels 
In vivo - Wound healing 
- Neutrophil trafficking on 
inflamed endothelium 
- Along oriented ECM fibers 
- Within dense fibrillar tissues 
- Pre-formed ECM-free tunnels 
Structural and Phenotypic Properties 
Actin - Organized and elongated stress 
fibers 
 
- Suppression of stress fibers 
- Actin organized in cortex or 
concentrated on the 
leading/trailing edge 
Microtubules - Centrosome in front of nucleus 
- Nearly isotropic microtubule 
polymerization from MTOC 
- Centrosome behind the nucleus 
- Stabilized microtubules as 
parallel bundles in front of 
nucleus  
- Alpha tubulin and microtubule 
growth towards leading edge 
Focal adhesion - Large distinct mature focal 
adhesions around cell periphery 
 
- Smaller in size 
- Diffuse and homogenous 
distribution of focal adhesion 
proteins 
Nuclear shape - Rounded - Elongated 
Traction force - Larger 
- Directed to the cell center 
- Significantly lower 
- Directed towards channel wall  
Roles of different molecular determinants 
MMPs - Not critical - Essential in 3D ECM to 
generate migration tracks 
- Not required if tracks are 
already pre-formed  
Matrix adhesion - Migration stops when adhesion 
is blocked  
- Migration persists even when 
adhesion is blocked, especially 
in stiff PDMS-based channels 
Actomyosin 
contractility 
- Indispensable - Effect is cell-type dependent 
- Can be dispensable for cells in 
rigid microchannels 
Microtubule - Required for signal polarization - Needed to maintain persistence 
and directionality 
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Chapter 3 - A Direct Podocalyxin-Dynamin-2 Interaction Regulates 
Cytoskeletal Dynamics to Promote Migration and Metastasis in 
Pancreatic Cancer Cells 
3.1 Abstract  
The sialoglycoprotein podocalyxin is absent in normal pancreas but is overexpressed in 
pancreatic cancer and is associated with poor clinical outcome. Here we investigate the role of 
podocalyxin in migration and metastasis of pancreatic adenocarcinomas using SW1990 and 
Pa03c as cell models. Although ezrin is regarded as a cytoplasmic binding partner of 
podocalyxin that regulates actin polymerization via Rac1 or RhoA, we did not detect 
podocalyxin-ezrin association in pancreatic cancer cells. Moreover, depletion of podocalyxin did 
not alter actin dynamics or modulate Rac1 and RhoA activity in pancreatic cancer cells. Using 
mass spectrometry, bioinformatics analysis, co-immunoprecipitation, and pulldown assays, we 
discovered a novel, direct binding interaction between the cytoplasmic tail of podocalyxin and 
the large GTPase dynamin-2 at its GTPase, middle, and pleckstrin homology domains. This 
podocalyxin-dynamin-2 interaction regulated microtubule growth rate, which in turn modulated 
focal adhesion dynamics and ultimately promoted efficient pancreatic cancer cell migration via 
microtubule- and Src-dependent pathways. Depletion of podocalyxin in a hemispleen mouse 
model of pancreatic cancer diminished liver metastasis without altering primary tumor size. 
Collectively, these findings reveal a novel mechanism by which podocalyxin facilitates 




Podocalyxin (PODXL) is a type 1 transmembrane sialomucin glycoprotein belonging to the 
CD34 protein subfamily that is endogenously expressed by kidney podocytes (133), 
hematopoietic progenitor stem cells (134) and vascular endothelium (135). First discovered in 
adult kidney, the negatively charged ectodomain of PODXL is instrumental for the maintenance 
of glomerular filtration slits via an anti-adhesive charge repulsion effect (133). In contrast, 
PODXL expressed on high endothelial venules is instead pro-adhesive, capable of mediating 
binding to L-selectin on lymphocytes, thereby facilitating lymphocytes tethering, rolling and 
recruitment to secondary lymphoid organs during inflammation (135).  
 
PODXL plays a pivotal role in regulating cell adhesion, a fundamental aspect of many 
(patho)physiological processes, including embryonic development, inflammatory and immune 
responses and cancer metastasis. Importantly, PODXL is also overexpressed by cancer cells, 
including lung (136), breast (137), ovarian (138), bladder (139), renal (140), colorectal (141) and 
pancreatic cancers (142). Overexpression of PODXL in cancer cells is associated with aggressive 
clinicopathological characteristics and poor clinical outcomes (136-142). Both the anti- and pro- 
adhesive roles of the PODXL ectodomain have been implicated in cancer dissemination. For 
instance, PODXL has been reported to disrupt cell-cell contact and induce tumor shedding from 
monolayers of ovarian carcinoma (138), and breast cancer cells (137). Conversely, PODXL, 
expressed on colon carcinoma (143) and pancreatic cancer cells (144), binds to E- and L-selectin, 
thereby facilitating circulating cancer cell rolling on vascular endothelium and subsequent 
extravasation to secondary tumor sites. The structure of PODXL consists of an N-terminal 
extracellular domain with extensive N- and O-glycosylation and sialylation, and a cytoplasmic 
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intracellular tail with a C-terminal DTHL consensus sequence capable of interacting with PDZ 
binding domain (145). The cytoplasmic tail of PODXL, despite its small size has been reported 
to interact with proteins such as ezrin (140,146) and Na(+)/H(+) exchange regulatory cofactor 
(NHERF) 1 or 2 (147,148) to activate downstream intracellular signaling, primarily via the PI3K 
(149), RhoA (147) and Rac1 (140) pathways, leading to epithelial-mesenchymal transition (150), 
migration (151) and invasion (152). 
 
While typically absent in normal pancreas and non-malignant pancreatic epithelial cells, 
approximately 30-69% of pancreatic ductal adenocarcinomas express PODXL, with the strongest 
expression exhibited by the invasive front of primary tumors (144,153,154). Moreover, high 
PODXL expression is associated with poor clinicopathological characteristics and the 
development of distant metastasis (155,156). PODXL has also been shown to be an independent 
predictor of poor prognosis and is linked to higher risk of death and reduced survival (142,154-
156). These effects are hypothesized to be at least partially due to the ability of PODXL to 
regulate cell migration and invasion (154,156). Although ezrin is regarded as the main 
intracellular binding partner of PODXL, our data reveal the lack of any association between 
PODXL and ezrin in pancreatic cancer cells. Consequently, the mechanism by which PODXL 
exerts its downstream effects to promote pancreatic cancer cell migration remains unknown. 
Furthermore, the functional significance of PODXL in promoting pancreatic cancer cell 
metastasis in vivo has yet to be delineated. 
 
In this study, we examined the roles of PODXL in migration and metastasis of pancreatic cancer 
cells in vitro and in vivo, using two metastatic pancreatic cancer cell lines, SW1990 and Pa03c. 
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To identify the cytoplasmic binding partner of PODXL in pancreatic cancer cells, we 
immunoprecipitated PODXL from SW1990 cells, and subjected the specimens to tandem mass 
spectrometry. Bioinformatics analysis identified dynamin-2 as a potential binding partner of 
PODXL. Reciprocal co-immunoprecipitation (co-IP) verified the association of PODXL and 
dynamin-2. This direct binding interaction was further confirmed by in vitro His-tag binding 
assays, which identified the GTPase, middle and pleckstrin homology domains of dynamin-2 as 
critical for binding to PODXL. Of note, co-IP assays failed to demonstrate any PODXL-ezrin 
association. The novel PODXL-dynamin-2 interaction modulates microtubule dynamics, which 
in turn modulates focal adhesion (FA) assembly/disassembly. Dynamin-2 also regulates FA 
turnover via Src kinase-dependent pathway. As a result, inhibition or downregulation of 
dynamin-2, microtubule or Src kinase reverses the pro-migratory phenotype of PODXL in both 
two-dimensional (2D) and microchannel migration assays. Along these lines, knockdown of 
PODXL significantly impairs unconfined and confined migration by decreasing microtubule 
dynamics and increasing FA density. The functional role of PODXL in promoting metastasis is 
demonstrated using a preclinical murine hepatic metastasis model via a hemispleen injection 
technique (157).  
 
3.3 Materials and methods 
3.3.1 Cell culture and drug treatment 
SW1990 pancreatic cancer cells and MDA-MB-231 breast cancer cells were purchased from the 
American Type Culture Collection (Manassas, VA), while Pa03c pancreatic cancer cells were 
obtained as previously described (158). All cell lines were cultured in standard Dulbecco's 
Modified Eagle Medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine 
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serum (FBS, Gibco) and 1% penicillin/streptomycin (Gibco). All cell lines were used for 10 
passages after thawing from the frozen vials and were tested routinely for mycoplasma via 
quantitative polymerase chain reaction. The cell lines were not further authenticated. In select 
experiments involving drug treatments, cells were incubated with culture media containing 40 
µM dynasore (Sigma-Aldrich), 1.2 µM taxol (Sigma-Aldrich), 10 nM dasatinib (Cell Signaling), 
10 µM PP2 (EMD Millipore), or the corresponding vehicle control. 
 
3.3.2 Generation of stable knockdown cell lines  
Stable cell lines of scramble control and PODXL-KD SW1990 were generated with short hairpin 
RNA (shRNA) as previously described (144). Additional PODXL-KD cell lines with Pa03c and 
MDA-MB-231 were generated using two different lentiviral shRNA sequences. PODXL-KD1, 
which is identical to the original PODXL-KD sequence used for SW1990 cells (144), targets the 
3’ untranslated region, whereas PODXL-KD2 targets the coding region of the PODXL mRNA. 
The shRNA target sequences are (5’ to 3’ sense strand), Scramble: 
GCACTACCAGAGCTAACTCAGATAGTAC. PODXL-KD1: 
GAGCCAGGATGAGAACAAA. PODXL-KD2: 
CCTAACACCACAAGCAGCCAGAATGGAGC. The shRNA sequences were cloned into 
pLVTHM (Addgene, plasmid # 12247) lentivector expressing shRNA with a GFP selection 
marker via Mlul and Clal restriction sites or pLKO.1 puro (Addgene, plasmid # 8453) lentivector 
with a puromycin antibiotic selection marker via BshT1 and EcoR1 restriction sites with 
standard molecular cloning techniques. The viruses were produced in HEK293T cells. Pa03c 
PODXL-KD cell lines were generated using the pLVTHM lentivector while MDA-MB-231 
PODXL-KD cell lines were generated using the pLKO.1 puro lentivector. Successfully 
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transduced cells were sorted using Sony Biotechnology SH800 Cell Sorter for GFP expression or 
selected with puromycin accordingly.  
 
Stable cell lines of scramble control and NHERF2-KD SW1990 were generated using a lentiviral 
approach. The shRNA target sequences for knocking down NHERF2 are (5’ to 3’ sense strand), 
NHERF2-KD1: AACAGGAAGCGTGAAATCTTCAGCAACTT. NHERF2-KD2: 
CGAGACAGATGAACACTTCAA. NHERF2-KD3: GAAGCGTGAAATCTTCAGCAA. 
NHERF2-KD4: GTCCTGCCATTGCCCAGAAAT. The NHERF2 shRNA sequences were 
cloned into pLKO.1 puro lentivector. 
 
3.3.3 siRNA knockdown 
Transient dynamin-2 knockdown was established by transfecting cells with Dynamin-2 siRNA 
(Santa Cruz Biotechnology, sc-35236) using Lipofectamine RNAiMAX (Invitrogen) following 
the manufacturer’s protocol. As a control, cells were transfected with scramble control siRNA 
(Santa Cruz Biotechnology, sc-35236). Cells were incubated with the lipid complex for 72 h 
before they were used for subsequent experiments. 
 
3.3.4 Western blot and antibodies 
Standard western blot techniques were performed as previously described (159) using NuPAGE 
4-12% Bis-Tris Protein Minigels (Invitrogen). The antibodies used are listed below. Primary 
antibodies: 1) Podocalyxin-like 1 (3D3) mouse monoclonal antibody (Santa Cruz Biotechnology, 
sc-23904, 1:500). 2) PODXL (EPR9518) rabbit monoclonal antibody (Abcam, ab150358, 
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1:1000). 3) Dynamin-2 (DYN2-11) mouse monoclonal antibody (Sigma Aldrich, SAB4200661, 
1:500). 4) Dynamin-2 rabbit polyclonal antibody (Abcam, ab3457, 1:1000). 5) Ezrin (3C12) 
mouse monoclonal antibody (Abcam, ab4069, 1:500). 6) NHERF2 (D3A5) rabbit monoclonal 
antibody (Cell Signaling, 9568, 1:1000). 7) GST (26H1) mouse monoclonal antibody (Cell 
Signaling, 2624, 1:2000) 8) 6x-His tag (4E3D10H2/E3) mouse monoclonal antibody 
(ThermoFisher Scientific, MA1-135, 1:2000). 9) RhoA (7F1.E5) mouse monoclonal antibody 
(Cytoskeleton, ARH04, 1:500). 10) Rac1 mouse monoclonal antibody (Cytoskeleton, ARC03, 
1:500). 11) Actin (C4) mouse monoclonal antibody (BD Transduction, 612656, 1:10000). 
Secondary antibodies: 1) Anti-mouse IgG, HRP-linked antibody (Cell Signaling, 7076S, 1:2000). 
2) Anti-rabbit IgG, HRP-linked antibody (Cell Signaling, 7074S, 1:2000). 
 
3.3.5 Random 2D migration assay 
22mm×22mm square glass coverslips glued to the bottom a 6-well plate were coated for 1 h with 
20 µg/ml of rat tail type I collagen (Gibco). 5×104 cells were seeded onto the coverslips with 2 
ml of culture media. The cells were imaged via a 10x Ph1 objective every 10 min for 10 h using 
stage automation on a Nikon Inverted microscope with a stage top incubator (Tokai Hit Co., 
Shizuoka, Japan) maintained at 37°C with 5% CO2 and humidity. At least 5 individual migrating 
single cells from 5 different locations per sample were analyzed using ImageJ (National 
Institutes of Health, Bethesda, MD). The cell outlines were tracked at every time point to record 
their spatial position and morphology parameters including projected area, circularity and 
solidity as previously described (160). A rose plot with the cell migration trajectories and their 
average mean square displacement were also calculated as described in (160).   
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3.3.6 Polydimethylsiloxane (PDMS)-based microchannel migration assay 
PDMS-based microchannels devices were fabricated using a photolithography and standard 
replica molding technique as previously described (77,97). Each device comprises a series of 
parallel 200 µm-long and 10 µm-high microchannels of prescribed widths varying from 6, 10, 20 
to 50µm arrayed perpendicularly between a cell and chemoattractant inlet lines. The 
microchannels devices were coated with 20 µg/ml of collagen type I to facilitate cell adhesion. 
Cell migration was visualized and recorded via time-lapse live microscopy in an enclosed, 
humidified microscope stage maintained at 37°C and 5% CO2 using stage automation and a 
Nikon Inverted microscope. Phase contrast time-lapse images were taken at every 10 min for 24 
h with a 10x Ph1 objective. The spatial x and y positions of all non-dividing and viable cells that 
entered and migrated in the microchannels were tracked overtime with the Manual Tracking 
plugin in ImageJ. Motility parameters, namely velocity, speed and persistence, were computed 
using a custom-written Matlab code as previously described (77,97).  
 
3.3.7 Actin dynamics with fluorescence recovery after photobleaching (FRAP) 
Cells were transfected with LifeAct-GFP (Addgene, plasmid # 58470) using Lipofectamine 3000 
(Invitrogen) according to manufacturer’s protocol. 48 h post transfection, cells were replated 
onto a 35 mm glass bottom dish coated with 20 µg/ml of collagen type I and allowed to adhere 
overnight to grow into a 70-80% confluent monolayer. The cells were imaged using a Zeiss LSM 
700 laser scanning confocal microscope (Zeiss, Oberkochen, Germany) with a 63×/1.4 NA oil-
immersion objective every 1.04 s before and after photobleaching. A circular region of interest of 
4 µm diameter was positioned at cell-cell borders of cells expressing LifeAct-GFP, which was 
then photobleached using a 488nm laser at 100% power. At least 25 different cell-cell borders 
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were imaged per condition. The FRAP time-lapse video was analyzed with ImageJ by as 
previously described (161).  
 
3.3.8 Microtubule dynamics with EB1-GFP 
Cells were transfected with EB1-GFP (Addgene, plasmid # 17234) using Lipofectamine 3000. 
48 h post transfection, cells were replated onto collagen I-coated glass bottom dishes and 
allowed to adhere overnight. Individual cells expressing EB1-GFP were imaged at an interval of 
3.08 s for a total duration of 6 min with a 63×/1.4 NA oil-immersion objective on a Zeiss LSM 
700 laser scanning confocal microscope. At least 20 different EB1-GFP expressing cells were 
imaged per condition. The time-lapse confocal raw images were exported to and analyzed via 
ImageJ as previously described (97).  
 
3.3.9 FA density measurement with total internal reflectance fluorescence (TIRF) 
microscopy 
5×104 cells were seeded onto collagen I-coated glass bottom dishes and allowed to adhere 
overnight. Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized in 0.25% Triton 
X-100 for 5 min, and blocked for 2 h in PBS with 10% normal goat serum (Cell Signaling) and 
1% bovine serum albumin. Cells were incubated with primary antibody against phosphor-
paxillin (Tyr118) (Cell Signaling, 2541S, 1:100) overnight at 4°C, followed by 2 h incubation 
with Alexa Fluor 488 goat anti-rabbit secondary antibody (Invitrogen, A11034, 1:200). The cells 
were washed thoroughly with PBS between each step. The immunostained cells were imaged by 
TIRF microscopy using a 3i Mariana inverted microscope (Intelligent Imaging Innovation, 
Denver, CO, USA) equipped with a 100×/1.45 NA oil immersion objective and Slidebook 8.0 
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software. At least 60 cells were analyzed per condition. The TIRF images were processed and 
analyzed for FA density as previously described (160).  
 
3.3.10 RhoA and Rac active pulldown assays 
RhoA Pulldown Activation Assay (Cytoskeleton, BK036) and Rac1 Pulldown Activation Assay 
(Cytoskeleton, BK035) were conducted according to manufacturer’s protocols. 
 
3.3.11 Co-IP and mass spectrometry 
Co-IP was performed to identify the binding partner(s) of PODXL in pancreatic cancer cells with 
Pierce co-IP Kit (Thermo Scientific). The co-IP assays were performed by incubating pre-cleared 
cell lysates containing 500 µg of total protein with 25 µl of resin immobilized with 10 µg of 
antibody overnight at 4°C. PODXL (EPR9518) rabbit monoclonal antibody (Abcam, ab150358) 
was used to immunoprecipitate PODXL. A rabbit IgG monoclonal isotype (EPR25A, Abcam, 
ab172730) or beads-only controls were included to account for non-specific binding. Unbound 
proteins were washed away from the antibody-immobilized resin by centrifugation with IP lysis 
buffer supplemented with 1M NaCl for 10 times. Bound proteins were eluted with 1% SDS and 
concentrated. The co-IP elution was submitted to the Johns Hopkins Mass Spectrometry and 
Proteomics Core Facility (Baltimore, MD, USA) for protein identification or analyzed with 
standard western blot protocol once the candidate protein was identified. In subsequent 
reciprocal co-IP experiments, Dynamin-2 rabbit polyclonal antibody (Abcam, ab3457) or 
NHERF2 (D3A5) rabbit monoclonal antibody (Cell Signaling, 9568) were used to 
immunoprecipitate dynamin-2 or NHERF2, respectively.  
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3.3.12 In-Vitro His-tag pulldown assay 
In-vitro His-tag pulldown assays were conducted using a recombinant purified His-DNM2 probe 
(Gift from Dr. Mark McNiven) (162). Additional His-DNM2 constructs consisting of select 
Dynamin-2 domains, and the His-tagged PODXL cytoplasmic tail (PCT, aa484 to aa558) were 
created using standard molecular cloning techniques with the same pQE-80L vector as the full 
length His-DNM2 probe. His-tagged constructs were transformed into and produced with BL21 
Competent E.coli under 0.1 mM Isopropyl β-D-1-thiogalactopyranoside induction at 16°C 
overnight. The recombinant His-tagged proteins were purified using HisPur™ Ni-NTA Spin 
Purification Kit (Thermo Scientific). The in vitro pulldown assay was performed using Pierce™ 
His Protein Interaction Pull-Down Kit (Thermo Scientific). For experiments involving purified 
glutathione S-transferase (GST)-tagged PCT, GST-PCT is cloned into pGEX-2T vector via 
standard molecular cloning techniques. The recombinant GST-PCT proteins were induced and 
purified from E.coli using glutathione–agarose beads (Pierce). 
 
3.3.13 Colocalization staining 
5×104 cells were plated onto collagen I-coated glass bottom dishes and allowed to adhere 
overnight. Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized in 1% Triton X-
100 for 10 min, and blocked for 2 h in blocking buffer comprising PBS with 2% bovine serum 
albumin and 0.1% Triton X-100. Cells were incubated with Podocalyxin-like 1 (3D3) mouse 
monoclonal antibody (Santa Cruz Biotechnology, sc-23904, 1:50) and Dynamin-2 rabbit 
polyclonal antibody (Abcam, ab3457, 1:300) diluted in blocking buffer simultaneously overnight 
at 4°C, followed by 2 h incubation with Alexa Fluor 488 goat anti-mouse secondary antibody 
(Invitrogen, A11001, 1:200), Alexa Fluor 568 goat anti-rabbit secondary antibody (Invitrogen, 
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A11011, 1:200) and Hoechst 33342 (ThermoFisher Scientific, H3570, 1:2000) diluted in 
blocking buffer. The samples were washed thoroughly with PBS between each step. Imaging 
was performed with a 63×/1.4 NA oil-immersion objective on a Zeiss LSM 700 laser scanning 
confocal microscope. 
 
3.3.14 Hemispleen mice model 
A preclinical murine model of hepatic metastasis was performed via a hemispleen injection 
technique (157) to assess the metastatic potential of PODXL-expressing and PODXL-KD 
pancreatic cancer cells. All animal work was approved and performed in compliance with the 
Institutional Animal Care and Use Committee (IACUC) at the Johns Hopkins University. Prior 
to surgery, trypsinized cells were incubated in DMEM with 10% FBS at 37°C with intermittent 
mixing to restore surface glycoprotein expression. Next, the cells were washed with PBS 3X and 
resuspended in anti-clumping buffer diluted 1:1000 in Hanks’ balanced salt solution (Gibco) to 
single cell suspensions of 1×107/ml for Pa03c and 2.5×106/ml for SW1990. The cells were 
maintained on ice at all times for subsequent steps. 6 to 8 weeks old female NOD-SCID mice 
were purchased from Johns Hopkins Research Animal Resources (Baltimore, MD, USA) and 
maintained in accordance with Institutional Animal Care and Use Committee guidelines. At 
surgery, the spleen of a fully anesthetized mouse was eviscerated, clipped and excised into 2 
halves. 100 µl of cell suspension was injected into one half of the excised spleen, followed by a 
flush with 150 µl of ice-cold PBS. The cells were allowed to flow into the liver via the splenic 
vessels for 2 min, after which the splenic vessels were clipped and removed, followed by 
suturing. All mice were monitored regularly and sacrificed when they display morbid 
characteristics. At necropsy, livers were harvested and examined macroscopically and 
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microscopically with haematoxylin and eosin staining for evidence of metastases. Additionally, 
any visible splenic tumors formed at the injection sites were collected and measured for size with 
the formula, V=(LxWxW)/2, where V is the tumor volume, L is the tumor length and W is the 
tumor width.  
 
3.3.15 Immunohistochemistry 
Immunohistochemistry staining for PODXL in the primary splenic tumor samples was 
performed manually. Following tissue deparaffinization and hydration, heat-induced antigen 
retrieval was performed in EDTA buffer (pH9.0) using a steamer for 40 min at 100°C. The tissue 
was then blocked for endogenous peroxidase and alkaline phosphatase (Dual Endogenous 
Enzyme Blocking Reagent, Dako), and endogenous biotin, biotin receptors and avidin binding 
sites (Avidin/Biotin Blocking Kit, Vector Laboratories). Primary antibody incubation with 
PODXL (EPR9518) rabbit monoclonal antibody (Abcam, ab150358, 1:500) for 1 h was followed 
by incubation with biotinylated secondary goat antibodies against rabbit IgG (Vector 
Laboratories, BA-100, 1:500) for 30 min, with TBST washes following each incubation steps.  
For detection, the sample was first incubated with ABC Vectastain reagent (Vector Laboratories) 
for 30 min, followed by development with DAB substrate (Dako) for 4 min. All slides were 
counterstained with haematoxylin.  
 
3.3.16 In vitro and in vivo tumor growth assays 
To quantity the effects of PODXL knockdown on in vitro growth rate, equal number of scramble 
control and PODXL-KD SW1990 or Pac03c cells at 1×105 were seeded into 6 well plates. Cell 
growth was quantified each day by counting the total number of cells per well following 
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trypsinization using a Countess Automated Cell Counter (Invitrogen) for each cell line in 
triplicates for 6 days. To assess the same parameter in vivo, a subcutaneous implantation model 
was used. 1×106/ml scramble control or PODXL-KD SW1990 or Pa03c cancer cells in 50% 
matrigel (Sigma Aldrich, diluted into 50% with equal volume of culture media) were injected 
subcutaneously into both flanks of 6-8 weeks old NOC-SCID mice. The animals were sacrificed 
appropriately when at least a mouse started to develop tumor that exceed 2 mm in diameter. 
Tumors were harvested post mortem and weighed with an electronic balance. All animal work 
was approved and performed in compliance with the Institutional Animal Care and Use 
Committee at the Johns Hopkins University.  
 
3.3.17 Statistical analysis 
All data are presented as mean±S.E.M. from 3 independent experiments unless otherwise stated. 
Graphing and statistical analyses were performed with GraphPad Prism. Statistical significance 
was determined between pairs of data with a t-test, or between groups of data with one-way 
ANOVA and a Tukey’s Multiple Comparison post-hoc test.  
 
3.4 Results 
3.4.1 PODXL knockdown impairs pancreatic cancer cell migration in vitro 
We generated scramble control and stable PODXL-KD SW1990 cells via lipofectamine 
transfection followed by clonal selection.  PODXL knockdown was verified via immunoblotting 
(Figure 3.1.A). We first investigated the potential role of PODXL in regulating random 2D 
migration of pancreatic cancer cells on collagen I-coated glass coverslips. Scramble control 
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relative to PODXL-KD SW1990 cells were more motile (Figure 3.1.B), as evidenced by their 
higher mean squared displacement (Figure 3.1.C), and as such, were able to explore a larger 
surrounding area (Figure 3.1.D). Interestingly, morphometric analysis revealed that PODXL 
knockdown renders cells smaller, more circular and less protrusive (Figure 3.S1.A). Depletion 
of PODXL also diminishes cell morphodynamics, as evidenced by smaller changes of their 
various morphological indices (Figure 3.S1.B). In line with random 2D migration data, PODXL 
knockdown significantly suppressed chemotactically-driven cell migration inside both 
unconfined and confined PDMS-based microchannels (Figure 3.1.E), which resulted in lower 
velocity, speed and persistence relative to scramble control cells (Figure 3.1.F). 
 
To validate our observations, we knocked down PODXL on both SW1990 and Pa03c pancreatic 
cancer cells using two different shRNA lentivirus sequences. Both sequences were able to 
knockdown PODXL (Figure 3.S1.C) and suppress migration of SW1990 (Figure 3.S1.D) and 
Pa03c (Figure 3.S1.E) cells through both unconfined and confined microchannels. To further 
generalize our findings and to extend their significance to other cancer cell types, we also 
knocked down PODXL in the widely-used human breast cancer cell line, MDA-MB-231 (Figure 
3.S1.C), and observed a similar inhibition in cell migration through both unconfined and 
confined microchannels (Figure 3.S1.F). 
 
3.4.2 PODXL knockdown alters microtubule and adhesion dynamics in pancreatic cancer 
cells 
Given the pronounced effect of PODXL knockdown in altering cell morphology and slowing 
down cell migration, we hypothesized that PODXL mediates these changes by regulating 
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cytoskeletal and/or adhesion dynamics in pancreatic cancer cells. We first quantified actin 
dynamics in scramble control and PODXL-KD LifeAct-GFP-transfected SW1990 cells using 
FRAP. Both control and PODXL-KD cells exhibited nearly identical mobile fractions of 
LifeAct-GFP molecules and half-lives of recovery (Figure 3.2.A), suggesting that PODXL 
knockdown does not alter actin dynamics. We next investigated the effects of PODXL 
knockdown on microtubule dynamics by imaging and quantifying the rate of EB1-GFP 
incorporation to the positive growing ends of microtubules. Interestingly, SW1990 PODXL-KD 
cells demonstrated a significantly lower microtubule growth rate compared to the scramble 
control cells (Figure 3.2.B), thereby indicating that PODXL depletion slows down microtubule 
dynamics. 
 
To investigate the potential role of PODXL in regulating cell adhesion, we visualized FAs by 
staining scramble control and PODXL-KD SW1990 cells for phosphorylated paxillin and 
imaging by TIRF microscopy (Figure 3.2.C). PODXL-KD cells relative to scramble controls 
displayed a higher FA density, quantified either as number of individual FAs over total cell area 
or as percentage of total cell area covered by FAs (Figure 3.2.D). Interestingly, the sizes of the 
individual FAs were not different between scramble control and PODXL-KD cells. 
 
Most cytoskeletal and adhesion dynamics changes are regulated by the activity of small GTPase 
proteins, such as RhoA and Rac1 (163). However, neither active RhoA (Figure 3.S2.A) nor 
active Rac1 (Figure 3.S2.B) were differentially modulated following PODXL knockdown, 
indicating that the microtubule and adhesion changes induced by PODXL are mediated by a 
distinct mechanism that is independent of both Rac1 and Rho.  
	 62	
 
3.4.3 PODXL associates with dynamin-2 in pancreatic cancer cells 
Ezrin is one of the most commonly reported cytoplasmic binding partners of PODXL, where it 
serves as a scaffold that links the plasma membrane to actin cytoskeleton (140,149). PODXL-
ezrin interaction has also been reported to promote migration by activating Rac1 and RhoA 
(140,147,152). Given that PODXL knockdown fails to alter both actin dynamics and the 
activities of RhoA and Rac1 (Figure 3.2.A, Figure 3.S2.A-B), we questioned the validity of 
PODXL-ezrin interaction in pancreatic cancer cells. Interestingly, we failed to detect ezrin in 
immunoprecipitated PODXL specimens from SW1990 cell lysates (Figure 3.3.A), thereby 
indicating that PODXL does not associate with ezrin in pancreatic cancer cells. 
 
To identify the cytoplasmic binding partner of PODXL in pancreatic cancer cells, we 
immunoprecipitated PODXL using a PODXL-specific antibody, EPR9518, along with an 
appropriate IgG isotype and beads-only (no antibody) controls. Specimens were subjected to 
mass spectrometry followed by bioinformatics analysis. Only proteins enriched by at least two-
fold in PODXL immunoprecipitated samples relative to those of isotype or beads-only control 
specimens were selected for further analysis (Table 3.1). 
 
Among the listed proteins, dynamin-2 emerged as a promising candidate for the following 
reasons. First, dynamin-2 is a large GTPase protein that associates with microtubules and 
promotes their dynamic instability (164). Second, dynamin-2 triggers FA disassembly (162). 
Third, dynamin-2 is overexpressed in pancreatic ductal carcinoma cells and potentiates migration 
and invasion (165). As such, we hypothesized that dynamin-2 could serve as a novel cytoplasmic 
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binding partner of PODXL and function as its effector to induce cytoskeletal and migratory 
changes in pancreatic cancer cells. 
 
By performing reciprocal co-IP experiments using specific antibodies against PODXL and 
dynamin-2, we demonstrated their physical association in SW1990 pancreatic cancer specimens. 
Specifically, in PODXL co-IP samples, dynamin-2 was also pulled down and detected only in 
the PODXL antibody lane, but not in the beads-only or isotype control lanes (Figure 3.3.B). 
Similarly, in dynamin-2 immunoprecipitated specimens, PODXL was also found to be co-IPed 
(Figure 3.3.B). These findings were validated and extended using Pa03c pancreatic cancer cells 
(Figure 3.S3.A) as well as MDA-MB-231 breast cancer cells (Figure 3.S3.B).  
 
Immunofluorescence followed by confocal microscopy revealed the colocalization of PODXL 
and dynamin-2 around the cell membrane and the thin cytoplasmic area surrounding the nucleus 
in SW1990 cells (Figure 3.S3.C). While PODXL localizes apically in primary cilium (166), 
embryonic and stem cells (167), normal endothelial and epithelial cells (168,169), and is crucial 
for the formation of apical lumen in blood vessels (170,171), its spatial localization is not as 
extensively characterized in cancer cells. Although ectopically expressed PODXL has been 
reported to localize to the apical surface of OVCAR-3 ovarian and MCF7 breast cancer cells 
(138,172), confocal imaging disclosed the presence of endogenous PODXL not only at the apical 
but also at the basal surfaces of SW1990 pancreatic cancer cells (Figure 3.S3.C). This spatial 
localization pattern of PODXL at the basal surfaces enables it to interact and ultimately affect 
focal adhesion dynamics in pancreatic cancer cells.  
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To identify the essential domains of dynamin-2 responsible for binding to PODXL, probes 
consisting of 6x His tags fused to either full-length or truncated constructs encompassing 
different domains of dynamin-2 were generated and used in in vitro His-tag pulldown assays 
(Figure 3.3.C). His-tagged full-length dynamin-2 pulled down PODXL following incubation 
with SW1990 cell lysate (Figure 3.3.D). These assays further revealed that the GTPase, middle 
and pleckstrin homology domains of dynamin 2 are responsible for binding PODXL, as His-
constructs containing either of these domains individually or in combination with others were 
able to pull down PODXL (Figure 3.3.D). On the other hand, the GTPase effector domain and 
the proline-rich domain of dynamin-2 were found to be dispensable for this binding interaction 
(Figure 3.3.D). Moreover, recombinant His-tagged PCT (aa484 to aa558) was sufficient to bind 
to endogenous dynamin-2 from SW1990 cell lysate (Figure 3.3.E). Importantly, we herein 
demonstrate the direct and specific binding interaction between PODXL and dynamin-2 via in 
vitro His-tag pulldown assays using both purified recombinant dynamin-2 domains and PCT. 
Specifically, we show that purified GST-tagged PCT binds to recombinant His-tagged dynamin-
2 D3+D4 domains, but not to D4 alone (Figure 3.3.F). To further demonstrate the specificity of 
this binding interaction, we show that purified GST alone does not bind to either His-tagged 
constructs (Figure 3.3.F). Taken together, mass spectrometry followed by bioinformatics 
analysis, co-IP, colocalization staining and in vitro His-tag pulldown assays disclose that 
PODXL and dynamin-2 interact directly to form a complex in pancreatic cancer cells.  
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3.4.4 Pro-migratory phenotypes of PODXL-expressing cells are coupled to dynamin-2 
function 
To assess the functional significance of PODXL-dynamin-2 interaction, a dynamin-2 inhibitor, 
dynasore, or siRNA (siDNM2) were used in both scramble control and PODXL-KD SW1990 
cells. Dynasore (40 µM) significantly reduced the migration velocities of scramble control 
SW1990 cells to the identical levels of the DMSO-treated PODXL-KD cells in both unconfined 
and confined microchannels (Figure 3.4.A). Interestingly, dynasore had no additional inhibitory 
effect on PODXL-KD SW1990 cells. Similar phenotypic mimicry was also observed in the 
microtubule growth rate using EB1-GFP (Figure 3.4.B) and FA density (Figure 3.4.C). 
 
To eliminate any potential off-target effects of dynasore, siDNM2 was used to knock down 
dynamin-2 expression in both scramble control and PODXL-KD SW1990 cells (Figure 3.S4.A). 
Of note, PODXL knockdown did not affect dynamin-2 expression (Figure 3.S4.A). Similar to 
the data acquired using dynasore, dynamin-2 depletion decreased the migration of the scramble 
control SW1990 cells to the levels of PODXL-KD, without altering migration in PODXL-KD 
cells (Figure 3.S4.B). Cumulatively, these data disclose the functional role of dynamin-2 in 
mediating the cytoskeletal remodeling and pro-migratory effects of PODXL on pancreatic cancer 
cells.  
 
According to mass spectrometry results, NHERF2 was also enriched in the immunoprecipitate 
fraction of PODXL (Table 3.1). Since NHERF2 has been reported to act as a scaffolding protein 
that bridges the interaction between PODXL and ezrin in glomerular foot processes (148), we 
sought to delineate the potential role of NHERF2 in PODXL-dependent migration. Although 
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NHERF2 interacts with PODXL in SW1990 pancreatic cancer cells as evidenced by co-IP 
assays, dynamin-2 was not detected in the NHERF2 immunoprecipitate fraction (Figure 
3.S4.C). Also, NHERF2 was not detected in the dynamin-2 immunoprecipitate fraction (Figure 
3.S4.D). We next generated NHERF2-KD SW1990 cells using shRNA lentivirus (Figure 
3.S4.E), and compared their migratory potential to that of scramble controls. In distinct contrast 
to PODXL-KD and dynamin 2-KD cells, which displayed a markedly reduced migration 
velocity, NHERF2-KD cells moved much faster than scramble control cells (Figure 3.S4.F). Of 
note, NHERF2-KD cells exhibit a clear mesenchymal/protrusive phenotype in contrast to the 
epithelial/rounded morphology of scramble control or PODXL-KD cells. In view of these 
findings and given that PODXL and/or dynamin-2 knockdown suppress migration to an 
equivalent extent without any additive effect, we conclude that dynamin-2 regulates PODXL-
mediated migration of pancreatic cancer cells via its direct binding interaction with PODXL 
(Figure 3.3.F). The precise role of NHERF2 in pancreatic cancer cell migration, which may 
extend beyond PODXL, deserves further investigation that goes beyond the scope of this current 
study. 
 
3.4.5 Microtubule and Src kinase are downstream effectors of PODXL-dynamin-2 complex 
Because PODXL knockdown (Figure 3.2.B) and dynamin-2 inhibition (Figure 3.4.B) slow 
down microtubule growth with similar efficiency, we reasoned that microtubules represent a 
downstream target of the PODXL-dynamin-2 signaling cascade. In light of prior work showing 
that dynamin-2 regulates microtubule dynamic instability (164), we examined the effects of 
taxol, which stabilizes microtubules by preventing their depolymerization. Treatment of 
scramble control SW1990 cells with taxol (1.2 µM) had the same effect as dynamin-2 
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inhibition/knockdown or PODXL knockdown. Specifically, taxol suppressed the migration 
velocities of scramble control cells to the levels of untreated PODXL-KD cells (Figure 3.4.D). 
Of note, PODXL-KD SW1990 cells treated with taxol displayed a further, albeit moderate, 
reduction of migratory potential in microchannels with a width ≥10 µm, thereby indicating a 
potential mild synergistic effect.  
 
Microtubule polymerization towards FAs has been reported to induce FA disassembly, leading to 
more dynamic FAs (173). Along these lines, stabilizing microtubules via cell treatment with 
taxol increased both FA density and the percentage of total cell area covered by FAs in scramble 
control, but not PODXL-KD, SW1990 cells (Figure 3.4.E). Taken together, our data are in 
concert with the notion that PODXL, through its binding to dynamin-2, regulates microtubule 
dynamics, which in turn modulates FA assembly and disassembly. 
 
Evidence suggests that dynamin-2 forms a trimeric complex with FAK and Src kinase to induce 
FA disassembly by activating integrin endocytosis (162). Interestingly, treatment of scramble 
control SW1990 cells with the Src kinase inhibitor dasatinib (10 nM) recapitulated the 
phenotypic responses of PODXL knockdown. Specifically, dasatinib concurrently reduced the 
migration velocities (Figure 3.4.F) and increased the FA density and the percentage of total area 
covered by FAs (Figure 3.4.G) in scramble control cells. In marked contrast, Src kinase 
inhibition had a negligible effect on PODXL-KD SW1990 cells (Figure 3.4.F, Figure 3.4.G). 
Interestingly, dasatinib failed to modulate microtubule dynamics (Figure 3.S4.G), suggesting 
that Src kinase regulates migration and FA dynamics downstream of PODXL without involving 
microtubules. To validate the role of Src kinase in PODXL-dynamin-2-dependent migration of 
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pancreatic cancer cells, we also assessed the effect of PP2, a more specific Src kinase inhibitor, 
on migration of both SW1990 scramble control and PODXL-KD cells. Similar to Dasatinib, PP2 
inhibition reduced the velocity of the scramble control cells down to the same level as the 
PODXL-KD cells, without affecting the velocity of PODXL-KD cells (Figure 3.S4.H).  
 
3.4.6 PODXL knockdown decreases liver metastasis in vivo  
To test whether the enhanced migratory propensity of PODXL-expressing cells observed in vitro 
facilitates metastasis in vivo, we employed the well-established preclinical model of pancreatic 
cancer metastasis to the liver following a hemispleen injection technique (157). To this end, we 
injected 1×106 scramble control or PODXL-KD Pa03c pancreatic cancer cells into the spleen of 
mice (n=15 for scramble, n=12 for PODXL-KD). Knockdown of PODXL significantly 
decreased liver metastasis, as evidenced by the gross anatomy photographs (Figure 3.5.A) and 
further confirmed microscopically via histology (Figure 3.5.B). PODXL knockdown generated 
significantly smaller number of visible liver macrometastasis foci in mice (Figure 3.5.C). It is 
noteworthy that the size of the primary splenic tumor at the injection site was similar between 
scramble control and PODXL-KD Pa03c cells (Figure 3.5.D). Of note, immunohistochemistry 
staining for PODXL in primary splenic tumors derived from mice injected with PODXL-KD 
Pa03c cells showed a dramatic reduction in PODXL staining intensity relative to scramble 
control specimens (Figure 3.5.E), indicating that PODXL knockdown was maintained 
throughout the entire duration of the in vivo hemispleen experiment.  
 
We replicated the aforementioned findings with a second pancreatic cancer cell line, SW1990. 
Because of the larger size of SW1990 than Pa03c cells, injection of the 1×106 cells resulted in 
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high post-operative mortality approximating 90%, possibly due to clotting and thrombosis. 
Another potential reason for the differential prothrombotic profile of the two pancreatic cancer 
cell types could stem from inherent differential surface expression of procoagulant molecules, 
such as tissue factor that can initiate the coagulation cascade (174). In breast cancer cells, 
clotting time was determined to be both tissue factor- and cell number- dependent (175). As 
such, a lower number of cells (2×105) was attempted for injection into the spleen of mice to 
mitigate this issue. While the lower cell number did improve postoperative survival, about 40% 
of the mice still died after surgery. Despite the lower sample size (n=7 for scramble, n=5 for 
PODXL-KD), the inhibitory effect of PODXL knockdown on liver metastasis was even more 
pronounced, as almost all mice injected with the scramble control SW1990 cells developed liver 
metastasis, whereas only one out of five mice injected with PODXL-KD SW1990 cells 
developed metastasis (Figure 3.S5.A, Figure 3.S5.B, Figure 3.S5.C).  In concert with our 
findings using Pa03c cells, PODXL also failed to alter primary splenic tumors size (Figure 
3.S5.D). Moreover, PODXL knockdown was preserved in vivo for SW1990 tumors as evidenced 
by immunohistochemistry (Figure 3.S5.E). 
 
The growth of scramble control versus PODXL-KD cells was unaltered in vitro and in a 
subcutaneous injection model in vivo as quantified by the weight of tumors harvested post-
mortem, using Pa03c (Figure 3.S5.F, Figure 3.S5.G) and SW1990 (Figure 3.S5.H, Figure 
3.S5.I) cells. Collectively, these data reveal that the increased metastatic potential of PODXL-
expressing cells is attributed to their elevated capacity to migrate and metastasize in the liver 




By employing mass spectrometry followed by bioinformatics analysis, co-immunoprecipitation 
and in vitro His-tag pulldown assays, we herein demonstrate a novel direct binding interaction 
between the cytoplasmic tail of PODXL and the large GTPase dynamin-2. Given that PODXL 
knockdown and dynamin-2 inhibition suppress with similar efficiency microtubule growth rate, 
and that dynamin-2 is a microtubule-associated large GTPase, we reasoned that microtubules are 
a downstream target of the PODXL-dynamin-2 signaling cascade. This is further substantiated 
by a previous study showing that dynamin-2 regulates dynamic instability of microtubules (164). 
Because PODXL knockdown or dynamin-2 inhibition or stabilization of microtubules via cell 
treatment with taxol increase FA density and the percentage of total cell area covered by FAs, we 
propose a model by which PODXL, through its binding to dynamin-2, regulates microtubule 
dynamics, which in turn modulates FA assembly and disassembly (Figure 3.6). Specifically, we 
postulate that PODXL binds to and activates dynamin-2 at the cell periphery, where dynamin-2 
could enhance the dynamic instability of microtubules, causing microtubules to polymerize more 
towards existing FA and promote FA disassembly. Alternatively, dynamin-2, by forming a 
trimer with FAK and Src kinase (162), could also regulate FA turnover via a Src kinase pathway 
(Figure 3.6). Along these lines, our data reveal that Src kinase inhibition concurrently reduces 
cell migration and increases the FA density in scramble control, but not PODXL-KD, cells. We 
further postulate that both the microtubule- and Src kinase-dependent pathways, which are 
downstream of the PODXL-dynamin-2 signaling axis, regulate FA dynamics, thereby ultimately 
facilitating cell migration and metastasis (Figure 3.6). This proposed model was rigorously 
tested by inhibiting dynamin-2, microtubules and Src kinase. Interfering with any of these 
downstream targets causes the scramble cells to phenotypically mimic the PODXL-KD cells, as 
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evidenced by their slower cell migration, decreased microtubule growth rate and increased FA 
density, thus validating their functional significance in propagating the downstream effects of 
PODXL.  
 
The cytoplasmic domain of PODXL, despite its short size, has been reported to associate with 
proteins, such as ezrin and NHERF1/2 to mediate downstream signaling involved in cytoskeletal 
remodeling and cell migration (140,146). PODXL is considered to form a stable complex with 
ezrin, which in turns connects to actin filaments, leading to redistribution of actin towards the 
apical membrane in kidney podocytes (146). NHERF1 and 2, which are two highly homologous 
scaffold proteins with two PDZ domains and an ERM binding domain, interact directly with 
PODXL and serve as a linker between PODXL and ezrin (148). Interestingly, the N-terminus of 
ezrin has also been reported to bind directly to the HQRIS sequence in the juxtamembrane region 
of PODXL independent of NHERF1/2 (147). Binding of ezrin to PODXL, either directly or 
indirectly, activates ezrin, which in turn activates RhoA through sequestration of RhoGDI by 
activated ezrin (147). With its second PDZ domain binding to PODXL, the first PDZ domain of 
NHERF1 can also bind to Rac1 guanine nucleotide exchange factor ARHGEF7 to activate Rac1, 
promoting lamellipodia formation and cell migration (140).  
 
Although ezrin has emerged as a widely accepted binding partner of PODXL, there are reports 
showing that PODXL and ezrin may have non-related or even opposing effects in certain cancer 
types, thereby suggesting that the PODXL-ezrin association may not be as universal as one is led 
to believe. In urothelial bladder cancer, for instance, while high membranous PODXL expression 
correlates with poor prognosis (139), low membranous expression ezrin was instead an 
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independent marker of progression and disease-specific survival in another study (176). In our 
study, we consistently and repeatedly failed to identify the presence of ezrin in 
immunoprecipitated PODXL specimens either via immunoblotting or mass spectrometry. 
Moreover, the inability of PODXL knockdown to alter actin dynamics and RhoA or Rac1 
activity in pancreatic cancer cells further suggests that the pro-migratory role of PODXL is 
independent of the actin cytoskeleton and the classical Rac1 and/or RhoA signaling induced by 
ezrin following its binding to PODXL. Collectively, these previous reports showing that PODXL 
and ezrin have opposing effects on tumor cells, coupled with our data showing the absence of 
PODXL-ezrin association and the inability of PODXL knockdown to alter actin polymerization, 
strongly support the existence of a novel cytoplasmic binding partner, which we demonstrated to 
be dynamin-2. 
 
While there have been several in vitro studies on PODXL and its involvement in cancer, there is 
no preclinical animal model study aimed to evaluate the potential oncogenic role of PODXL in 
pancreatic cancer. To the best of our knowledge, the well-established preclinical model of 
pancreatic cancer metastasis to the liver via an injection using the hemispleen technique 
represents the first ever-reported in vivo model that directly assesses the effect of PODXL on 
pancreatic cancer metastasis. Prior in vivo models associated with PODXL have been performed 
primarily with breast cancer cells, where impairment in the formation of lung metastases was 
demonstrated with tail vein injection, subcutaneous injection and orthotopic implantation into 
mammary fat pad for PODXL-KD cells (152,177). In our work, we demonstrate that PODXL 
knockdown exerts a pronounced inhibitory effect on liver metastasis using two distinct 
pancreatic cancer cell lines without affecting primary splenic tumor growth. 
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The KRAS oncogene undergoes mutational activation in 95% of pancreatic ductal 
adenocarcinoma patients, and plays a crucial role in initiating and driving pancreatic cancer 
pathogenesis (178). In addition to KRAS, signal transducer and activator of transcription 3 
(STAT3) has been implicated in malignant transformation of pancreatic cancer (179). 
Interestingly, both KRAS and STAT3 interact with tubulin and microtubules (180,181). 
Moreover, oncogenic KRAS upregulates Src in pancreatic cancer cells (182). Because 69% of 
pancreatic ductal adenocarcinomas stain positively for PODXL (144), and given that MTs and 
Src regulate PODXL-dependent pancreatic cancer cell migration, the potential link among 
oncogenic KRAS, STAT3 and PODXL deserves to be investigated. 
 
In conclusion, we discovered a novel direct binding interaction between PODXL and dynamin-2 
that is critical for promoting the efficient migration in vitro and metastasis in vivo of pancreatic 
cancer cells. PODXL, through its binding to dynamin-2, regulates microtubule dynamics and Src 
activation, which in turn modulate FA assembly and disassembly, and ultimately regulate 
migration. The functional role of PODXL in promoting pancreatic cancer metastasis in vivo was 
demonstrated using a physiologically relevant hemispleen-based hepatic metastasis model.  
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3.6 Figures and tables 
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Figure 3.1 PODXL knockdown in pancreatic cancer cells suppresses random 2D migration 
and chemotactic migration inside unconfined and confined channels  
(A) Western blot showing efficient knockdown of PODXL in SW1990 pancreatic cancer cells 
using shRNA lipofectamine transfection followed by stable clonal selection. (B) Representative 
time-lapse micrographs of scramble control and PODXL-KD SW1990 cells migrating on 2D 
collagen I-coated glass coverslips. The images are spaced at 2 h intervals. (C) Average mean 
squared displacement (MSD) over time of migrating scramble control and PODXL-KD SW1990 
cells. Data represent the mean±S.E.M from 3 independent experiments. (D) Superimposed 
images of individual trajectories of scramble control and PODXL-KD SW1990 cells migrating 
on 2D collagen I-coated surfaces. (E) Representative time-lapse micrographs of scramble control 
(top row) and PODXL-KD (bottom row) SW1990 cells migrating inside 6 µm-wide, confined 
microchannels (left panels) and 50 µm-wide, unconfined microchannels (right panels). The 
images are spaced at 2 h intervals. Arrowheads indicate the leading edge of a migrating cell. (F) 
Migration velocity (left panel), speed (middle panel) and persistence (right panel) of scramble 
control and PODXL-KD SW1990 cells in PDMS-based microchannels of 10 µm in height, 200 
µm in length, and either 6, 10, 20 or 50 µm in width. Data represent the mean±S.E.M from at 






Figure 3.2 PODXL knockdown decreases microtubule growth rate and increases FA 
density without altering actin dynamics  
(A) Actin dynamics was assessed using FRAP at cell-cell junctions of scramble control and 
PODXL-KD SW1990 cells transiently transfected with LifeAct-GFP. Representative FRAP 
curves of the fraction of initial fluorescence intensity as a function of time for scramble control 
(red) and PODXL-KD (blue) cells (left panel). Mobile fraction (middle panel) and recovery half-
life (right panel) of LifeAct-GFP molecules in scramble control and PODXL-KD SW1990 cells. 
Data represent the mean±S.E.M. from 3 independent experiments.  (B) Average microtubule 
growth rate of scramble control and PODXL-KD SW1990 cells, as determined from the life 
history plots and kymographs of EB1 comets in cells transiently transfected with EB1-GFP. Data 
represent the mean±S.E.M from 3 independent experiments. (C) Representative TIRF 
microscopy images of immunostained phospho-paxillin in scramble control and PODXL-KD 
SW1990 cells. (D) Quantification of the average number of discrete FAs per cell area (left 
panel), FA area per total cell area (middle panel) and FA size (right panel) of scramble control 
and PODXL-KD SW1990 cells. Data represent the mean±S.E.M from 3 independent 






Figure 3.3 PODXL interacts with dynamin2 in pancreatic cancer cells 
(A) Ezrin was not detected in the immunoprecipitate fraction generated from SW1990 pancreatic 
cancer cells using a PODXL specific antibody. An IgG isotype antibody was used as a control. 
The right lane shows the presence of both PODXL and ezrin in SW1990 cell lysate input. (B) 
Co-IP experiments from SW1990 cell lysates were performed using either a PODXL (left 
panels) or a dynamin-2 (right panels) specific antibody along with matched isotype controls. The 
resultant immunoprecipitates were subsequently resolved with SDS-PAGE and blotted with 
antibodies against PODXL and dynamin-2. Dynamin-2 was detected in the immunoprecipitates 
of PODXL and vice versa.  The right lanes in both panels reveal the presence of both PODXL 
and dynamin-2 in SW1990 cell lysate inputs. The left lanes in both panels show the beads-only 
(no antibody) controls. (C) His-tagged constructs encompassing different domains of dynamin-2 
were used for the in vitro His-tag pulldown assay. Mid, middle domain; PH, pleckstrin homology 
domain; GED, GTPase effector domain; PRD, proline-rich domain. (C) In-vitro His-tag 
pulldown assays demonstrating that the GTPase, middle and pleckstrin homology domains of 
dynamin-2 are responsible for binding PODXL from SW1990 cell lysates. * denotes the 
respective His constructs. (E) In-vitro His-tag pulldown assay showing that His-tagged PODXL 
cytoplasmic tail (PCT) is sufficient to bind to endogenous dynamin-2 from SW1990 cell lysates. 
(F) In-vitro His-tag pulldown assay demonstrating that purified GST-tagged PCT binds to 
recombinant His-tagged dynamin-2 D3+D4 domains but not to D4 alone (left panel). Purified 
GST alone does not bind to either His-tagged constructs. # denotes the protein band of GST 





Figure 3.4 Inhibiting dynamin-2, microtubules or Src kinase abrogates the migratory 
potentiation and cytoskeletal remodeling effects of PODXL 
(A) Migration velocity of scramble control and PODXL-KD SW1990 cells inside microchannels 
of prescribed width after treatment with dynasore (40 µM). Data represent the mean±S.E.M. 
from 3 independent experiments. * represents p<0.05 between scramble DMSO control and all 
three other conditions, ¶ represents p<0.05 between scramble DMSO control versus scramble 
plus dynasore or PODXL-KD plus dynasore. (B) Microtubule growth rate of scramble control 
and PODXL-KD SW1990 cells following dynasore (40 µM) treatment as measured by an EB1-
GFP assay. Data represent the mean±S.E.M from 3 independent experiments. ** represents 
p<0.01, *** represents p<0.001. (C) FA density quantified as the number of discrete FAs per cell 
area (left panel) or FA area per total cell area (middle panel) and FA size (right panel) of 
scramble control and PODXL-KD SW1990 cells following dynasore (40µM) treatment, as 
assessed by TIRF imaging of phospho-paxillin immunostaining. Data represent the mean±S.E.M, 
* represents p< 0.05, ** represents p<0.01, *** represents p<0.001, **** represents p<0.0001. 
(D) Migration velocity of scramble control and PODXL-KD SW1990 cells inside microchannels 
of prescribed width after taxol (1.2 µM) treatment. Data represent the mean±S.E.M. from 3 
independent experiments. * represents p<0.05 between scramble DMSO control and all three 
other conditions. # represents p<0.05 between PODXL-KD plus taxol versus scramble plus taxol 
or PODXL-KD plus DMSO control. ¶ represents p<0.05 between PODXL-KD plus taxol versus 
PODXL-KD plus DMSO control. (E) FA density quantified as described in (C) using scramble 
control and PODXL-KD SW1990 cells after taxol (1.2µM) treatment, as assessed by TIRF 
imaging of phospho-paxillin immunostaining. Data represent the mean±S.E.M. from 3 
independent experiments. ** represents p<0.01, *** represents p<0.001, **** represents 
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p<0.0001. (F) Migration velocity of scramble control and PODXL-KD SW1990 cells inside 
microchannels of prescribed width after dasatinib (10 nM) treatment. Data represent the 
mean±S.E.M. from 3 independent experiments. * represents p<0.05 between scramble DMSO 
control and all three other conditions, ¶ represent p<0.05 between scramble DMSO control 
versus scramble control plus dasatinib or PODXL-KD plus dasatinib. (G) FA density quantified 
as described in (C) using scramble control and PODXL-KD SW1990 cells after dasatinib (10 
nM) treatment, as assessed by TIRF imaging of phospho-paxillin immunostaining. Data 
represent the mean±S.E.M from 3 independent experiments. *** represents p<0.001, **** 





Figure 3.5 PODXL knockdown decreases metastasis in vivo in a preclinical murine model 
of pancreatic cancer metastasis using a hemispleen injection technique 
(A) Gross anatomical pictures of representative livers harvested from mice injected with 
scramble control (top row) or PODXL-KD (bottom row) Pa03c cells via the hemispleen 
technique. Yellow arrowheads indicate visible liver macrometastases. (B) Representative 
histological sections of livers harvested from mice injected with scramble control (top row) or 
PODXL-KD (bottom row) Pa03c cells. Black arrowheads indicate areas of metastasis. (C) 
Quantification of the number of visible liver macrometastasis foci observed on the harvested 
livers and (D) the volume of the primary splenic tumor of mice injected with scramble control or 
PODXL-KD Pa03c cells. Data represent the mean±S.E.M from 15 and 12 mice for the scramble 
control and PODXL-KD groups, respectively. * represents p<0.05. (E) Representative 
immunohistochemistry sections of primary splenic tumors derived from scramble control (left) 
or PODXL-KD (right) Pa03c cells stained for PODXL reveal that PODXL knockdown is 





Figure 3.6 Proposed mechanism by which PODXL facilitates pancreatic cancer cell 
migration and metastasis 
(1) PODXL is a transmembrane protein expressed on pancreatic cancer cells. The cytoplasmic 
tail of PODXL binds to dynamin-2, thereby recruiting dynamin-2 close to the plasma membrane. 
(2) The local enrichment of dynamin-2 causes increased microtubule growth rates and dynamics. 
(3) Polymerization of microtubules towards FA sites induces FA disassembly. (4) Alternatively, 
dynamin-2 proximal to the membrane could also interact with FAK and Src kinase to form a 
trimeric complex next to FAs. (5) Src kinase then phosphorylates and activates dynamin-2, 
leading to endocytic internalization of integrin and FA disassembly. (6) All these events lead to 
the cells having less FAs, ultimately resulting in increased migration in vitro and enhanced 
metastasis in vivo. Dashed lines denote data from prior work while solid lines represent findings 





Figure 3.S1 PODXL knockdown alters cellular morphology and diminishes 
morphodynamics of SW1990 cells, and decreases migration in Pa03c pancreatic and MDA-
MB-231 breast cancer cells 
(A) Morphological parameters (projected area, circularity and solidity) of scramble control and 
PODXL-KD SW1990 cells migrating on 2D collagen I-coated surfaces. (B) Morphodynamic 
parameters (changes in projected area, circularity and solidity) of scramble control and PODXL-
KD SW1990 cells migrating on 2D collagen I-coated surfaces. Data represent the mean±S.E.M 
from 3 independent experiments. ** represents p<0.01, *** represents p<0.001, **** represents 
p<0.0001. (C) Western blots showing efficient knockdown of PODXL in SW1990 (left panel), 
Pa03c (middle panel) pancreatic cancer cells, and MDA-MB-231 breast cancer cells (right panel) 
using shRNA lentiviruses. Migration velocity of scramble control, PODXL-KD1 and PODXL-
KD2 SW1990 (D), Pa03c (E) and MDA-MB-231 cells (F) inside microchannels of prescribed 
widths. Data represent the mean±S.E.M. from 3 independent experiments. * represents p<0.05 





Figure 3.S2 PODXL knockdown does not modulate RhoA/Rac1 activity 
Western blot of scramble control and PODXL-KD SW1990 specimens using pull-down 
activation assays for active RhoA (A) and active Rac1 (B). PODXL silencing does not alter the 
levels of active RhoA or active Rac1. Total RhoA/Rac1 and β-actin served as loading controls. 





Figure 3.S3 PODXL interacts and colocalizes with dynamin-2 
Co-immunoprecipitation experiments from Pa03c pancreatic cancer cell lysates (A) and MDA-
MB-231 breast cancer cell lysates (B) were performed using either a PODXL (left panels) or a 
dynamin-2 (right panels) specific antibody along with match isotype controls. The resultant 
immunoprecipitates were subsequently resolved with SDS-PAGE and blotted with antibodies 
against PODXL and dynamin-2. Dynamin-2 was detected in the immunoprecipitates of PODXL 
and vice versa. The right lanes in both panels reveal the presence of both PODXL and dynamin-2 
in Pa03c and MDA-MB-231 cell lysate inputs. The left lanes in both panels show the beads-only 
(no antibody) controls. (C) Representative immunofluorescence images of PODXL (green) and 
dynamin-2 (red) with a counter-stained nucleus (blue) showing colocalization of PODXL and 
dynamin-2 in SW1990 pancreatic cancer cells as shown in a XY (top panel) and a YZ projection 







Figure 3.S4 Effects of knocking down dynamin-2 and NHERF2, and inhibiting Src kinase 
on PODXL-mediated cytoskeletal changes and migration of SW1990 cells 
(A) Western blot showing efficient knockdown of dynamin-2 using siRNA in both scramble 
control and PODXL-KD SW1990 pancreatic cancer cells. (B) Migration velocity of scramble 
control and PODXL-KD SW1990 cells following dynamin-2 knockdown by siRNA treatment in 
microchannels of prescribed widths. Data represent the mean±S.E.M. from 3 independent 
experiments. * represents p<0.05 between scramble siCtr and all three other conditions. ¶ 
represents p<0.05 between scramble siCtr and PODXL-KD siDNM2. (C) Co-
immunoprecipitation assays from SW1990 pancreatic cancer cell lysates were carried out using a 
NHERF2 specific antibody along with a match isotype control. The resultant immunoprecipitates 
were subsequently resolved with SDS-PAGE and blotted with antibodies against PODXL, 
dynamin-2 and NHERF2. NHERF2 and PODXL, but not dynamin-2, were detected in the 
NHERF2 immunoprecipitate fractions. The right lanes reveal the presence of PODXL, dynamin-
2 and NHERF2 in SW1990 cell lysate inputs. (D) Co-immunoprecipitation assays from SW1990 
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pancreatic cancer cell lysates were carried out using a dynamin-2 specific antibody along with a 
match isotype control. The resultant immunoprecipitates were subsequently resolved with SDS-
PAGE and blotted with antibodies against dynamin-2 and NHERF2. NHERF2 was not detected 
in the dynamin-2 immunoprecipitate fractions. The right lanes reveal the presence of dynamin-2 
and NHERF2 in SW1990 cell lysate inputs. (E) Western blot showing efficient knockdown of 
NHERF2 in SW1990 pancreatic cancer cells using shRNA lentiviruses. NHERF2-KD1 and KD4 
resulted in the highest degree of knockdown and were used in subsequent migration experiments. 
(F) Migration velocity of scramble control, NHERF2-KD1 and NHERF2-KD4 SW1990 cells in 
microchannels of prescribed widths. Data represent the mean±S.E.M. from 3 independent 
experiments. * represents p<0.05 between scramble control and NHERF2-KD1 or NHERF2-
KD4. # represents p<0.05 between NHERF2-KD1 and NHERF2-KD4. (G) Microtubule growth 
rate of scramble control and PODXL-KD SW1990 cells following dasatinib (10 nM) treatment 
as measured by an EB1-GFP assay. Data represent the mean±S.E.M. from 3 independent 
experiments. * represents p< 0.05, ** represents p<0.01, *** represents p<0.001. (H) Migration 
velocity of scramble control and PODXL-KD SW1990 cells inside microchannels of prescribed 
width after PP2 (10 µM) treatment. Data represent the mean±S.E.M. from 3 independent 
experiments. * represents p<0.05 between scramble DMSO control and all three other 







Figure 3.S5 PODXL knockdown decreases liver metastasis in vivo for SW1990 pancreatic 
cancer cells and does not affect tumor growth in vitro or in vivo 
(A) Gross anatomical pictures of representative livers harvested from mice injected with 
scramble control (top row) or PODXL-KD (bottom row) SW1990 cells via the hemispleen 
technique. Yellow arrowheads indicate visible liver macrometastases. (B) Representative 
histological sections of livers harvested from mice injected with scramble control (top row) and 
PODXL-KD (bottom row) SW1990 cells. Black arrowheads indicate areas of metastasis. (C) 
Quantification of the number of visible liver macrometastasis foci observed on the harvested 
livers and (D) the volume of the primary splenic tumor of mice injected with scramble control or 
PODXL-KD SW1990 cells. Data represent the mean±S.E.M from 7 and 5 mice for the scramble 
control and PODXL-KD groups, respectively. * represents p<0.05. (E) Representative 
immunohistochemistry sections of primary splenic tumor derived from scramble control (left) or 
PODXL-KD (right) SW1990 cells stained for PODXL showing that PODXL knockdown is 
maintained in vivo. In vitro growth curves of scramble control and PODXL-KD Pa03c (F) and 
SW1990 (H) pancreatic cancer cells. Data represent the mean±S.E.M. from 3 independent 
experiments. In vivo growth of scramble control and PODXL-KD Pa03c (G) and SW1990 (I) 
pancreatic cancer cells in a subcutaneous injection model, as assessed by the weight of tumors 
harvested post-mortem. Data represent the mean±S.E.M from 20, 20, 12 and 8 mice for scramble 
control Pa03c, PODXL-KD Pa03c, scramble control SW1990 and PODXL-KD SW1990, 










Normalized Spectra Count Protein functions 
Bead Isotype PODXL Ab 
Podocalyxin isoform 
2 precursor  
33598950 55 - - 3.0 Cell adhesion, cell migration, 
glomerular microvillus assembly 
Dynamin-2 isoform 5  299758394 98 - - 3.0 Endocytosis, membrane fusion, 
mitochondrial fission, golgi 
organization, G2/M transition of 
mitosis, apoptosis, transcription, 
Rac signaling, lamellipodium 
assembly, adhesion-dependent 
cell spreading, antigen processing 
and presentation, nitric oxide 
biosynthesis, synaptic vesicle 
transport, development of neuron, 
cilium, heart and sperm 
Na+/H+ exchange 
regulatory cofactor 
NHERF2 isoform a 
194018553 
 




16A isoform a  
15100151 63 - - 3.0 Monoacylglycerol catabolism 
Cytochrome P450 
2S1 precursor 
13449277 56 - - 3.0 Redox process 
Serine-tRNA ligase, 
cytoplasmic 
16306548 59 - - 3.0 Translation, tRNA processing, 
selenocysteine metabolism 
Acyl-protein 




23 0.6 - 2.4 Fatty acid metabolism, golgi to 
plasma membrane protein 
















215820635 89 0.2 0.4 2.4 Transcription, apoptosis, cell 
differentiation, cell-cell adhesion, 
p53 signal transduction, cardiac 
development, hair cycle 








- 0.6 2.4 Energy production and 
conversion 
60S ribosomal 
protein L18 isoform 1 
4506607 22 - 0.7 2.3 Translation, ribosomal structure 
and biogenesis 




Table 3.1 Summary of results from mass spectrometry analysis of immunoprecipitate 
fraction generated from SW1990 pancreatic cancer cells using a PODXL specific antibody 
An isotype antibody and beads-only samples were included as additional controls to account for 
non-specific interactions. Immunoprecipitate fractions were submitted for mass spectrometry 
analysis. Proteins presented in the table were filtered to include only those that showed 
preferential enrichment in the PODXL antibody samples relative to the other controls (≥2X 
enrichment relative to the two controls). A brief description of the protein function is also 










isoform 1 precursor 
614458221 71 0.7 - 2.3 Pyruvate metabolism, 
gluconeogenesis, insulin 
secretion, response to 
lipopolysaccharide and glucose 
UDP-glucose 6-
dehydrogenase 
isoform 2  
296040443 
 
48 0.4 0.3 2.3 Carbohydrate metabolism, redox 
process, 
Histone H4 77539758 11 1.0 - 2.0 Nucleosome assembly, 












29 0.5 0.5 2.0 rRNA processing, ribosome 
assembly, mitotic spindle 
organization, cell proliferation, 
bone development, leukocyte 
chemotaxis,  
Tubulin alpha-4A 
chain isoform 1 
17921989 
 





Chapter 4 - Predicting Progression-Free Survival and Recurrence 
Time of Primary Glioblastoma Using a Microfluidic Invasion 
Network Device (MIND) 
4.1 Abstract 
Glioblastoma (GBM) is the most aggressive form of brain cancer, characterized by high 
recurrence and dismal prognosis. Presently, there is no effective in vitro platform that can rapidly 
measure complex cellular phenotypic traits and accurately predict patient-specific clinical 
outcomes. Here, we fabricated and employed an in vitro testing platform, Microfluidic Invasion 
Network Device (MIND), and screened a panel of 22 patient-derived primary GBM specimens in 
a blind manner. We evaluated the ability of GBM cells to navigate and squeeze through confined 
microenvironments that mimic in vivo tight perivascular conduits and white matter tracts in the 
brain parenchyma, as well as the proliferative capacity of highly motile subpopulations. By 
combining migratory- and proliferative-based indices, MIND predicts progression-free survival 
(p=0.008) and time to recurrence (p=0.006) retrospectively with high sensitivity (85%), 
specificity (89%), and accuracy (86%). In a pilot prospective study, MIND classified all patients 
accurately based on their survival outcomes. Overall, our study suggests that invasive growth is 
intimately linked with GBM progression and patient outcomes, and reveals the translational 
potential of MIND for personalized GBM care. 
 
4.2 Introduction 
Glioblastoma (GBM) is the most common and aggressive type of primary brain cancer in adults, 
accounting for about 15-20% of all brain malignancies (19). Owing to its high proliferative and 
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infiltrative nature, the median patient survival of GBM is only approximately 14.6 months with 
less than 5% of patients surviving past 5 years (19,25). GBMs invade locally into the 
surrounding brain parenchyma and frequently spread to the contralateral hemisphere through the 
corpus callosum, thereby confounding local therapy and rendering gross total resection nearly 
impossible (23-25). As a result, despite aggressive radical surgical resection coupled with 
concurrent chemo- and radio- therapy, GBMs remain incurable and recur frequently (26).  
 
To date, there is a lack of testing platforms that can effectively predict GBM outcomes in a 
patient-specific manner. While certain demographic (e.g. age), tumor (e.g. tumor locations, 
cytologic and histologic compositions) and clinical parameters (e.g. Karnofsky Performance 
Score) have demonstrated some prognostic values in terms of survival correlation, they are often 
confounded by patient comorbidities, and thus rarely affect GBM treatment decision (183,184). 
Recent advancements in proteomics and genomics have identified certain molecular markers, 
such as O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation and isocitrate 
dehydrogenase 1 (IDH1) mutation status, as independent prognostic factors for gliomas 
(30,41,42,185-189). MGMT promoter methylation has been shown to be associated with longer 
overall survival and enhanced sensitivity to therapy (43,190-192). However, inter- and intra- 
tumoral heterogeneity coupled with the lack of standardization and reproducibility of MGMT 
methylation status classification have prevented its widespread use in the clinic (193,194). IDH1 
mutation status has emerged as one of the leading prognostic markers for gliomas. Specifically, 
low-grade glioma patients harboring the mutant form of IDH1 have improved prognosis and 
median survival compared to those expressing the wildtype IDH1 (195). Yet, the prognostic 
power of IDH1 mutation status on primary GBM remains limited as IDH1 mutations are often 
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associated with lower grades diffuse gliomas (Grade II and III) and with secondary GBM (46). 
Finally, the use of laborious and time-consuming ex vivo expansion of cancer cells in murine 
xenograft model for phenotypic testing is impractical for informing patient care given the short 
survival span of GBM patients (196). 
 
Cell population-based molecular analysis techniques often overlook the inherent diversity of 
cancer cells and suffer from the inability to discern inter- and intra- tumoral heterogeneity that 
may contribute to the aggressiveness of GBM (197). While high throughput single-cell genomic 
and proteomic analyses could potentially ameliorate the problem of tumor heterogeneity, these 
techniques require sophisticated and expensive equipment and facilities, rendering their 
widespread application rather infeasible in most clinical settings (198,199). Importantly, the 
aggressiveness of cancers is frequently a result of an amalgamation of multiple distinct 
combinations of genetic and proteomic alterations, which cannot be predicted accurately by just 
one or two molecular markers and might be difficult to decipher (200). The heterogeneous and 
complex nature of GBM therefore necessitate the development of more direct, faster, 
inexpensive, high throughput and unbiased in vitro testing platform for GBM prognosis at single 
cell resolution capable of dissecting the heterogeneity among the cancer cells derived from 
individual patients. It is known that highly metastatic subpopulations of cancer cells have 
enhanced motility and proliferation rates that are linked to the aggressiveness and invasiveness 
of the cancer (201,202). The ability to identify a subpopulation of migratory and proliferative 
cells from a patient’s heterogeneous tumor could therefore be the key to predicting prognosis and 
tailoring optimal personalized treatments for GBM patients.  
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With the aim to identify GBM patients with highly aggressive disease and therefore poor 
prognosis, we developed and fabricated a Microfluidic Invasion Network Device (MIND) that 
can be used to concurrently evaluate the migratory and proliferative potentials of patient-derived 
primary GBM cells. MIND consists of two parallel seeding and media channels connected by a 
series of 10 µm-high Y-shaped microchannels (99) with 20 µm-wide stem feeder channels 
bifurcating into either a 10 µm- or 3 µm-wide branches (Figure 4.1.A). These microchannels 
aim to recapitulate aspects of the complex topography and confining longitudinal pores or 
perivascular tracks of the brain parenchyma formed between glial cells and the basement 
membrane of vascular smooth muscle cells which ranges from 10-300 µm2 in diameter (57). By 
quantifying the abundance of highly motile cells that have successfully navigated the Y-shape 
microchannels and the proliferative potential of these migratory subpopulations, we demonstrate 
that MIND can predict individual patient survival and time to recurrence with close to 90% 
sensitivity, specificity and accuracy in our retrospective patient cohort. Furthermore, in a pilot 
prospective study MIND successfully classified all patients accurately based on their survival 
outcomes. Overall, our study suggests that invasive spread and tumor growth are primary 
hallmarks of tumor aggressiveness, which can be exploited to accurately predict patient clinical 
outcomes. 
 
4.3 Materials and methods 
4.3.1 Cells and cell culture 
Patient-derived primary human GBM cells (Retrospective: GBM153, GBM276, GBM318, 
GBM496, GBM499, GBM501, GBM549, GBM609, GBM612, GBM626, GBM651, GBM653, 
GBM692, GBM714, GBM731, GBM832, GBM897, GBM940, GBM960, GBM965, GBM1049, 
	 104	
GBM1298; Prospective: GBM1280, GBM1283, GBM1295, GBM1296) were isolated from 
primary tumor tissue samples of patients undergoing brain resection surgery for GBM at the 
Johns Hopkins Hospital with approval of the Institutional Review Board. All tumor samples 
were pathologically confirmed to be GBM. Tissue donors did not receive any treatment prior to 
surgery. The primary cells were isolated, purified and maintained through previously described 
methods that eliminate cross-contamination from other cell types and are capable of maintaining 
the stemness and molecular characteristics of the original primary tumors (203). The primary 
GBM cells were grown as adherent cultures on tissue culture flasks pre-coated with laminin 
(Trevigen) at a density of 1 µg/cm2 surface area diluted with PBS without magnesium and 
calcium for 3 h at 37°C. The culture media consisted of 1:1 Dulbecco's Modified Eagle 
Medium/Nutrient Mixture F-12 (DMEM/F12, Invitrogen), Gem21 NeuroplexTM without vitamin 
A serum-free supplement (Gemini), 1× antibiotic/antimycotic solution (Sigma-Aldrich), 10 
ng/ml of recombinant human fibroblast growth factor (Peprotech) and 20 ng/ml of recombinant 
human epidermal growth factor (Peprotech). Accutase solution (Sigma-Aldrich) was used to 
dissociate cells from the laminin-coated tissue culture flasks instead of trypsin. 
 
4.3.2 Microfluidic Invasion Network Device (MIND) 
MIND comprised a series of 400 µm-long and 10 µm-tall Y-shape microchannels (99), with a 20 
µm-wide feeder channel bifurcating at an angle of 65° to 10 µm-wide or 3 µm-wide branches, 
arrayed perpendicularly between cell seeding (100 µm-wide, 50 µm-high) and media channels 
(400 µm-wide, 50 µm-high). There are a total of 243 Y-shape microchannels per device spaced 
at an interval of 50 µm from each other.  
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MIND was fabricated using standard multilayer photolithography and replica molding 
techniques (77,98). The design of the microfluidic device was created in AutoCAD (Autodesk) 
and transferred to chrome-on-glass darkfield photolithography masks (Photoplot Store). The 
primary feature of the negative silicon wafer mold, corresponding to the Y-shape microchannels, 
was fabricated using SU-8 3010 negative photoresist (Microchem). SU-8 3010 was spun to a 
thickness of 10 µm on a cleaned silicon wafer (University Wafer) with a spin-coater (Single 
Wafer Spin Processor, Model WS-400A-6NPP-LITE, Laurell Technologies). The film was soft 
baked and UV-exposed through a photomask defining the Y-shape microchannels array using an 
EVG620 mask aligner (EVG) at 170 mJ/cm2. The exposed wafer was then baked, developed 
with SU-8 developer, rinsed with isopropanol and dried. To fabricate the cell and medium inlet 
lines, the photolithography step was repeated using a 50 µm-thick layer of SU-8 3025, with 
exposure through a mask defining the cells and medium feed lines aligned over primary features 
at 250 mJ/cm2. The completed wafer was passivated by treating with (tridecafluoro-1,1,2,2,-
tetrahydrooctyl)-1-trichlorosilane (Pfaltz & Bauer) overnight in a vacuum desiccator. 
 
Completed MIND was formed using standard replica molding from the silicon wafer. PDMS 
elastomer and crosslinker (Sylgard® 184 Silicone Elastomer Kit, Dow Corning) were mixed at a 
10:1 w/w ratio, poured over the wafer, degassed in a vacuum, and cured at 85 °C for 2 h.  
Solidified PDMS were peeled off of the wafer, punched with a 5 mm-diameter hole puncher at 
the designated well inlets and outlets and cut into appropriate sizes. The cut PDMS devices and 
25 mm × 75 mm microscope slides (Electron Microscopy Sciences) were cleaned with 100% 
ethanol, blown dry with filtered air, and treated with oxygen plasma (Plasma Cleaner PDC-32G, 
Harrick Plasma) for 2 min at 18W to render the surfaces hydrophilic. The plasma treated PDMS 
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devices were subsequently attached and sealed to the glass slides. To enable cell binding and 
adhesion, each MIND device was coated with 3 µg of laminin 1 (Trevigen) diluted in PBS 
without magnesium and calcium at 37 °C for 1 h followed by 4 °C overnight.  
 
4.3.3 MIND assay 
Patient-derived primary GBM was detached from laminin-coated tissue culture flask with 
Accutase, counted and resuspended to a final concentration of 1 × 106 cells/ml. Prior to cell 
seeding, laminin coating solution was aspirated from the microchannels and the devices were 
washed once with PBS without magnesium and calcium. 30 µl was added to the bottom most 
medium inlet reservoir as backpressure to prevent the cells from prematurely traversing the Y-
shape microchannels by convective flow. 50 µl of cell suspension, which is equivalent to 5 × 105 
cells, was then introduced to the right cell seeding inlets and the cells were allowed to incubate at 
37 °C for 5 min to allow for attachment and seeding at the entrance of the Y-shape 
microchannels. After 5 min, 30 µl was transferred to the left cell seeding inlets to enable cell 
flow and seeding from the other direction, followed by another 5 min of incubation. Afterwards, 
all cell suspension was removed and transferred from the right cell seeding inlets and the left cell 
seeding inlets, and the cells were then incubated again for another 5 min. All remaining cells in 
the cell inlets reservoir were then removed. 100 µl of GBM media was then introduced to each of 
the three medium inlet reservoirs and also the cell seeding inlets on the right side of the device. 
Migration of GBM in MIND was visualized and recorded via time-lapse live microscopy via 
software-controlled stage automation. The cells were imaged via a 10x/0.30 numerical aperture 
Ph1 objective lens every 20 min for 24 h using a Digital Sight Qi1Mc camera mounted on a 
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Nikon Inverted microscope equipped with a stage top incubator (Tokai Hit Co., Shizuoka, Japan) 
maintained at 37°C with 5% CO2 and humidity.  
 
The video was inspected visually and analyzed using the NIS Elements Viewer to quantify the 
number of highly motile and lowly motile cells. Highly motile cells are defined as cells that 
migrate up the feeder channels, reach the bifurcation and enter either one of the two branches. 
Conversely, lowly motile cells include the cell population that enter and migrate in the feeder 
channels but do not enter the bifurcations. Tracking for a cell ceases either after more than half 
of the cell body has entered the bifurcations or has exited the bottom of the feeder channels. 
Cells are excluded from analysis if they 1) started already more than half way in the feeder 
channels at the beginning of the experiment; 2) undergo cell division; 3) exited and reenter the 
microchannels. The % of highly motile cells was calculated as the ratio of highly motile cells 
over the sum of both highly motile and lowly motile cells. The number of cells that either enter 
the 3 µm or and 10 µm-wide branches were also recorded for the calculation of % of narrow 
entry, which is defined as the % of highly motile cells that enter the 3 µm narrow channels. 
 
4.3.4 Ki67 Immunofluorescence staining 
Patient-derived primary GBM cells were seeded into MIND as per the protocol used for the 
migration study and allowed to migrate in MIND for 24 h at 37°C. Cells were fixed in 4% 
paraformaldehyde for 20 min, permeabilized in 1% Triton X-100 for 10 min and blocked for 2 h 
in blocking buffer comprising PBS without magnesium and calcium with 2% bovine serum 
albumin and 0.1% Triton X-100. Cells were incubated with Ki67 (8D5) mouse monoclonal 
antibody (Cell Signaling, 9449S, 1:800) diluted in blocking buffer at 4°C overnight, followed by 
	 108	
2 h incubation with Alexa Fluor 488 goat anti-mouse secondary antibody (Invitrogen, A11001, 
1:200) and Hoechst 33342 (ThermoFisher Scientific, H3570, 1:2000) diluted in blocking buffer 
in room temperature protected from light. The cells were washed thoroughly with PBS without 
magnesium and calcium between each step. Imaging of the immunostained samples was 
performed on an inverted Eclipse Ti epifluorescence microscope (Nikon) with a 10×/0.30 
numerical aperture lens. The % Ki67-positive cells was calculated for the highly motile cells (i.e. 
% highly motile Ki67-positive cells) and for all of the cells that enter the Y-shape microchannels 
(i.e. % unsorted Ki67-positive cells). 
 
4.3.5 Western blot and antibodies 
Standard western blot techniques were performed as previously described (159). The antibodies 
used are listed below. Primary antibodies: 1) IDH1 (D2H1) rabbit mouse monoclonal antibody 
(Cell Signaling, 8137S, 1:1000). 2) Anti-IDH1 R132H mouse monoclonal antibody (Sigma 
Aldrich, SAB4200548, 1:250). 3) GAPDH (14C10) rabbit monoclonal antibody (Cell Signaling, 
2118S, 1:2000). Secondary antibodies: 1) Anti-mouse IgG, HRP-linked antibody (Cell Signaling, 
7076S, 1:2000). 2) Anti-rabbit IgG, HRP-linked antibody (Cell Signaling, 7074S, 1:2000). 
 
4.3.6 Correlation between in vitro MIND and clinical data 
To assess the relationship between the migratory and proliferative measurements obtained with 
MIND to clinical patient outcome, the samples were separated into low and high survival groups 
based on the threshold of 14.6 month of median GBM patient survival established by Stupp et al. 
(25). Student’s t-test was conducted to detect statistical difference between the MIND 
measurement metrics between the high versus low survival groups. Additionally, Pearson’s 
	 109	
correlation analysis was conducted to assess the linear correlation between the MIND 
measurement metrics and patient survivals (in months).  
  
4.3.7 Identification of optimal threshold 
The thresholds of the in vitro MIND measurement metrics were systematically varied. For each 
threshold value, the % of the in vitro MIND measurement metric was compared against to 
classify the samples into either high survivors (< threshold) or low survivors ((≥threshold). 
MIND’s prediction was then compared to the actual patient survival months which have been 
previously stratified into high and low survivors based on the 14.6 months median GBM patient 
survival established by Stupp et al (25), to label each prediction as true positive, true negative, 
false positive, or false negative (where true represents a match between MIND’s prediction and 
actual patient survival, and positive/negative denotes low/high survivors respectively). With 
these classifications, the prediction performance characteristics, including sensitivity, specific, 
PPV, NPV and accuracy, of the MIND measurement metric at that particular threshold value was 
computed. This process is iterated for the entire range of each MIND measurement metric and 
the optimal threshold value was selected at a value that maximizes the average of all the 
prediction performance characteristics. 
 
4.3.8 Assessment of the prognostic value of MIND measurement metrics 
The patient survival data was plotted as a Kaplan-Meier graph and the mean survival time in 
months of patients were compared between the groups separated by the optimal threshold 
determined. Log-Rank (Mantel Cox) test was conducted to detect statistical significance between 
the two survival curves. The performance characteristics, including sensitivity, specificity, 
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positive predictive value (PPV), negative predictive value (NPV), accuracy and area under 
curves of receiver operating characteristic curve, of each of the MIND measurement metric in 
successfully classifying patients into either low and high survivors was computed and tabulated. 
Additionally, the time to recurrence of the samples was compared between groups as separated 
by the optimal threshold. Similar Kaplan-Meier curve comparisons were also made with 
demographic, surgical and tumor characteristic information collected from the patients to assess 
the prognostic values of these other clinically available indices.  
 
4.3.9 Logistic Regression 
A composite MIND score that combines the individual MIND measurement metrics was 
computed via logistic regression, where the probability of each sample belonging to the low 
survival group (i.e <14.6 months) was calculated based on the predictors (Xi): % highly motile 
cells, % narrow entry and % highly motile Ki67-positive cells (Equation 1). Logistic regression 
coefficients (bi) were determined in MATLAB using the glmfit function for all the retrospective 
cell lines (n=22) based on the high and low GBM survival stratification of 14.6 months (Table 
4.S2). Probability values, namely composite MIND scores, were calculated in MATLAB using 
the glmval function. Similar threshold identification, correlation and Kaplan-Meier curve 
comparison analyses as described above were repeated with the composite MIND score to 
evaluate its prognostic performance. 
𝑝 = !
(!! ! ! !!! ! ! !!! ! ! !!!)
!! !(!! ! ! !!! ! ! !!! ! ! !!!)
           (Equation 1) 
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4.3.10 Statistical analysis 
All data are presented as mean±S.E.M. from n≥3 independent experiments unless otherwise 
stated. Graphing and statistical analyses were performed with GraphPad Prism 7 (GraphPad 
Software). Statistical significance was determined between pairs of data with an unpaired 
student’s t-test for continuous variables and Fisher’s exact test for categorical variables. 
Pearson’s correlation was used to assess the degree of correlation between two continuous 
variables. Two-tailed log-rank (Mantel-Cox) test was employed to assess the statistical difference 
between two Kaplan-Meier survivor curves.  
 
4.4 Results 
4.4.1 MIND distinguishes patient-derived primary GBM cells based on their migratory and 
proliferative potentials 
To assess the capacity of MIND to predict individual GBM patient outcomes, we evaluated the 
migratory and proliferative potentials of patient-derived primary GBM cells. All cells that enter 
the feeder channels were analyzed and classified into 2 categories based on their migratory 
behaviors: lowly motile cells are defined as cells that migrated into the feeder channels but failed 
to reach and/or enter the bifurcations, while highly motile cells are defined as cells that 
successfully traversed the entire length of the feeder channels and entered either one of the 
branch channels (Figure 4.1.A). Using live-cell imaging, we calculated the percentage of highly 
motile cells that migrated in the microchannels, and the percentage of these highly motile cells 
that preferentially entered the narrower 3 µm-wide branches (termed as percentage of narrow 
entry). Aside from cell migration, cell proliferation is also an important factor that governs 
cancer aggressiveness and ability to colonize (204). Ki67 is a nuclear antigen that is specific to 
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actively proliferating cells and has been used in the clinic to evaluate cancer patient prognosis 
(205,206). With MIND, we have the unique ability to assess the proliferative capacities of 
GBMs, either for the unsorted total population or specifically for the sorted highly motile 
subpopulation. Actively proliferating cells would stain positive for Ki67 (Figure 4.1.B). The 
percentages of Ki67-positive highly motile or unsorted cells were quantified.  
 
A retrospective panel of 22 patient-derived primary GBM cells with complete clinical outcome 
information was tested in MIND in a blind manner to assess their % highly motile cells, % 
narrow entry, % highly motile Ki67-positive cells and % unsorted Ki67-positve cells. The 
median survival of this retrospective population was 12.2 months and consisted of 13 patients 
whom are classified as low survivors (<14.6 months, median=6.3 months) and 9 patients whom 
are classified as high survivors (>14.6 months, median=29.3 months) based on the 14.6 months 
of median GBM patient survival threshold established by Stupp et al (25) (Figure 4.S1.A). A list 
of the demographic, tumor, surgical and clinical characteristics of the retrospective cohort is 
available in Table 4.S1. Notably, these demographic (age and gender), tumor (pre-operative 
tumor volume and tumor spread) and surgical attributes (number of surgical resections) all failed 
to predict survival of GBM patients between the two cohorts (Figure 4.S1.B-F).  
 
Representative magnetic resonance imaging of the brains of GBM patients reveals that low GBM 
survivors typically possess a larger degree of butterfly tumor spread than high survivors (Figure 
4.1.C), alluding to the potential roles of migration and proliferation as determinants of patient 
prognosis. The retrospective panel of 22 patient-derived primary GBM cells exhibited a 
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heterogeneous and wide range of migratory patterns and proliferative potentials as tested with 
MIND (Figure 4.1.D).  
 
4.4.2 Migratory and proliferative potentials of GBMs correlate with GBM patient survival 
To begin evaluating the prognostic values of the various MIND measurement metrics, namely % 
highly motile cells, % narrow entry, % highly motile Ki67-positive cells and % unsorted Ki67-
positive cells, we separated the retrospective patients into either low or high survival groups. 
Interestingly, primary GBM cells that are derived from the low survivors displayed higher 
migratory and proliferative potentials, as evidenced by their significantly higher % highly motile 
cells (Figure 4.2.A) and % highly motile Ki67-positive cells (Figure 4.2.C). The low survival 
groups also exhibited a trend of higher % narrow entry (Figure 4.2.B). The % of unsorted Ki67-
positive cells, on the other hand, was similar between the two groups (Figure 4.2.D).  
 
Linear regression between each of the MIND measurement metrics and GBM patient survival in 
months revealed that % of highly motile cells, % of narrow entry and % of highly motile Ki67-
positive cells were all negatively correlated with GBM patient survival (Figure 4.2.E). 
Interestingly, there was no correlation between % of unsorted Ki67-positive cells and GBM 
patient survival (Figure 4.2.E). 
 
We next sought to determine a threshold value for each MIND measurement metric that can be 
used to classify the retrospective cohort into either low or high survivals based on the 14.6 
months of median GBM survival threshold established by Stupp et al (25). The individual 
thresholds used to separate the patients were determined at levels that optimized the sensitivity, 
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specificity, PPV, NPV and accuracy of MIND to correctly categorize GBM patients into either 
high or low survivors (Figure 4.S2.A-D). Segmenting the 22 retrospective patients based on the 
optimal threshold of 14% highly motile cells or 12% narrow entry achieved a significant 
separation of the Kaplan-Meier survival curves, with the curves corresponding to the group 
exceeding the threshold (high) exhibiting a significantly shorter median survival months than the 
group that fell below the threshold (low) (Figure 4.2.F). The optimal threshold % of Ki67-
positive cells, either for the highly motile subpopulation (40%) or the entire unsorted population 
(45%), failed to achieve significant survival curve separation (Figure 4.2.F). 
 
Lastly, receiver-operating characteristic (ROC) curves and corresponding area under curve 
(AUC) were generated and calculated for each MIND measurement metric to quantify their 
ability to correctly identify patients based on their survival outcomes (Figure 4.2.G). ROC curve 
is a graphical representation of the benefit-cost tradeoff between the true positive (i.e. sensitivity) 
and false positive (i.e. 1 minus specificity) of a binary classifier system as its discriminatory 
threshold is systematically varied. The AUC of ROC indicates the usefulness of a test, where a 
higher value (with a maximum of 1) corresponds to a more useful test. In addition, the 
sensitivity, specificity, PPV, NPV and accuracy for each MIND measurement metric at their 
optimal threshold were also tabulated in Table 4.1. In general, all of the individual MIND 
measurement metrics were able to achieve similar values of around 70-80% sensitivity, 
specificity, PPV, NPV and accuracy (Table 4.1). It is noteworthy that % of unsorted Ki67-
positive cells represented the most inferior discriminators as compared to the other 3 metrics as it 
had the lowest value of AUC of ROC (Figure 4.2.G).   
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4.4.3 Combining the migratory and proliferative indices into a single composite score 
maximizes the prognostic performance of MIND 
The % highly motile cells, % narrow entry and % highly motile Ki67-positive cells correlated to 
GBM patient survival but exhibited a rather suboptimal prognostic capability compared to what 
is considered to be clinically ideal. In order to further improve the predictive power of MIND, 
we combined these 3 indices into a composite MIND score (ranging from 0 to 1) using logistic 
regression (Figure 4.3.A). A composite MIND threshold score of 0.5 was used to stratify 
patients into high (>0.5, n=12) and low composite MIND score groups (<0.5, n=10) (Figure 
4.S2.E). The differences in composite MIND score between the low and high survivors were 
magnified, with low survivors having a higher composite MIND score than the high survivors 
(Figure 4.3.B). The linear correlation between composite MIND score and GBM patient survival 
in months also improved substantially with a markedly higher R2 value (Figure 4.3.C). This 
classification was able to achieve the greatest degree of Kaplan-Meier survival curves separation 
with the largest difference in median survival (Figure 4.3.D). Importantly, the sensitivity, 
specificity, PPV and NPV and accuracy of employing composite MIND score to correctly 
identify high and low survival patients markedly improved to approximately 90% (Table 4.1). 
Finally, the AUC of ROC of the composite MIND score was also increased to 0.90 from around 
0.80 for the individual MIND measurement metrics, signifying that the composite MIND score 
could now be considered an optimal discriminator (Figure 4.3.E). 
 
Aside from GBM patient survival, MIND measurement metrics and the composite MIND score 
can also be used to predict time to recurrence. GBM lines which were derived from patients with 
a high composite score, % narrow entry and % of highly motile Ki67-positive cells (Figure 
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4.3.F) had a significantly shorter time to recurrence. % highly motile cells alone also showed a 
trend in predicting time to recurrence though not statistically significant (p=0.09) (Figure 4.3.F). 
 
4.4.4 MIND predicts GBM patient survival retrospectively and prospectively with high 
effectiveness 
The ability for each individual MIND measurement metric and the MIND composite score to 
categorize the 22 retrospective GBM patients into low versus high survival cohorts is 
summarized in a heat map (Figure 4.4.A). The patient-derived primary GBM lines were 
arranged in order of increasing survival and color coded with a red-blue double gradient with 
white color set at the threshold of 14.6 months while the true red and true blue colors represent 
the lowest and highest survival respectively. The effectiveness of the individual MIND 
measurement metrics and the composite MIND score were also represented in the red-blue 
double gradient with white color being set as the optimal threshold previously determined (i.e. 
14% migratory cells, 12% narrow entry, 40% migratory Ki67-positive cells, 0.5 composite score) 
and the true red and true blue color represents the highest and lowest value of each 
discriminators, respectively. With these heat maps, the false positive (i.e. patients who were high 
survivors but incorrectly predicted as low survivors) and the false negative (i.e. patients who 
were low survivors but incorrectly predicted as high survivors) results were identified by a 
mismatch in color hue to the survival heat map panel. The composite MIND score emerged as 
the most accurate discriminator compared to the individual MIND measurement metrics as it 
produced the least number of false positive and false negative predictions (Figure 4.4.A). Of 
note, the survival prediction made by MIND is independent of the demographics, surgical, tumor 
and clinical attributes of the retrospective patient cohorts. There were no significant differences 
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in terms of age, gender, KPS score, pre-operative tumor volume, extent of resection and tumor 
extension when the patients are separated based on low versus high MIND measurement metrics 
or composite MIND score with their optimized threshold (Figure 4.S3.A-G).  
 
While IDH1 mutation status has been shown to be an independent prognostic predictor for lower 
grade gliomas(195), screening of the IDH1 mutation status of our retrospective patient cohort 
(Figure 4.S4.A) revealed its shortcomings in predicting the survival of patients suffering from 
primary GBM. Low and high survivors exhibited similar incidence of IDH1 mutation (Figure 
4.S4.B). There was also no difference in terms of mean or median progression-free survival 
(Figure 4.S4.C-D) of GBM patients harboring wild type or mutated IDH1. With an overall 
accuracy of only 40% and an AUC of 0.43 (Figure 4.S4.E, Table 4.1), IDH1 mutation status 
possessed no utility in identifying patients based on their survival outcomes. Overall, these 
findings demonstrate the superiority of MIND over IDH1 mutation status to accurately determine 
the clinical outcomes of primary GBM in our retrospective patient cohort. 
 
To further evaluate the potential for MIND to be used in an actual clinical setting for GBM 
prognosis, we collected and tested in MIND specimens from patients that we followed 
prospectively (n=4). For this cohort, the patients were still alive at the time when the in vitro 
experiments were conducted and hence the survival outcomes were not available to the 
researchers. We measured the % of highly motile cells, % narrow entry, % highly motile Ki67-
positive cells for these 4 prospective samples and computed the MIND composite score (Figure 
4.4.B, Table 4.2). Only 1 out of the 4 samples (GBM1295) displayed a composite score of >0.5 
and was predicted to be a low survivor, while the other 3 samples (GBM1296, GBM1283, 
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GBM1280) were predicted to be high survivors. We continued to follow up with the patients 
over time and only 1 patient passed away at 6 months, before the 14.6 months of median GBM 
patient survival threshold. That patient is GBM1295, which MIND had correctly identified 
(Table 4.2). The other 3 patients survived past 14.6 months, making them high survivors, which 
MIND had also correctly predicted (Table 4.2). The prognostic performance of MIND for the 
prospective cohort is illustrated in a heat map similar to the retrospective cohort as described 
earlier (Figure 4.4.A), where it is evident that the predicted survival outcome based on the 
composite MIND score matches the actual survival outcome perfectly (Figure 4.4.C).  
 
4.5 Discussion 
Cell motility is a key process that contributes to a cancer cell’s ability to disseminate and invade 
(69). In fact, enhanced motility of cancer cells has been widely linked with higher metastatic 
potential, aggressiveness of cancer and overall poor prognosis (51). As such, the migratory 
capacity of cancer cells has been proposed and used to correlate with patient and clinical 
outcomes in a wide variety of cancer types, such as breast and brain cancer cells (202,207). 
While previous studies have revealed that migratory behavior of GBM cells is qualitatively 
instructive in determining tumor aggressiveness (208), no study or method to date has defined an 
effective quantitative approach to predicting individual patient prognosis for GBM. Moreover, 
most of our knowledge of cell migration stems from 2D or 3D collagen assays that do not 
recapitulate the complex in vivo brain tissue microenvironment. In vivo, invasive GBMs have to 
navigate confining 3D perivascular tracks in brain vessels formed between glial cells and the 
basement membrane of vascular smooth muscle cells (54,209). Indeed, prior attempts at 
examining the relationship between glioma cell migration on 2D surfaces and disease 
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progression have failed to achieve significant predictions to clinically relevant patient features 
(210). Introducing complexity to the migration assays by examining the migratory behaviors of 
individual GBM cells on 1D nano-pattern substratum in response to platelet-derived growth 
factor (PDGF) stimulation enabled successful prediction of GBM location and recurrence 
potential in a small retrospective cohort of patients (202). However, no significant correlation to 
patient survival outcomes or prognosis was observed (202). Furthermore, it is unclear whether 
and how such parameters can independently or in conjunction with other cellular behavior(s) to 
quantitatively and precisely predict individual patient clinical outcomes for GBM patients.  
 
In MIND, the microchannels were designed to recapitulate and mimic key aspects of the 
complex topography and confining longitudinal pores or perivascular tracks of the brain 
parenchyma. By examining the migratory behaviors of patient-derived primary GBM cells in 
response to topographical cues in the absence of any growth factor or chemoattractant 
stimulation, we found that the % of highly motile cells correlates remarkably well with overall 
progression-free survival, an unprecedented observation for any in vitro phenotypic-based 
prognostic assay for GBM. The success of this simple and easy-to-interpret analysis could be 
attributed to the ability of MIND to provide a more physiologically relevant confining 
microenvironment compared to conventional 1D or 2D migration assays. Along these lines, we 
have also observed significant correlation between patient survival and the % of highly motile 
cells that entered even more confining 3µm narrow branches (i.e. % narrow entry), indicating 
once again the value of subjecting the cells to migrate in a confined microenvironment and how 
this phenotypic trait can be exploited to determine patient outcome.  
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Aside from elevated motility, another key hallmark of aggressive cancer is its ability to grow and 
proliferate uncontrollably. Ki67 is a marker that is commonly used in the clinical setting to 
assess the proliferation potentials of cancer biopsies via immunohistochemistry staining and has 
been explored for cancer prognosis application with variable success (206,211). However, owing 
to the inherent heterogeneity of cancer cells, it is challenging to ascertain if migratory and non-
migratory cells display different proliferative potentials and if these potential differences possess 
any prognostic values. With MIND, we have the unique ability to sort the bulk total cancer cell 
population into different subpopulations based on their motility and assess their Ki67 status 
independently. Notably, if we just quantify the % of Ki67+ cells for the total unsorted cell 
population, similar to just performing a regular Ki67 staining without the use of MIND, we fail 
to achieve any correlation to patient survival. In stark contrast, the % of Ki67+ cells for the 
highly motile cell subpopulation significantly correlated to GBM patient survival showcasing the 
importance of MIND as a sorting device. Interestingly, at the optimal threshold that maximized 
the accuracy of categorizing patients into either low or high survival groups, both % of highly 
motile Ki67+ and % of unsorted Ki67+ incidentally identified the same sets of patient into each 
group. Of note, both metrics were unable to achieve significant survival curve separation, unlike 
the migratory indices, suggesting proliferation alone is not sufficient for GBM prognosis despite 
demonstrating some promising correlation to patient survival.  
 
While individually, migration indexes, namely % of migratory cells and % of narrow entry, and 
proliferative indices, such as % of highly motile Ki67+ cells, each possess certain degree of 
prognostic values for GBM patient prognosis, they also have their respective shortcomings and, 
with sensitivity, specificity and accuracy values of only around 70%, they are far from what is 
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considered clinically ideal. Given that all GBMs exhibit enhanced cellular proliferation, it is 
difficult to utilize proliferation index alone as a benchmark for determining individual patient 
outcomes. Similarly, in order for invasive cells to colonize after they have migrated to distant 
sites, they need to be able to proliferate in order to establish secondary colonies. To further 
improve the prognostic performance of MIND, we combined the migratory- and proliferative-
based indices using logistic regression into a single composite MIND score. Remarkably, the 
composite MIND score emerged as the most accurate predictor compared the individual MIND 
measurement metrics, demonstrating the strongest correlation to patient survival, separating the 
survival curves to the greatest degree, and achieving sensitivity, specificity and accuracy of 
categorizing patients based on their survival outcomes to close to 90%. Moreover, MIND 
composite score predicts recurrence time successfully in our retrospective patient cohort. 
Recurrence of GBM following surgical resection represents the primary cause of death in 
patients and is intimately associated with future patient outcome (23,26). By quantifying the 
ability of GBMs to both migrate and proliferate, MIND is able to capture this aggressive invasive 
growth behavior and capitalize on this knowledge to make meaningful predictions regarding 
recurrence time and patient survival. Overall, these results reveal the benefits of combining 
multiple cellular parameters into making accurate prediction related to patient-specific outcomes 
and prognosis. 
 
Our results also highlight the advantages of MIND over traditional non-molecular and molecular 
characterizations. Notably, demographic, tumor and surgical parameters, such as age, gender, 
tumor volume, tumor spread, number of surgical resections and KPS score, were all non-
indicative of GBM patient survival and prognosis. MIND also outperforms IDH1 mutation 
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status, which is a clinically utilized independent prognosis indicator for certain subsets of 
glioma. Interestingly, in our retrospective patient cohort, we observed a complete lack of 
correlation between patient survival and IDH1 mutation status.  
 
Our retrospective-based findings provide an impetus to test the efficacy of MIND in a 
prospective manner. As a proof of concept, we have collected and tested 4 samples. Out of the 4 
prospective patients, only one patient passed away before the established median threshold of 
14.6 months and was hence classified as a low survivor, while the other 3 patients were high 
survivors. Remarkably, MIND was able to predict all four patients specifically and successfully. 
This suggests promising potential for MIND to be tested in a larger prospective pre-clinical 
study.  
 
Looking forward, MIND has the potential to be used in the clinical setting to rapidly distinguish 
between aggressive and less-aggressive cancers to inform patient care, management, and 
potential therapies that can impact the disease. During surgical resection of brain 
cancer, excess tumor specimen, which is generally discarded as medical waste after allocating a 
portion for pathological evaluation, can be used to perform MIND-related prognostic testing. 
Such excess specimen is frequently used by research laboratories to establish primary cell lines 
for future studies. MIND technology can thus enable us to examine patient-derived cells in order 
to quantitatively predict patient cancer aggressiveness. Moreover, MIND can serve as a platform 
for therapeutic screening to determine individual response and identify patient-specific effective 
therapies that can reduce the abundance of highly motile and proliferative cells. Given the 
promising performance of MIND in GBM, this functional assay may be useful for determining 
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patient surgical and clinical outcomes of other solid cancers, including those with increased 
propensity to migrate beyond tumor margins and ultimately metastasize to distal sites. MIND can 
also be extended for basic science applications where in depth molecular and genetic 
characterizations can be performed on highly motile and/or proliferative cells that can be 
physically isolated from the device following migration.  
 
Overall, our study reveals that invasive growth is intimately associated with disease progression 
and overall patient outcomes. By quantitatively evaluating both migratory and proliferative 
behaviors of patient-derived primary GBM cells in a physiologically relevant confining 
microenvironment that mimics the natural invasive routes of native GBM cells, our in vitro 
testing platform, MIND, can precisely determine prognosis in a patient-specific manner (Figure 
4.5). We believe that this in vitro testing platform will provide a useful prognostic tool that can 
be translated into the clinics to improve personalized management of GBM patients.  
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4.6 Figures and tables 
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Figure 4.1 Microfluidic Invasion Network Device (MIND) distinguishes patient-derived 
primary GBM cells based on their migratory and proliferative potentials 
(A) Schematic of MIND consisting of a series of 10 µm-tall and 400 µm-long Y-shape 
microchannels, with a 20 µm-wide feeder channel bifurcating to an either 10 µm- or 3 µm-wide 
branch. Inset: Representative time-lapse micrographs of GBM714 migrating in MIND. Lowly 
motile cells (top row) are defined as cells that remain in the feeder channels and fail to enter the 
bifurcations (blue and cyan triangles). Highly motile cells (bottom row) are defined as cells that 
traverse through the entire length of the feeder channel and enter either the 10 µm wide (red 
triangle) or 3 µm narrow branches (orange triangle). Duration between each frame is 4 h. (B) 
Representative epifluorescence images of Ki67-negative non-proliferative (top row) and Ki67-
positive proliferative (bottom row) GBM965 that have migrated in MIND. The cells (white 
triangles) were immunostained for Ki67 (green) and counterstained for nucleus with Hoechst 
33342 (blue). (C) Preoperative axial T1-weighted MRI with contrast showing GBM lesions of a 
low survivor (top panel) and a high survivor (bottom panel). White triangles represent the 
bilateral extension of GBM through the corpus callosum into the contralateral hemisphere known 
as the butterfly spread. (D) % highly motile cells (1
st
 row), % narrow entry (2
nd
 row), % highly 
motile Ki67-positive cells (3
rd
 row) and % unsorted Ki67-positive cells (4
th
 row) of a 
retrospective panel of 22 patient-derived primary GBM cells tested with MIND. Red bars 
represent cells that are derived from patients with low survival (<14.6 months, n=13). Blue bars 
represent cells that are derived from patients with high survival (>14.6 months, n=9).  Data 








Figure 4.2 Migratory and proliferative potentials of GBMs correlate with patient survival 
The retrospective GBM patient cohort is separated into low (red bars, n=13) and high survival 
(blue bars, n=9), and compared for their % highly motile cells (A), % narrow entry (B), % highly 
motile Ki67-positive cells (C) and % unsorted Ki67-positive cells (D). * represents p<0.05 as 
assessed by unpaired student’s t-test. (E) Linear regression analysis of GBM patient survival in 
months against % highly motile cells (1
st
 panel), % narrow entry (2
nd
 panel), % highly motile 
Ki67-positive cells (3
rd
 panel) and % unsorted Ki67-positive cells (4
th
 panel). Black solid line 
represents the best-fit line while black dotted line represents the 95% confidence interval. * 
represents p<0.05. Pearson’s correlation was used to assess the significance between the 
variables. (F) Kaplan-Meier curves based on MIND measurements, comparing survival of the 
retrospective cohort as separated by % highly motile cells (1
st
 panel), % narrow entry (2
nd
 panel), 
% highly motile Ki67-positive cells (3
rd
 panel) and % unsorted Ki67-positive cells (4
th
 panel). * 
represents p<0.05, ** represents p<0.01 and ns represents p>0.05  as assessed by two-tailed log-
rank (Mantel-Cox) test. (G) Receiver operating characteristic curves of classifying GBM patients 
into high or low survivors based on % highly motile cells (1
st
 panel), % narrow entry (2
nd
 panel), 
% highly motile Ki67-positive cells (3
rd
 panel) and % unsorted Ki67-positive cells (4
th
 panel). 













Figure 4.3 Combining migratory and proliferative indices into a single composite score 
maximize the prognosis performance of MIND 
(A) The values of composite MIND score computed with logistic regression by combining % 
highly motile cells, % narrow entry and % highly motile Ki67-positive cells as independent 
predictors. (B) Mean composite MIND score of low (red bar, n=13) versus high (blue bar, n=9) 
survivors. *** represents p<0.001 as assessed by unpaired student’s t-test. (C) Linear regression 
analysis of GBM patient survival against composite MIND score. Black solid line represents the 
best-fit line while black dotted line represents the 95% confidence interval. *** represents 
p<0.001. Pearson’s correlation was used to assess the significance between the variables. (D) 
Kaplan-Meier curve based on composite MIND score, comparing survival of the retrospective 
cohort as separated by high (>0.5, n=12) or low (<0.5, n=10) composite MIND score. ** 
represents p<0.01 as assessed by two-tailed log-rank (Mantel-Cox) test. (E) Receiver operating 
characteristic curve of classifying GBM patients into high or low survivors based on composite 
MIND score. AUC was calculated to indicate the prognostic utility of composite MIND score in 
classifying GBM patient into high or low survivals. (F) Mean time to recurrence of low versus 
high % highly motile cells (1st panel), % narrow entry (2nd panel), % highly motile Ki67-positive 
cells (3rd panel), and composite MIND score (4th panel). * represents p<0.05 and ** represents 












Figure 4.4 MIND predicts GBM patient survival retrospectively and prospectively with 
high effectiveness 
(A) Heat maps summarizing the ability of individual MIND measurement metrics and composite 
MIND score in categorizing GBM patients into low or high survivors. The 22 GBM patients are 
arranged in increasing order with survival (1
st
 panel). % highly motile cells (2
nd
 panel), % narrow 
entry (3
rd
 panel) and % highly motile Ki67-positive (4
th
 panel) and composite MIND score (5
th
 
panel) of the 22 retrospective GBM patients as presented in a red-blue double gradient with 
white color set as the threshold. False positive (FP: patients who are incorrectly categorized as 
low survivors) and false negative (FN: patients who are incorrectly categorized as high 
survivors) are indicated. (B) % highly motile cells (1
st
 panel), % narrow entry (2
nd
 panel), % 
highly motile Ki67-positive (3
rd
 panel) and composite MIND score (4
th
 panel) of 4 prospective 
patient-derived primary GBM cells. Data represent the mean±S.E.M. from n≥3 independent 
experiments. (C) Heat maps summarizing the individual MIND measurement metrics and 





MIND correctly matches the predicted survival (5
th
 panel; red=predicted to be low survivors; 
blue=predicted to be high survivors) to the actual survival of the 4 prospective GBM patients (6
th
 











Figure 4.5 Schematic of the clinical usage of MIND 
Primary GBM specimens harvested from patient following surgical resection are allowed to 
migrate in MIND, which recapitulates key aspects of the complex topography and the confining 
microenvironment that GBM invasion occurs natively in brain parenchyma. The migratory and 
proliferative potentials of the patient-derived GBM cells are measured and used to compute a 
composite MIND score, which is then subsequently used to predict patient prognosis and identify 
patient-specific effective therapies. Higher composite score correlates with lower progression-











Figure 4.S1 Demographic, tumor and surgical attributes do not correlate with GBM 
patient survival 
(A) Kaplan-Meier curve based on the 14.6 months median survival for GBM patients as 
established by Stupp et al, comparing survival between low (<14.6 months, n=13, red line) and 
high survivors (>14.6 months, n=9, blue line). Grey line indicates the survival curve of all of the 
22 GBM patients. (B-F) Kaplan-Meier curve based on demographic, tumor and surgical data of 
GBM patients, comparing survival of cohorts as divided by median age (B), gender (C), median 
pre-operation tumor volume (D), tumor spread (E) and number of surgical resections (F). All of 
these attributes fail to separate the population significantly (p>0.05) as assessed by two-tailed 






Figure 4.S2 Determination of threshold value for each MIND measurement metric and 
composite MIND score as predictors for GBM patient survival 
(A-D) Heat maps as presented in a red-blue double gradient (blue=minimum 0%, red=maximum 
100%, white=base line 50%) indicating the values of sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV), accuracy and average of the above-mentioned 
five parameters of correctly categorizing the GBM patients into either high or low survivors as 
one varies the threshold of % highly motile cells (A), % narrow entry (B), % highly motile Ki67-
positive cells (C), % unsorted Ki67-positive cells (D), and composite MIND score (E). An 
optimal threshold value was determined that maximizes the each of 5 measures of performance. 















Figure 4.S3 MIND does not discriminate against the demographic, surgical, tumor and 
clinical attributes of GBM patients 
(A-G) The retrospective GBM patients cohort is separated into low and high groups based on the 
threshold of % highly motile cells (1
st
 panel), % narrow entry (2
nd
 panel), % highly motile Ki67-
positive (3
rd
 panel) or composite MIND score (4
th panel) and compared for their mean age (A), 
gender (B), Karnofsky Performance Status (KPS) score (C), pre-operative tumor volume (D), 
extent of resection (E) and tumor extension (multifocal versus unifocal) (F). Significance 
between the low versus high groups for each classifier were assessed using an unpaired student’s 









Figure 4.S4 IDH1 mutation status does not predict GBM patient survival 
(A) Western blot panels of primary GBM cells derived from the retrospective patient cohort for 
the mutant form of IDH1 (IDH1R132H, top panel), total IDH1 (middle panel) and GAPDH 
(bottom panel) as housekeeping and loading control. The patients are classified as IDH1 mutant 
or IDH1 wild type (WT) based on the presence or absence of IDH1R132H bands. (B) Percentage of 
patients exhibiting either IDH1 WT or mutant of low versus high survivors. Statistical 
significance was assessed by unpaired student’s t-test. (C) Mean GBM patient survival in months 
of patients exhibiting IDH1 WT or mutant. Statistical significance was assessed by unpaired 
student’s t-test (D) Kaplan-Meier curve based on IDH1 mutation status, comparing survival of 
the retrospective cohort as grouped into IDH1 WT (n=8) or IDH1 mutant (n=14). ns represents 
p>0.05 as assessed by two-tailed log-rank (Mantel-Cox) test. (E) Receiver operating 
characteristic curve of classifying GBM patients into high or low survivors based on IDH1 
mutation status. AUC was calculated to indicate the prognostic utility of IDH1 mutation status in 










Table 4.1 Measures of performance for individual MIND measurement metrics and 
composite MIND score in classifying the retrospective GBM patient cohort into either high 
or low survivors 
A positive event is defined as low survival (<14.6 months) while a negative event is defined as 
high survival (>14.6 months). Sensitivity is defined as the probability of correctly identifying a 
low survival patient from all of the low survival patients. Specificity is defined as the probability 
of correctly identifying a high survival patient from all of the high survival patients. Positive 
predictive value (PPV) is defined as the proportion of patients who are predicted to be low 
survival that are truly the low survivors. Negative predictive value (NPV) is defined as the 
proportion of patients who are predicted to be high survival that are truly the high survivors. 
Accuracy is defined as the probability of correctly identifying both the low and high survivors 
from the entire population. Area under curve (AUC) is defined as the area under the receiver 
operating characteristic curve (ranges from 0 to 1). AUC measures how capable each classifier is 





Table 4.2 Individual MIND measurement metrics, composite MIND score and survival 




Table 4.S1 Summary of the demographic, tumor, surgical and clinical characteristics of the 









Table 4.S2 Values of the coefficients and constant of logistic regression as determined and 








Chapter 5 Future Directions 
5.1 Characterizing the roles of NHERF2 on pancreatic cancer cell migration 
In Chapter 3, we investigated the molecular mechanisms by which PODXL promotes pancreatic 
cancer cell migration. Contrary to the widely reported binding partners of PODXL as being ezrin 
and/or NHERF1/2, we instead discovered a novel direct binding interaction between PODXL 
and dynamin-2, which in turn modulates microtubules and focal adhesion dynamics to facilitate 
cell motility (Figure 3.6). While ezrin is ubiquitously absent in the immunoprecipitate fraction 
of PODXL, as assessed by both mass spectrometry and western blot (Table 3.1, Figure 3.3.A), 
NHERF2 was actually enriched in the immunoprecipitate fraction of PODXL (Table 3.1). Co-
immunoprecipitation experiment using NHERF2 specific antibody also pulled down PODXL 
(Figure 3.S4.C). Interestingly, while both dynamin-2 and NHERF2 independently pulled down 
PODXL, they were unable to pull down each other, indicating that PODXL forms distinct 
complexes with dynamin-2 and NHERF2 independently (Figure 3.S4.C-D). 
 
To examine the role of NHERF2 on the motility of PODXL-expressing pancreatic cancer cells, 
we knocked down NHERF2 in SW1990 and subjected them to our standard microchannel 
migration assay (Figure 3.S4.E). In distinct contrast to the inhibitory effect of knocking down 
PODXL and dynamin-2 on cell migration, NHERF2-KD cells moved much faster than scramble 
control cells (Figure 3.S4.F). Of note, NHERF2-KD cells also exhibit a clear 
mesenchymal/protrusive phenotype as opposed to the epithelial/rounded morphology of 
scramble control or PODXL-KD cells (Figure 5.1.A). In view of these results and given that 
PODXL and/or dynamin-2 knockdown suppress migration to an equivalent extent without any 
additive effect, we conclude that dynamin-2 regulates PODXL-mediated migration of pancreatic 
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cancer cells via its direct binding interaction with PODXL, independent of PODXL binding to 
NHERF2. The precise role of NHERF2 in pancreatic cancer cell migration, which may extend 
beyond PODXL, deserves further investigation. 
 
Given that both dynamin-2 and NHERF2 are capable of binding to PODXL independently and 
the divergent effects of knocking down either of these proteins on cell migration, one can 
reasonably postulate that NHERF2 may serve as a competitive binding inhibitor to dynamin-2. 
When the level of NHERF2 is decreased as a result of NHERF2-KD, more PODXL may become 
available for binding to dynamin-2, leading the faster microtubule growth, reduced focal 
adhesion density, and ultimately enhanced cell migration. Several experiments can be performed 
to test this hypothesis. Firstly, we can knock down NHERF2 in cells with also PODXL and/or 
dynamin-2 knockdown (or using dynamin-2 inhibited cells with dynasore) to assess the effect of 
this double knockdown intervention on cell migration. If the hypothesis is true, knocking down 
NHERF2 will not be able to increase the migration of cells with depleted PODXL or dynamin-2 
as they are the important upstream signaling molecules that sustain efficient cell migration. 
Secondly, we can compare the levels of dynamin-2 that are being co-immunoprecipitated with 
PODXL in both scramble control and NHERF2-KD cells. If NHERF2 is indeed a competitive 
binding inhibitor to dynamin-2, we will expect to detect higher level of dynamin-2 in the 
immunoprecipitate fraction of PODXL derived from NHERF2-KD cells. Thirdly, we can 
measure and compare the rate of microtubule growth and focal adhesion density of scramble 
control and NHERF2-KD cells. If the proposed mechanism is correct, we will expect a higher 
rate of microtubule growth and a lower focal adhesion density in NHERF-2 KD cells. However, 
this result will only at best be supporting the hypothesis and not proving it directly, as there 
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could be other factors independent of PODXL and/or dynamin2 that can alter microtubule and 
focal adhesion dynamics following the loss of NHERF2 (as discussed further below). 
 
While it is true that PODXL binds to NHERF2, it is also entirely possible that there exist other 
distinct mechanisms by which NHERF2 promotes pancreatic cancer cell migration that is 
independent of PODXL. One striking difference between the scramble control and the NHERF2-
KD cells is their morphology. Scramble control cells assumed a more rounded and epithelial-like 
morphology while NHERF2-KD cells were significantly more protrusive and mesenchymal 
(Figure 5.1.A), leading one to suspect that loss of NHERF2 may be triggering EMT. In fact, 
preliminary evidence from western blot and quantitative polymerase chain reaction (QPCR) 
indicate that EMT is indeed induced by knocking down NHERF2. Specifically, NHERF2-KD 
cells demonstrated significantly lower mRNA expression of epithelial marker such as E-
cadherin, and higher levels of mesenchymal markers like N-cadherin, vimentin, TWIST, 
fibronectin, α smooth muscle actin and α1-integrin (Figure 5.1.B). Western blot further verified 
that NHERF2 KD cells expressed lower amount of epithelial markers such as E-cadherin and 
ZO-1, and higher amount of mesenchymal markers including N-cadherin, vimentin, ZEB1, 
SNAIL, SLUG (Figure 5.1.C). Aside from the apparent differences in cellular morphology 
induced by EMT, there is also preliminary evidence revealing that other oncogenic pathways 
may have also been altered. NHERF2-KD cells showed significantly higher rate of proliferation 
(Figure 5.1.E), suggesting that signaling pathways that are crucial for cell proliferation and 
survival such as PI3K/Akt/mTOR, NF-κB and Ras/Raf/MAPK may be activated. This 
hypothesis can be tested by performing western blots using antibodies specific for 
phosphorylation of key proteins involved in the signaling pathways of interest using cell lysates 
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derived from scramble control versus NHERF2-KD cells. The effects of knocking down 
NHERF2 on the other hallmarks of cancer, such as immune evasion, energy metabolism, MMP-
dependent invasion and drug resistance, also deserve to be further characterized. 
 
While it has become evident that the loss of NHERF2 in pancreatic cancer cells enhances cell 
migration and proliferation (and potentially also other relevant hallmarks of cancer), there is still 
the important question as to why it occurs. The first natural suspect is PODXL. PODXL has been 
reported to be needed for TGF-β induced EMT in lung carninoma (150). Even though knocking 
down PODXL alone did not induce EMT (Figure 5.1.D), it may be possible that this is due to 
the inhibitory role of NHERF2 binding to PODXL. In the absence of NHERF2, more PODXL 
may become available to induce EMT. While the exact mechanism by which PODXL may be 
inducing EMT is still not convincingly proven or established, it will be interesting to ascertain if 
PODXL is required for EMT caused by the loss of NHERF2. This can be achieved by accessing 
EMT induction in PODXL-KD cells with concurrent NHERF2-KD. In the literature, NHERF2 
has been reported to be primarily a scaffolding protein that connects the actin cytoskeleton to the 
plasma membrane with limited signaling function. Yet, we have observed a multitude of 
oncogenic changes as a result of knocking down NHERF2. It is therefore possible that loss of 
NHERF2 may cause some disturbances in linkages between the plasma membrane and the actin 
cytoskeleton, which could potentially result in changes in cellular and/or membrane tension. 
Changes in cell membrane tension have been reported to alter YAP/TAZ signaling and trigger 
EMT via a mechanosensitive channel-dependent manner (212,213). As such, changes in the 
other biophysical properties of NHERF2-KD cells which have the potential to affect global 
transcriptional gene changes deserves further examination. 
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Finally, in order to provide some clinical perspective to the role of NHERF2 in pancreatic cancer 
progression, a preliminary Kaplan-Meier curve analysis was generated using data from mRNA 
expression levels of NHERF2 among patients with pancreatic ductal adenocarcinoma obtained 
from the open source online KM-Plotter software. The data revealed a significantly better 
prognosis and longer median survival in patients with higher expression of NHERF2 (Figure 
5.1.F). To further substantiate its clinical relevance, pancreatic cancer tissue microarray can be 
immunostained for NHERF2 to compare the expression of NHERF2 between normal healthy 
pancreatic tissues and pancreatic tumors of varying grades. The immunohistochemistriy staining 
experiment will reveal if NHERF2 expression is decreased during the transformation of healthy 
tissues to pancreatic cancers. A western blot panel can also be performed to compare the 
endogenous levels of NHERF2 in normal pancreatic epithelial cells such as HPNE and HPDE to 
that of pancreatic ductal adenocarcinoma cell lines like SW1990 and Pa03c. Lastly, the in vivo 
significance of NHERF2-KD on pancreatic cancer metastasis can also be investigated via the 
same hemispleen mice model as used in the PODXL project. 
 
5.2 Assessing the roles of giant obscurin on pancreatic cancer metastasis 
Aside from PODXL and NHERF2, another protein that our lab has previously shown to affect 
pancreatic cancer cell migration is obscurin. Obscurins are giant cytoskeletal proteins with 
structural and regulatory roles that are encoded by the OBSCN gene (214,215).  Mutations to 
the OBSCN gene have been associated with pancreatic ductal carcinoma and the loss of obscurin 
from breast cancer has resulted in increased tumorigenicity and cell migration (216-220).	
Previously, we established that obscurin expression is depleted in pancreatic ductal 
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adenocarcinoma tissue and metastatic cell lines, but remains unaltered in normal pancreatic 
tissue and non-tumorigenic human pancreatic ductal epithelial cells (HPDE). Stable clones of 
HPDE cells lacking obscurins resulted in the modification of two key signaling pathways, RhoA 
and PI3K/AKT, which in turn leads to major cytoskeletal alterations including increased actin 
and microtubule dynamics and decreased focal adhesion density, ultimately resulting in faster 
cell migration (Figure 5.2). However, we have yet to establish the in vivo functional significance 
of obscurin loss in promoting pancreatic cancer metastasis. Previous attempts at generating 
tumors in vivo with HPDE, either via subcutaneous injection or hemispleen models, have failed 
as HPDE cells are non-tumorigenic in vivo, despite even using a modified variant HPDE with 
activating KRAS mutation. To circumvent this issue, we knocked down obscurins in another 
pancreatic ductal adenocarcinoma cell lines, Panc5.04. We verified that obscurin loss in 
Panc5.04 resulted in the same mechanobiological phenotype as obscurin-depleted HPDE cells, 
namely Panc5.04 Obscurin-KD cells display downregulation of RhoA activity, activation of 
PI3K/Akt pathway, increased actin and microtubule dynamics, decreased focal adhesion density 
and enhanced cell migration. We plan to next investigate the ability for these obscurin-depleted 
Panc5.04 cells to facilitate metastasis in vivo with the hemispleen mice model.  
 
5.3 Validating the prognostic capability of MIND for personalized medicine 
In Chapter 4, we described the development of a novel in vitro testing platform, MIND, which 
can be used to assess the migratory and proliferative potentials of patient-derived GBM cells to 
predict patient survival. We achieved high sensitivity, specificity and accuracy in correctly 
classifying patients into either low or high survivals using a retrospective dataset consisting of 22 
patients. We further validated the prognostic ability of MIND with a small number of 4 
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prospective patients, where we successfully predicted the survival outcome of all 4 patients. We 
plan to recruit more patients prospectively and test these new and fresh GBM specimens in 
MIND to increase the sample size of the prospective patient cohort to validate the prognosis 
power of MIND for actual clinical usage.  
 
Aside from improving and substantiating the performance of MIND as a survival prediction tool, 
we also plan to extend MIND for testing various therapeutic agents against cells isolated from 
individual patients to predict responses to therapy. Since the migratory and proliferative abilities 
(as assessed simultaneously via composite MIND score) of GBMs correlate with patient 
survival, if a drug is able to decrease the composite MIND score to below the low versus high 
survival threshold, it would then suggest that there is a high probability that the drug has the 
potential to prolong patient survival. We can further validate the prediction using in vivo mice 
models to see if that particular drug is also able to improve outcome and extend survival in mice. 
As a proof of concept, we have tested an EGFR inhibitor, erlotinib that has investigated 
clinically in patients with recurrent malignant gliomas, on the migration of patient-derived 
primary GBM cells in MIND and observed a consistent inhibitory effect (Figure 5.3.A). The 
ultimate goal is to develop MIND as a companion tool by which clinician can rapidly obtain 
useful prognostic information, as well as to use it as a drug-testing platform to optimize 
therapeutic strategies for individual patients to hopefully extend their survival. 
 
Lastly, we plan to extend MIND beyond GBMs to other solid cancer cell types for precision 
medicine. The versatility of MIND to other cancer cell types has already been demonstrated 
previously in breast cancer where the migratory and proliferative potentials of these cells 
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correlate with metastatic potential (Figure 5.3.B). Using a similar approach, we plan to expand 
the utility of MIND to pancreatic cancer. We will first test a panel of pancreatic cancer cell lines 
and correlate with their ability to metastasize, either as accessed from literature search or 
empirically with hemispleen mice model. Already we have tested the migratory behaviors of 
several pancreatic cancer cell lines in vitro with MIND (Figure 5.3.C). Furthermore, we also 
propose to collaborate with surgeons who have accessed to pancreatic cancer specimen to see if 





Figure 5.1 NHERF2 downregulation promotes EMT and proliferation in pancreatic cancer 
cells, and is associated with poorer patient survival 
(A) Morphology of scramble control, NHERF2-KD1 and NHERF2-KD4 SW1990 pancreatic 
cancer cells on 2D collagen I-coated glass coverslips. NHERF2-KD cells displayed more 
elongated and protrusive phenotypes as compared to scramble control cells. (B) QPCR results 
showing mRNA downregulation of epithelial marker (CDH1/E-cadherin) and upregulation of 
mesenchymal marker (CDH2/N-cadherin, vimentin, Zeb1, Zeb2, TWIST1, fibronectin, α smooth 
muscle actin, α1 integrin) in NHERF2-KD cells. Data represent the mean±S.E.M. from 3 
independent experiments. * represents p<0.05 between scramble control and NHERF2-KD1 or 
NHERF2-KD4. (C) Western blot results showing protein downregulation of epithelial marker 
(ZO-1, E-cadherin) and upregulation of mesenchymal marker (Zeb1, N-cadherin, Vimentin, 
SNAIL, SLUG) in NHERF2-KD cells. GAPDH was blotted as the loading control. (D) Western 
blot showing no changes in epithelial (E-cadherin) or mesenchymal markers (N-cadherin, 
Vimentin, SNAIL) in PODXL-KD cells. β-actin was blotted as the loading control. (E) in vitro 
growth rate of scramble control, NHERF2-KD1 and NHERF2-KD4 SW1990 cells. Data 
represent the mean±S.E.M. from 3 independent experiments. * represents p<0.05 between 
scramble control and NHERF2-KD1 or NHERF2-KD4. (F) Kaplan-Meier survival curve 
comparison of patients with low versus high expression of NHERF2 (also known as 










Figure 5.2 Downregulation of obscurin in HPDE cells enhances migration by regulating 
microtubule, actin and focal adhesion dynamics, and modulating RhoA and PI3K signaling 
(A) Western blot showing successful knockdown of giant obscurin in HPDE cells. HSP90 was 
blotted as the loading control (B) Obsc shRNA-1 cells migrate faster than the scramble control 
cells in microchannels of 10 µm in height and width and 200 µm in length. (C) Microtubule 
growth rate as assessed by EB1-GFP of scramble control versus Obsc shRNA-1 cells. (D) FRAP 
curves showing the fraction of LifeAct-GFP recovery overtime for scramble control, Obsc 
shRNA-1 and Obsc shRNA-2 HPDE cells (left panel). Average of the mobile fraction (middle 
panel) and the half-life of LifeAct-GFP recovery (right panel) are shown. (E) Average	 focal	




panel)	were	 increased	 in	 in	Obsc	 shRNA-1	HPDE	 cells.	* represents p< 0.05, ** represents 





Figure 5.3 MIND is amendable for drug testing and prognosis of other solid cancer cell 
types 
(A) An EGFR inhibitor, erlotinib, decreases the migratory potential of patient-derived primary 
GBM cells in MIND. Data represent the mean±S.E.M. from n≥3 independent experiments. * 
represents p< 0.05 between vehicle control and 25 µM erlotinib (B-C) MIND predicts the 
metastatic potential of breast cancer cell lines with 100% accuracy. (D) MIND is adaptable for 
the measurement of migratory potential of pancreatic cancer cell lines.  
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Chapter 6 Conclusion 
Cell motility is one of the key determinants of the spread and eventually lethality of cancer. This 
is especially pertinent for pancreatic cancer and GBM, which are notorious for their poor clinical 
outcomes due to aggressive local infiltration and/or widespread distant metastasis that impede 
complete and effective tumor eradication by currently available treatment options. A more in 
depth understanding of the molecular basis of cancer cell migration thus allows for identification 
of new oncogenic and/or tumor suppressor genes, and their associated downstream signaling 
pathways, that could potentially serve as novel diagnostic and therapeutic targets for these 
aggressive cancers. In the case of pancreatic cancer for instance, we have characterized and 
delineated the roles and mechanisms by which PODXL regulates cancer cell motility and 
metastasis, in which one could subsequently target to suppress migration and aggressiveness of 
pancreatic cancers. Besides examining cell migration at the biochemical and cellular levels, one 
can also adopt a more global and systematic approach to utilize the migratory phenotypes of 
cancer cells for actual clinical applications. By measuring and comparing the differences in the 
migratory and proliferative potentials of patient-derived primary GBM cells, we demonstrated 
that MIND can accurately predict patient survival and time to recurrence, illustrating promising 
potential to guide personalized medicine and improve the quality of life of GBM patients. 
Overall, by studying cell migration in a multidisciplinary approach, we are able to both attain a 
deeper understanding on the factors underlying cancer aggressiveness and translate this 
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• Cell	 Biology:	Bacterial	and	mammalian	 cell	 culture,	 transient	and	 stable	 transfection,	 lentivirus	
production	and	transduction,	cell	line	generation,	cell	sorting,	cell	viability	assays	
• Molecular	Biology:	Molecular	cloning,	plasmid	generation,	western	blotting,	QPCR,	zymography	
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